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Abstract
This thesis examines the contrasting roles of genetic drift and selection on the 
emergence of drug resistance in Mycobacterium tuberculosis. In clinical practice some 
alleles of rifampicin resistance are isolated more frequently than others. To identify if 
this variation is due to genetic drift or selection, the mutation rate to rifampicin 
resistance in M. tuberculosis (H37Rv) was determined. PCR-SSCP analysis revealed 
only three patterns from the rifampicin resistant isolates, each pattern arising at the same 
mutation rate (Mann-Whitney U test P>0.5). Fitness, defined as the ratio of generations 
of resistant and susceptible cells formed in mixed culture, of the differing rifampicin 
resistant alleles was determined relative to the parent fully susceptible strain. There was 
a significant correlation between fitness and the clinical isolation rate of each allele 
(regression analysis P=0.026).
The fitness of two isolates, with identical IS6110 RFLP pattern isolated from 2 siblings, 
was determined. One isolate had developed multi drug resistance, the second isolate had 
remained fully drug susceptible. The fitness of the drug resistant isolate was 
significantly lower than the drug susceptible isolate (matched pair t test p=0.002). The 
decreased relative fitness of the resistant isolate implied a physiological cost for the 
development of drug resistance.
Isolates of M. tuberculosis from three patients involved in a hospital outbreak of multi 
drug resistant tuberculosis were obtained. The fitness of these isolates was determined
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relative to H37Rv. Isolates obtained from the same patient did not vary in fitness (one 
way ANOVA p=0.34). However, the isolates from the three different patients had 
differing fitness values (one way ANOVA p=<0.001). This implied that there is 
adaptation of the isolates to the individual patient.
In conclusion, selection has a major role in adaptation of drug resistance in M. 
tuberculosis. This adaptation includes adaptation to the infected host as well as drug 
resistance.
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Chapter 1 
Introduction
1.1 Tuberculosis infection
Tuberculosis (TB) is caused by four species of Mycobacteria: M. tuberculosis, M 
africanum, M. bovis y and M. canettii (Goh, Legrand, Sola et al. 2001). These four 
species along with a fifth species M microti form the Mycobacterium tuberculosis 
complex (MTBC). These species are all obligate pathogens, unable to grow in the 
environment. All five species are genetically homogenous being characterised by 99.9 
% similarity at the nucleotide level and identical 16S r RNA sequences (Kapur, Whittam 
& Musser 1994; Sreevatsan, Pan, Stockbauer et al. 1997).
Species within the MTBC infect different ranges of hosts. M. microti is usually 
associated with voles, however Van Soolingen, Van der Zanden, de Haas et al. (1998) 
described four human infections with M. microti. M. bovis infects a range of mammals 
including ruminants and primates. Human infection with M. bovis is more common than 
with M. microti and usually occurs from consumption of infected animal products such 
as milk and not from person to person infection. M. tuberculosis M. canettii and M. 
africanum are pathogens of man and primates with only a significant natural reservoir in 
humans. M  tuberculosis has a substantially diminished virulence for other non-human 
animal species in comparison to M. bovis (Iseman 1994).
M. tuberculosis infection is usually transmitted between people by the inhalation of 
infected droplets and aerosols produced by infected people coughing and sneezing 
(Department of Health 1998a). Droplet nuclei of 1 to 5 pm in diameter are the largest 
particles that can reach the lung alveoli. These particles can only contain 1 to 3 bacilli 
(Barkley & Kupica 1994). Patients with tuberculosis do produce particles containing 
more than three bacilli but these are unlikely to reach the lung alveoli of a fresh host and 
so are less likely to result in infection. This means that fresh infection must arise from 
these particles of three or less bacteria.
The American Thoracic Society (2000) described four factors determining the likelihood 
of transmission of infection:
1. the number of organisms being expelled into the air;
2. the concentration of organisms;
3. the length of time an exposed person breathes the contaminated air; and
4. the immune status of the exposed individual.
Human immunodeficiency virus (HIV) infected individuals are more likely to develop 
infection, however, they are no more likely to transmit infection.
The initial lesion appears as an area of non-specific pneumonitis. It is only after delayed 
hypersensitivity develops, in 2-4 weeks, that granulomatous inflammation occurs and 
the characteristic tubercles are formed (Wolinskey 1980). The organisms grow until a
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population size of 103 to 104 bacilli is produced. This size of population stimulates a 
cellular immune response (Dannenberg, Jr. 1992). In the period before delayed 
hypersensitivity develops, bacilli are carried to the lymph nodes and then by way of the 
lymph fluid and infected macrophages in the blood are disseminated throughout the 
body.
Tuberculosis can occur in any site through out the body. The most common locations 
for extrapulmonary infection are the genitourinary system, bones and joints, lymph 
nodes, pleura, and peritoneum. This disseminated tuberculosis can lead to miliary 
tuberculosis (Wolinskey 1980). Prior to the HIV epidemic, extrapulmonary infection 
was mainly seen in young children. Pulmonary tuberculosis accounted for 
approximately 85% of reported cases prior to the HIV epidemic with only 15% of 
reported cases involving nonpulmonary infection. In HIV infected individuals solely 
nonpulmonary infection has been reported in 30% of cases, both pulmonary and 
nonpulmonary infection in 32% of cases and the remaining 38% of cases had solely 
pulmonary infection (American Thoracic Society 2000).
Primary tuberculosis in the immunocompetant host usually stabilises and heals. Lucas 
(1989) maintained that haematogenous spread is common in non-vaccinated infected 
patients, these patients frequently going through a stage in which M. tuberculosis is 
present in the urine indicating infection of the kidney. Disseminated or miliary 
tuberculosis is, however, an unusual disease and is usually associated with AIDS 
(Collins 1991).
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Caseous lesions heal by fibrosis and calcification. The healed and frequently calcified 
primary complex lesions are referred to as the Ghon complex, which may be recognised 
in chest X-rays for the remainder of the infected person’s life. In a small proportion of 
immunocompetent individuals, the infection is not brought under control and the 
primary lesions become larger, coalesce, and liquefy (Wolinskey 1980). These liquefied 
cavities enable M. tuberculosis to grow extracellularly to produce very large bacterial 
numbers (Dannenberg, Jr. 1991). When the cavity forms in the lung, liquification can 
result in the release of vast numbers of bacilli into the respiratory secretions of the 
infected host. The presence of large numbers of bacilli in sputa is evidence of active 
pulmonary tuberculosis and the patient is highly infective.
Reactivation of tuberculosis disease can occur decades after the primary infection. The 
foci are located mostly in the posteria and apical or subapical portions of the lung. By 
the time the disease is recognised, liquefaction of the caseous lesion has occurred 
(Wolinskey 1980). This liquefaction, as previously stated, can release vast numbers of 
bacilli with ready access to the lung.
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1.2 The development of chemotherapy for M. tuberculosis
Animal and clinical studies of antitubercular agents have been invaluable in measuring 
the effectiveness of both the eradication and sterilisation of M. tuberculosis. The 
reduction in colony forming units per day of treatment is an indication of the 
effectiveness of the killing activity of the antitubercular agent or early bactericidal 
activity of the agent (Gillespie, Gosling, & Charalambous 2002). The rate of re- 
emergence of tuberculosis is an indication of the sterilising activity (Burman 1997).
Streptomycin was first used as a single drug against tuberculous meningitis in 1946. 
Tuberculous meningitis was at that time invariably fatal. A good response was recorded 
for 12% of children under 3 years and 36% of older patients. This trial on miliary 
tuberculosis produced little drug resistance (Medical Research Council 1948).
Streptomycin trials on pulmonary tuberculosis appeared initially as favourable as those 
on tuberculous meningitis. Improvements in both bacteriological and radiographic 
measures were apparent. However, drug resistance emerged in 35 of 41 (85 %) of 
patients and mortality after 5 years was only slightly improved in streptomycin treated 
patients (Fox, Sutherland & Daniels 1954). There was almost universal selection of 
streptomycin resistance in pulmonary tuberculosis, whilst tuberculous meningitis did not 
select resistant strains. This difference was judged to be caused by the greater baccillary 
load in pulmonary tuberculosis and so the greater probability of a rare resistant mutant 
occurring.
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In 1948 combination therapy using para-aminosalycilic acid (PAS) and streptomycin 
was used in a trial of 166 patients. The use of combined therapy resulted in reduced 
emergence of streptomycin resistance and the rate of streptomycin resistance occurred 
more frequently as PAS dosage was reduced (British Medical Council 1950; Fox & 
Sutherland 1956), indicating that PAS did inhibit the emergence of streptomycin 
resistance.
Drug resistance in M tuberculosis arises from alteration of the genome with no 
transferable resistance genes. This occurs most commonly via single base mutation but 
insertion sequences can interrupt gene sequences and so produce resistance 
(Ramaswamy & Musser 1998; Lemaitre, Sougakoff, Truffot-Pemot et al. 1999). The 
use of combined therapy provided a defence against emergence of resistance, as mutants 
resistant to both drugs must occur on the same genome. If the probability of each 
resistant mutation being present is KX6 (one in a million) then the probability of both
m f\ j f \  1 7arising simultaneously in the same genome is (10 x 10 ) 10" (Shimao 1987).
Isoniazid became available in 1952. Treatment with isoniazid alone as with 
streptomycin rapidly produced strains resistant to isoniazid. Trials of combination 
therapy involving PAS, streptomycin and isoniazid were carried out. The use of 
streptomycin and isoniazid was found to almost completely suppress the emergence of 
drug resistance and had the highest bacteriological cure rates. The proportion of patients 
treated with isoniazid and streptomycin with negative cultures at 3 months was 67% of
18
117 compared to 55% of 83 streptomycin and PAS treated patients (Fox 1953; Medical 
Research Council 1953b; Medical Research Council 1953a).
The use of two antimycobacterial agents in an infection caused by a strain of 
tuberculosis resistant to one agent, results in only a single effective agent being used. 
Triple therapy involving streptomycin, isoniazid and PAS was initially used to prevent 
treatment with a single effective antibiotic against tuberculosis resistant to a single 
therapeutic agent. Triple therapy improved the success rate of therapy from an 
unfavourable response at one year of 16% to only 3% (Medical Research Council 1962). 
These trials also indicated that prolonged periods of treatment were required. Relapse 
occurred in 62% of patients treated for 6 months, 19% in those treated for one year and 
4% for those treated for 2-3 years. A single agent could however be effectively used for 
the continuation phase.
Triple therapy trials indicated that intensive combination therapy was only necessary 
during the initial 2 months of treatment. If therapy was incomplete during this intense 
period, failure was accompanied by development of drug resistance (Mitchison 1998). 
Treatment failure in the continuation phase would also result in relapse, but the infecting 
strain would not gain additional antibiotic resistance. This emphasises the importance to 
the emergence of drug resistance of large bacilli numbers, as was identified earlier with 
the comparison of miliary and pulmonary single agent treatment.
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Experimental infection of mice with M. tuberculosis revealed that isoniazid alone or in 
combination with streptomycin or (PAS) produced a 2-log drop in viable cultures in two 
months. Continued treatment was however essentially bacteriostatic with little or no 
further reduction in spleen culture. The addition of pyrazinamide produced sterile 
cultures after 4 months of treatment (Burman 1997). Testing against different phases of 
growth of M  tuberculosis has identified a decline in activity of isoniazid as 
Mycobacteria move into non-growing phases of growth (Yamori, Ichiyama, Shimokata 
et al. 1992).
The environment that the tubercle bacilli occupy has had a major effect on the selection 
of antibiotics used. Mitchison (1992) has argued that tubercle bacilli undergo four 
different growth phases, and that different antibiotics used in therapy affect these phases. 
The four phases are:
1. A population with continuous growth and replication (often found in large numbers 
inside cavities): isoniazid is most effective against this population in terms of killing 
power but rifampicin and streptomycin are also effective.
2. A population composed of dormant organisms, for which no drug appears to be 
effective.
3. A population of bacteria with slow growth and occupying an acid environment, 
possibly within the macrophage. This population is affected by pyrazinamide.
20
Treatment with pyrazinamide for the first 2 months greatly reduces the probability of 
a relapse occurring.
4. Dormant organisms with intermittent spurts of growth: rifampicin is most effective 
against this population.
The different phases of growth of Mycobacteria cause a problem with predicting the 
outcome of antimycobacterial treatment. Mitchison’s four-compartment model has two 
broad phases of M. tuberculosis infection. Actively growing bacteria against which 
routine susceptibility testing is aimed, and slow to stationary growth under acidic 
conditions. An antimycobacterial agent that affects the active growing phase will 
quickly eliminate M tuberculosis found in the sputum. For complete eradication of M 
tuberculosis, a sterilising agent capable of affecting the slow to stationary growth phase 
must also be used.
Following the emergence of drug resistance, it is necessary to use drugs based on the 
specific susceptibility pattern of the infecting strain. This therapy must take into account 
not only the need to ensure against further drug resistance by use of multiple antibiotics, 
but the different environments that need to be treated. Therapy must not only kill the 
rapidly growing large cavities of tuberculosis leading to smear negativity with apparent 
cure, but sterilise the more slow growing or dormant organisms to prevent re-emergence 
of tuberculosis.
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1.3 The current world wide spread of tuberculosis
A continuous decline in tuberculosis was disturbed in the 1980s, when for the first time 
in the developed world tuberculosis cases stopped declining. In the United Kingdom the 
lowest number of reported cases was in 1987. In the ten years between 1988 and 1998 
the reported number of tuberculosis cases in England and Wales increased by 21%. This 
increase was predominantly in London where tuberculosis cases increased 71 % over 
this period (Rose, Watson, Graham et al. 2001)
There has been a similar rise in tuberculosis in the United States of America. The causes 
of this increase in both the USA and UK have been largely due to HIV and immigration. 
In the USA 30% of the increase in tuberculosis from 1984 to 1990 was due to HIV 
(Schurmann, Nightingale, Bergmann et al. 1997). In Western Europe tuberculosis is 
found largely in immigrant groups from areas where tuberculosis is endemic (EuroTB 
2003).
Tuberculosis remains the most common infectious cause of death with an estimated 3 
million deaths annually (World Health Organization 2003). The chronic nature of TB 
means that headline figures, such as death rates of 3 million world wide, must be 
tempered with the much larger number of reported cases.
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The US government set up the Advisory Committee for the Elimination of Tuberculosis 
(ACET). This proposed a simple plan outlined in the Weekly Epidemiological Record 
(Anonymous 1989).
1. To concentrate on high risk groups.
2. To improve surveillance.
3. To improve case prevention, particularly through chemoprophylaxis.
4. To strengthen communication activities.
For the majority of countries, prevention through chemoprophylaxis for individual cases 
as in proposal 3 is likely to be less appropriate than in the USA. Emphasis instead is 
applied to effective case finding (Anonymous 1989).
The rise in tuberculosis cases world wide from 1985 to 1992 led the WHO in March 
1993 to declare TB a ‘global health emergency’. The first time that the WHO has ever 
so singled out any disease (Reichman 1996).
The WHO has set itself a global target of treatment of 70% of all TB cases and treatment 
success of 85%. This target was initially set to be achieved by the year 2000. This 
target has now been moved to the year 2005. In the WHO report 2002 a smear case 
detection rate of 37% was reported with 82% successfully treated (World Health 
Organization 2004).
A key component of this control is DOTS (Directly Observed Therapy Short term). This 
strategy involves a standardised therapy regime with an observer ensuring compliance 
over the period of therapy.
Globally the incidence of TB is increasing at about 0.4% per year, with much higher 
growth rates being reported in the former Soviet Union (6% per year) and in Eastern and 
Southern African countries most affected by HIV (5% per year) (World Health 
Organization 2003).
The latest WHO data refers to the year 2002 at which point 69% of the world population 
was covered by DOTS services (World Health Organization 2004). In that year 3.0 
million new cases of TB were reported to WHO of which 1.4 million were smear 
positive cases. The importance of adequate tuberculosis control programs is illustrated 
by the estimate that, globally, 20% of patients default or fail to respond to therapy but 
less than 2% have MDR-TB (Dye, Scheele, Dolin et al. 1999). It is those patients who 
default on therapy who are most likely to develop MDR-TB (Pablos-Mendez, Gowda & 
Frieden 2002).
Drug resistance may either arise from exogenous infection by a strain that is already 
drug resistant (primary drug resistance), or from mutation and selection of resident 
strains of tuberculosis (acquired drug resistance). Small, Shafer, Hopewell et al. (1993) 
found that in 17 patients who had developed MDR-TB, four patients had an MDR-TB 
strain with a restriction fragment length pattern (RFLP) significantly different from the
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initial drug susceptible strain. This indicated cross infection between patients leading to 
the supplanting of a resident drug susceptible tuberculosis strain with a drug resistant 
strain. The selective pressure of antibiotic usage will assist the invasion of a drug 
resistant strain, although the original drug resistant case was not identified. Van Rie, 
Warren, Richardson et al. (1999) reported exogenous infection with MDR-TB 
resembling strain ‘W’ in 2 HIV negative patients as a part of an MDR-TB outbreak 
involving 16 patients in a noninstitutionalised community. This indicates that drug 
resistance in tuberculosis infection can arise during treatment not only by acquisition of 
resistance mutations, but exogenous infection by MDR-TB.
Exogenous reinfection could be a major part of the tuberculosis relapse after successful 
treatment. Bandra, Gori, Catozzi et al. (2001) in a 5 year study in Lombardy, Northern 
Italy, identified 32 patients who had a tuberculosis relapse with a period of over 6 
months between infections. Five (16%) of these patients’ isolates had a significantly 
different IS6110 RFLP pattern in the second infection, indicating exogenous reinfection 
and not relapse of infection with the original isolate. Two of the exogenous reinfections 
were with a MDR-TB strain, however two of the reinfections were with a susceptible 
strain and one case was in the first infection an MDR-TB strain that caused two episodes 
of infection before reinfection with a susceptible strain. This indicates that reinfection is 
not just an event caused by drug resistant strains of M. tuberculosis and is not always 
driven by drug resistance.
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Despite the WHO control program, MDR-TB (defined as M. tuberculosis resistant to 
isoniazid and rifampicin) is a continuing problem. Pablos-Mendez, Raviglione, Laszlo 
et al. (1998) reported a median incidence of MDR-TB in a survey of 28 countries of 
2.2%, with a maximum incidence of 22.1% isolated in Latvia. Pablos-Mendez et al. 
(1998) reported the incidence of MDR-TB in Africa as low. This was described, as most 
likely due to the unavailability of rifampicin.
The announcement of the WHO control strategy has not, however, ended the problem of 
tuberculosis. Roselle, Danko, Kralovic et al. (2000) compared the US veterans’ anti­
tuberculosis hospital service to the US national service. Both systems used the DOTS 
strategy. The decline in reported tuberculosis in the veterans’ service was significantly 
greater than that reported by Centre of Disease Control, Atlanta (CDC) for the national 
data. Tuberculosis declined in the veterans from 35.8 to 17.7 per 100,000. The CDC 
data declined over the same period from 10.4 to 7.4 per 100,000. The incidence of 
reported tuberculosis declined by nearly 50% in the Department of Veterans’ Affairs, a 
large centrally administered health care system. The reported tuberculosis in the 
national data produced by CDC declined by 30%. The decline in reported tuberculosis 
in the veterans’ service was obtained by extensive training of staff and infection control. 
This indicates again the importance of contact tracing and effective treatment.
In the UK a divided picture emerges with TB declining in rural areas but increasing in 
urban areas, particularly London. The overall rate of tuberculosis has been increasing 
since 1988 (see figure 1.1). In 2002 there were 6,974 cases of tuberculosis in England,
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Wales and Northern Ireland (12.9/100,000 population). London contributed 3,005 
(43%) of these cases (Tuberculosis Section 2004). The incidence of drug resistance 
however remains stable about 1.4% isoniazid resistant and 1.2% being multi-drug 
resistant tuberculosis (Antoine, Gatto & Story 2003).
The division between rural and urban rates of tuberculosis is not unique to the United 
Kingdom. Hayward, Darton, Van-Tam et al. (2003) in a survey of 20 cities in Western 
Europe came to the conclusion that tuberculosis in Western Europe ‘is primarily a 
problem of large cities’.
Figure 1.1 Number of isolates in England and Wales and anti-TB drug resistance in 
initial isolates (graph taken from Tuberculosis Update 2004).
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The figures for TB rates in Europe represent the difference between western and eastern 
nations especially the former Soviet Union nations. In surveillance of tuberculosis in 
Europe (2003) it was reported that in the west, a rate of approximately 12 cases per 
100,000 is reported with declining notification rates in all but 4 nations. In the east, in 
the newly independent states of the former Soviet Union a rate of 90 per 100,000 
population was reported. The figures for primary drug resistance again show a marked 
increase in the eastern (4-12%) as against western nations (0.7%) within Europe.
Maguire, Dale, McHugh et al. (2002) estimated a recent rate of transmission of 
tuberculosis of 14.4% from a molecular epidemiological study of tuberculosis in 
London. The majority of tuberculosis in London was either reactivation of infection or 
importation by recent immigration from endemic areas. In the control and prevention of 
tuberculosis in the United Kingdom 56% of TB cases reported in England, Wales and 
Northern Ireland during 1998 were in people not bom in the UK (Joint Tuberculosis 
Committee of the British Thoracic Society 2000). The incidence of tuberculosis in 
foreign-born patients in England, Wales and Northern Ireland was reported as 63% in 
2000 and has remained at 63% in 2002 (Antoine et al 2003, Tuberculosis Section 
C.D.C.S.C 2004). Not only is the incidence of tuberculosis highest in foreign-born 
people but the incidence of drug resistance is also highest in this group. In 2000 in 
England, Wales & Northern Ireland the overall incidence of MDR-TB was about 1.2%, 
whilst in foreign-born cases the incidence of MDR-TB was 8%. Control of tuberculosis 
in the United Kingdom relies not just on adequate surveillance and treatment in the UK 
but also in potential immigrants.
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Tuberculosis has long been associated with poverty and overcrowding (Iseman 1994). 
This increase will occur predominantly in the less developed regions of the world (see 
table 1.1). The WHO has defined a mega city as a population of over 8 million. The 
numbers of mega cities are predicted to increase. The increasing concentration of 
people in mega cities, added to an increasing HIV incidence, produces an ideal 
environment for the transmission of tuberculosis. Rapid transport of people around the 
world means that tuberculosis from third world slums can spread into first world cities.
Table 1.1. World wide growth of mega cities (Horton 1996).
These are the 1996 estimates of where the number of mega cities would be formed and 
their geographical position
1970 1994 2000 2015
Less developed regions
Africa 0 2 2 3
Asia 2 10 12 19
Latin America 3 4 5 5
More developed regions
Europe 2 2 2 2
Japan 2 2 2 2
North America 2 2 2 2
World 11 22 25 33
The WHO 1989 stated that tuberculosis world-wide occurs mostly from reactivated 
disease (Anonymous 1989). HIV both predisposes the infected person to tuberculosis 
and raises the probability that the disease will re-emerge (Schurmann et al 1997). The 
lifetime probability of an immunocompetent-infected person developing clinical
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tuberculosis has been estimated as 10%. The annual probability of a patient coinfected 
with M. tuberculosis and HIV has been also estimated at 10%. HIV disease is predicted 
to increase, particularly in the less developed world, where the bulk of M. tuberculosis 
infected people live (Anonymous 1996). The increased likelihood for re-emergence of 
tuberculosis in this group is likely to lead to an increasing incidence of tuberculosis.
The increased susceptibility of HIV infected patients to tuberculosis can not be ignored 
as a factor in the spread of tuberculosis. Schurmann et al. (1997) estimated that in the 
USA, 40% of HIV positive tuberculosis patients were due to primary, not reactivated, 
disease. In the UK, tuberculosis and HIV co-infection has been estimated to contribute 
8.5% of the increase in tuberculosis notification between 1993 to 1998 (Joint 
Tuberculosis Committee of the British Thoracic Society 2000). Increasing numbers of 
highly susceptible individuals have lead to an increase in tuberculosis. This has 
occurred in the USA where the incidence of M  tuberculosis infected healthy individuals 
is low and so the probability of an HIV infected host being infected with tuberculosis is 
low.
Schurmann et al (1997) outlined factors associated with the spread of tuberculosis. 
Amongst these factors were failure to take an adequate number of anti-tuberculosis 
drugs for a sufficiently long time and failure to modify drug regimens based on 
sensitivity test results. Both of these failures can lead to increasing drug resistance in M. 
tuberculosis.
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Treatment of HIV sero-negative patients infected with MDR-TB, with treatments based 
on susceptibility data, can lead to good responses both clinically and microbiologically 
(Telzak, Sepkowitz, Alpert et al. 1995). Iseman (1993) in a review of MDR-TB 
infections found that 55-88% of MDR-TB infections responded favourably to treatment, 
the risk of failure being 80 times higher than that of drug susceptible TB infections.
Eltringham & Drobniewski (1998) report that relapses are unacceptably high in HIV 
sero-positive patients co-infected with MDR-TB if less than 18-24 months of 
appropriate treatment is used beyond culture conversion. Treatment of patients who are 
both HIV sera positive and infected with MDR-TB, may need to be continued for life 
and the outcome of treatment is less favourable than for HIV sero-negative patients 
infected with MDR-TB.
1.4 Methods of susceptibility testing M  tuberculosis
There are three basic methods of testing the susceptibility of M  tuberculosis to 
antitubercular agents. These methods are: the resistance ratio, the absolute 
concentration technique and proportion technique (Drobniewski 2002).
The resistance ratio technique uses Lowenstein-Jensen (LJ) media (Drobniewski 2002). 
This is an egg based media requiring insipisation at 80°C to both sterilise the media and 
to solidify the egg protein to form a solid slope. Heat and high protein concentration 
will affect the concentration of free antibiotic, by heat degradation and protein binding
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respectively. The effective concentration present in a batch of LJ media will vary 
between batches and antibiotic susceptibility testing must therefore determine the 
concentration of free active antibiotics as well as determine the susceptibility of the 
strain being tested. To control the media, a set of at least six known susceptible strains 
must be tested on each batch of media. The concentrations of streptomycin, isoniazid, 
rifampicin, and ethambutol routinely used in the resistance ratio technique are given in 
table 1.2a. The modal MIC of the known susceptible strain is then used as the criteria to 
judge susceptibility or resistance of the test strains. A test strain with an MIC of no 
more than double that of the modal MIC of the known susceptible strain is considered 
susceptible. A test strain with an MIC of greater than 4 times that of the test strains is 
resistant and a strain with an MIC of 8 times that of the test strains is highly resistant 
(Collins, Lyne & Grange 1989)
The absolute technique determines the MIC of a strain of tuberculosis growing on either 
LOwenstein Jensen media, Middlebrook agar or Middlebrook broth (Drobniewski 2002). 
The size of inocula needs be very carefully controlled to produce reproducible results.
The proportion technique uses Middlebrook agar or broth (Drobniewski 2002). The 
definition of resistance is growth of more than one percent of the inoculum. This 
definition of resistance controls for variation in the inoculum size. This technique has 
been reliably used in break point style susceptibility tests. In break point susceptibility 
tests an MIC of above a specified concentration is defined as resistant. Break point 
susceptibility tests measure the isolate’s ability to grow at a single drug concentration
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(the concentration defined as resistant) (Hamilton-Miller 1997). The recommended 
concentrations of streptomycin, isoniazid, rifampicin and ethambutol used in 
Middlebrook 7H10 agar are given in table 1.2b. This method of testing susceptibility 
using a single antibiotic concentration has lent itself to mechanisation and has been used 
as the basis for a number of rapid susceptibility tests (Scarparo, Ricordi, Ruggiero et al. 
2004; Marttila, Marjamaki, Viljanen et al. 2003).
The resistance ratio uses as a definition of susceptibility, the concentration of antibiotic 
that is capable of inhibiting the growth of the control strains. This is a population-based 
definition of susceptibility. This differs from the absolute and proportional techniques, 
which defines susceptibility as inhibition being exerted by a specified concentration of 
antibiotic. In practice these definitions may be very similar, and comparisons of 
susceptibility by proportional and resistant ratio techniques produce comparable results 
on clinical isolates, if differing MIC values (Laszlo, Gill, Handzel et al. 1983).
The minimal inhibitory concentrations of antibiotic in egg based media such as 
Lowenstein Jensen media can be higher than the MIC determined in more defined media 
such as the Middlebrook media (see tables 1.2a and 1.2b). Rastogi, Goh & David 
(1989) using the proportional technique on Middlebrook 7H10 agar and Ldwenstein 
Jensen media used a concentration of 40 pg/ml rifampicin in Lowenstein Jensen media 
and lpg/ml rifampicin in 7H10 agar. The concentration of ethambutol (2 pg/ml) and 
isoniazid 0.2 pg/ml were, however, the same in both media. As the antibiotic
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concentrations used in screening for resistance vary with the media used, published MIC 
figures in the literature using different media may not always be comparable.
A problem with in vitro susceptibility testing is that it tests a single criterion: the ability 
of a drug to inhibit the growth of actively growing bacteria. This ignores the need to 
affect the differing populations of M  tuberculosis described by Mitchison (1992). 
Antitubercular susceptibility tests are normally only targeted at the population of 
mycobacteria actively growing in a normal pH. The susceptibility testing of 
pyrazinamide is the obvious exception. Pyrazinamide is active only at an acid pH so 
susceptibility testing must take place in an acid environment.
There is a need to develop therapy against the full range of environments described by 
Mitchison (1992) and their accompanying infecting populations. This has led to the 
need to test new antitubercular agents against M. tuberculosis both at normal pH and 
acid pH (Salfmger & Heifets 1988; Gomes, Paul, Moreira et al. 1999), as well as testing 
the anti-tubercular agent against M. tuberculosis in rapid and slow growth phases 
(Yamori et al. 1992).
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Table 1.2a Drug concentration used to test for drug susceptibility used in resistance 
ratio technique using Lowenstein Jensen medium (Collins et al 1989).
Final concentraltion (mg/L)
Isoniazid 0.007 0.015 0.03 0.06 0.125 0.25 0.5
Ethambutol 0.07 0.15 0.31 0.62 1.25 2.5 5.0
Rifampicin 0.53 1.06 3.12 6.25 12.5 25 50
Streptomycin 0.53 1.06 3.12 6.25 12.5 25 50
Table 1.2b Drug concentration used to define resistance using proportion technique on 
solid media. Resistance being defined as growth of over 1% of inocula (Pablos-Mendez 
et al. 1998).
Drug Concentration tested (mg/L)
Isoniazid 0.2
Ethambutol 2
Rifampicin 1
Streptomycin 4
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The effect of the antibiotic does not disappear as the antibiotic falls beneath the MIC. 
Post antibiotic effect can have a major effect on dosage timing as can sub inhibitory 
concentrations. Short pulses of antitubercular drugs can inhibit the growth of M. 
tuberculosis for two to seven days (Burman 1997).
Wallis, Patil, Cheon et al. (1999) have described drug tolerance in M. tuberculosis to 
antitubercular agents. The MIC does not differ from drug susceptible strains of M. 
tuberculosis but the killing rate of isoniazid and rifampicin is reduced in tolerant 
organisms. Wallis et al. (1999) identified drug tolerance in two strains of M. 
tuberculosis where infection relapsed after successful treatment. The time taken for an 
infection to clear for rapid growth positivity, defined as growth in Bactec 460 media 
within 20 days of inoculation from a sample, has been correlated to the relapse of 
tuberculosis infection. A direct correlation between the time to clear for rapid positivity 
and drug tolerance of the bacilli was identified. Wallis et al. (1999) suggest that drug 
tolerance may be related to the ability of the bacilli to reside in the stationary phase.
This would emphasise the importance of population two in Mitchison’s model: dormant 
organisms at normal pH against which no antibiotic appears active.
The use of molecular probes to detect resistance opens the opportunity for rapid 
detection of antibiotic resistance (within 24 hours) without the need to isolate the 
organism. The low incidence of rifampicin mono resistance (0.2%) (Pablos-Mendez et 
al. 1998) makes probes for resistance to this antibiotic particularly valuable, detection of
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rifampicin resistance very frequently means the strain is multi-drug resistant. A 
commercial probe (Rossau, Traore, De Beenhouwer et al. 1997) has been developed to 
both identify the presence of M. tuberculosis and detect rifampicin resistance directly 
from samples, enabling both identification of M. tuberculosis and detection of rifampicin 
resistance within 24 hours of receipt of samples by the laboratory. However, molecular 
techniques can only identify resistance mutations identified from association with high 
MIC values determined using growth based sensitivity tests.
1.5 Activity of rifampicin and development of resistance to rifampicin
Rifampicin is in the rifamycin group of antibiotics. This group is based on the 
fermentation products of Amycolaptopsis mediteranei (Parenti & Lancini 1997).
The different antibiotics in the rifamycin group have the same activity, inhibiting the 
elongation step of RNA polymerase. Rifampicin binds to free RNA-polymerase and 
blocks the formation of a stable DNA-RNA-polymerase complex. This blockage leads 
to an accumulation of aborted RNA products (Wehrli 1983). The different side groups 
on the rifamycins affect the permeability of the antibiotic across the cell wall affecting 
the MIC and pharmacological properties (Parenti & Lancini 1997).
Resistance to rifampicin can arise either from mutation of RNA-polymerase blocking the 
binding of rifampicin to RNA-polymerase, or altered cell wall permeability inhibiting
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access of rifampicin to RNA-polymerase (Ramaswamy & Musser 1998; Hui, Gordon & 
Kajioka 1977).
The prokaryote RNA-polymerase core enzyme consists of four proteins, 2a chains, a (3 
chain and P’ chain. The binding of a sigma protein to the core enzyme creates the 
holoenzyme. The core enzyme can produce RNA from single stranded or nicked DNA, 
but is not able to bind to double stranded DNA or initiate strand separation. The 
holoenzyme is capable of recognising RN A promoter sites, separating DNA strands and 
initiating specific RNA synthesis. This indicates the sigma protein is responsible for 
RNA synthesis initiation. The sigma protein after initiation disassociates from the 
enzyme and the core enzyme continues elongation and termination of the RNA product. 
The transcription termination step can either be intrinsic, so that no other proteins are 
involved and signals beyond the termination sequence are not required, or a rho- 
dependant system exists. The rho-dependant system of transcription termination 
requires protein factors interacting with RNA-polymerase to effect termination (Von 
Hippel 1998).
Binding different sigma proteins to the core enzyme allows different initiation sites to be 
recognised and so enable different RNA transcripts to be produced in response to 
different environmental stimuli.
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Heil & Zillig (1970) recombined RNA-polymerase from rifampicin sensitive and 
resistant bacilli. Resistance to rifampicin only arose where the p ’ polypeptide from the 
resistant clone was present. The p’ polypeptide is coded for on the rpoB gene.
The rpoB gene of E. coli can mutate in three regions to confer rifampicin resistance. 
Telenti, Imboden, Marchesi et al. (1993a) used these regions as the basis for a search for 
rifampicin resistance in M. tuberculosis. Telenti’s study found a single region of the 
rpoB gene involved in rifampicin resistance in M. tuberculosis.
Permeability of the cell affects rifampicin resistance. A number of studies have 
compared the MIC of various M  tuberculosis isolates with rifampicin resistant 
mutations to different members of the rifamycin group (Moghazeh, Pan, Arain et al. 
1996; Bodmer, Zurcher, Imboden et al. 1995; Ohno, Koga, Kohno et al. 1996). These 
studies indicate that for all the rifampicin resistant mutations in the rpoB gene the MIC 
increases for all drugs of that class. However, for some rpoB mutations clinical 
susceptibility is retained for rifamycins with greater ability to cross the mycobacterial 
cell wall.
Wehrli (1983) purified RNA-polymerase from rifampicin resistant coliforms. The 
concentration of rifampicin required to inhibit by 50% the rate of RNA production, the 
ED50, of the purified RNA polymerase was then determined. Wehrli found there was no 
direct link between the MIC and the ED50 of these resistant coliforms. This indicates
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that the MIC is affected both by cell wall permeability and the binding affinity of 
rifampicin to RNA-polymerase.
1.6 Development of probes for mutation in the rpoB gene
Telenti, Imboden, Marchesi et al.( 1993b) cloned the rpoB gene of M. tuberculosis. A  
PCR was designed based on this sequence to amplify a 411 bp fragment of the rpoB 
gene from rifampicin resistant clinical isolates of M. tuberculosis. Single stranded 
conformation polymorphism (SSCP) technique was used to identify the presence of 
mutations in the PCR fragments from the rpoB gene.
SSCP identifies mutations by separation of single stranded DNA (ssDNA) on non­
denaturing gel using electrophoresis (Hayashi 1991). Single stranded DNA under non­
denaturing conditions refolds as a result of self-complementary and intramolecular 
interactions. This folding is dependent on the sequence and results in a unique three- 
dimensional shape for the DNA strand. Alteration of a single base per 400 base pairs 
alters the intramolecular interactions resulting in an altered shape.
Mutation will not always produce a recognisable change in SSCP patterns under all 
conditions (Vidal-Puig & Moller 1994). The presence or absence of glycerol (Vidal- 
Puig & Moller 1994) and temperature (Hongyo, Buzard, Calvert et al. 1993) of the gel 
can affect the sensitivity of the technique. However this technique has been used 
successfully by myself for screening mutations both in the rpoB gene (Billington,
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McHugh & Gillespie 1999) and the PZA gene (Hannon, McHugh, Billington et al. 1997; 
Davies, Billington, McHugh et al. 2000b) in M. tuberculosis.
The mutations in the rpoB gene of M. tuberculosis identified by Telenti et al. (1993a), 
were clustered in a single region coding for 23 amino acids (69bp). Telenti et al. 
(1993b) using PCR-SSCP were able to identity mutations present in clinical isolates 
from the band position on PCR-SSCP which were confirmed by sequencing.
The mutations identified by Telenti et al. (1993b) and Telenti et al. (1993a) were single 
base substitutions. A point mutation is defined where a single base is replaced by one of 
the other three possible bases (Drake 1991a). Ramaswamy & Musser (1998), in a 
review of the literature on molecular methods of resistance in M tuberculosis, reported 
that by extending the region of the rpoB gene amplified by PCR to an 81 bp core (coding 
for 27 amino acids) 96% of rifampicin resistant M  tuberculosis strains can be detected. 
Ramaswamy & Musser (1998) confirmed that the majority of rifampicin resistant 
mutations in the core region of the rpoB gene are single base substitutions (see figure 
1.2 for base substitutions identified in clinical isolates).
Ramaswamy & Musser (1998) identified a small proportion (4%) of clinical isolates 
with no apparent mutation in the rpoB gene. These rifampicin resistant isolates do not 
appear to have any mutations in the rpoB gene and the mechanism of resistance is 
unknown. Heep, Rieger, Beck et al. (2000) have identified rifamycin resistant mutations 
outside of the region on the rpoB gene identified by Telenti et al. (1993a)
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Figure 1.2 Mutations located in positions 507 through to position 533 of the rpoB gene of M  tuberculosis taken from Ramaswamy & Musser (1998). 478 
rifampicin resistant mutations were summarised in this diagram. The numbers correspond to the E. coli RNA-polymerase amino acid positions. The figures give 
the number of reported isolates. Only those mutations arising from base substitution (point mutation) are given in the diagram. The percentage of rifampicin 
resistant mutants are noted for positions 516, 526 and 531, these three positions accounting for over 80% of all rifampicin resistant isolates. 38 individual 
substitutions lead to rifampicin resistance. Of these 31 are single base substitutions (single point mutations) and 7 involve 2 base changes (two point mutations).
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1.7 The development of resistance in the host
The use of triple therapy involving isoniazid, rifampicin and pyrazinamide does result in 
occasional failure and development of antibiotic resistance. This development of 
resistance has been associated with poor compliance by the patient (Mitchison 1998). A 
patient neglecting to take all of the antibiotics prescribed is effectively subject to 
monotherapy. The unsuccessful trials of monotherapy against pulmonary tuberculosis 
indicated the necessity for combined therapy. The use of a number of antibiotics ensured 
that clones of bacilli resistant to one antibiotic are affected by other drugs being used.
The development of DOTS was to prevent poor compliance, each patient being directly 
observed to take the full drug regimen.
Antibiotics have different absorption rates across the gut and into various tissues. 
Antibiotics are similarly excreted at different rates. Pharmocokinetic data such as levels 
of antimicrobial agent present can, with varying degrees of difficulty, be determined. 
Serum levels of antimicrobial agents are relatively easily obtained and tissue levels can 
then be determined. The macrophage is the normal site of infection for M  tuberculosis 
and penetration into this site of anti-tubercular agents has been determined (see table 1.3). 
Other symptoms and concurrent diseases of the patient affect the drug absorption and 
excretion rates. Antibiotics can rise to different peaks within different regions of the 
body due to the difference in excretion and absorption rates in a similar fashion to the 
way that chemicals are separated by chromatography in the laboratory. This process leads 
to bacteria being exposed to periods of, what is effectively monotherapy..
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The extended pharmacological half-life of rifapentine can result in this antibiotic being 
present after other antibiotics simultaneously administered have been excreted. The use 
of rifapentine, a rifamycin in the same antibiotic group as rifampicin, has become 
associated with the rare emergence of mono-rifampicin resistance (Vernon, Burman, 
Benatoretal. 1999).
This model of pharmacological compartments, each with different antibiotic absorption 
and excretion rates, leading to periods of monotherapy, has been used as the basis for a 
model of antibiotic resistance development. Multidrug resistant strains accumulate each 
resistance sequentially.
Mitchison (1998) describes a ratchet mechanism based on these pharmacological 
compartments. Combined therapy is begun with all antibiotics initially present. Each 
antibiotic is then removed at different rates. This can produce a period of effective 
monotherapy during which a clone of monoresistant bacilli can expand. This clone is 
culled during effective therapy but then re-expands until such time as a multi drug 
resistant clone develops. This mechanism has been described in mathematical models 
(Lipsitch & Levin 1998).
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Drug
Isoniazid Streptomycin Pyrazinamide Rifampicin Ethambutol
Minimum inhibitory concentration 
(MIC)
<0.05 <2.0 15 <0.25 <3.8
Minimum bactericidal 
concentration (MBC)
<0.05 8 50 <0.5 30
Maximum serum concentration 
(Cmax)
3-5 25-50 45 4-16 5-5
Serum half life (Hours) 1-4 2-3 8-10 2.5-5.0 3.5-5.0
Cmax/MIC 60-100 15-25 3 8-64 0.5-1.3
Intracellular concentration 
/Extracellular concentration
0.62-0.98 3.0 1.2 5.0 9.5
MIC for extracellular bacilli <0.05 <2.0 15 0.02-0.12 1.0
MIC for intracellular bacilli <0.05 5.0 Not consistently active 0.1-0.25 20
Intracellular MIC/ExtracelluIar 
MIC
1.0 2.5 Not applicable 2.0-4.0 20
Table 1.3 Pharmokinetic characteristics of antitubercular drugs. All concentrations in jug/Litre (Burman 1997).
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Baquero & Negri (1997) uses this compartment model to describe a mechanism in which 
extended p-lactamase developed in coliforms. Extended p-lactamase is capable of 
degrading third generation cephalosporins such as cefotaxime. The initial wild type p- 
lactamase TEM-1 lacks extended P-lactamase activity. TEM-10 differs from TEM 1 by 
two mutations and TEM 12 differs by a single mutation (see table 1.4).
Table 1.4 MIC determined in an E. coli strain given site directed mutagenesis to 
construct TEM-10 and TEM 12 from TEM-1 (Baquero & Negri 1997)
p-lactamase mutation MIC cefotaxime (jug/ml)
TEM-1 none 0.03
TEM-12 Arg164Ser 0.06
TEM-10 Argl64Ser & Glu240Lys 1.0
Baquero & Negri (1997) identified the MIC of E. coli containing p-lactamase containing 
the mutations identified in TEM-12 and TEM 10 created by site directed mutagenesis. 
TEM-12, with a single mutation at position 164, has only a slightly raised MIC. Mixed 
cultures of E. coli containing TEM-1 and TEM-12 subject to 4 hours exposure of 
cefotaxime allowed selective multiplication of TEM-12 when the concentration of 
cefotaxime was between 0.008 to 0.06 pg/ml. TEM-10 was selected from mixed 
cultures of E. coli containing p-lactamase TEM 1 and TEM 12 when exposed for 4 
hours to a concentration of above 0.12 ug/ml. This led Baquero & Negri (1997) to the 
suggestion that extended p-lactamase is produced by sequential mutation. TEM-12 
containing a single mutation is primarily amplified at low concentrations of cefotaxime.
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TEM 12 then gains the second mutation leading to TEM-10 enabling growth in high 
concentrations of cefotaxime.
This model of sequential single antibiotic resistance raises the question as to whether the 
mutation rate for resistance can be determined, and what is the probability of resistance 
being present in a population.
1.8 Models of fitness and the movement of the genome in gene space
The relative fitness of a mutation, defined as the ratio of generations of the mutant and 
parental strain, can be determined. This led Wright (1932) to propose a theoretical 
fitness landscape. On this landscape all possible mutants and their respective relative 
fitness values can be plotted as a topographical map. This can lead to different 
landscapes. A single peak indicates a single optimum sequence. Multiple peaks or 
ridges on a fitness landscape indicate a number of genome sequences with equivalent 
relative fitness values.
Wright considered the evolution of a population of haploid organisms on a single peak 
fitness landscape. Wright described two types of genetic movement: selection and 
genetic drift. Selection leads the genome to climb the peak and achieve a population 
with a higher fitness than the parental strain (see figure 1.3). Genetic drift is the random 
movement of the genome across the fitness landscape, as more of the landscape has a
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lower fitness it is into this region of the fitness landscape the genome is most likely to 
travel.
The definition Wright used for fitness was the relative number of progeny produced by 
the mutant and wild type. This measure can be produced both in the laboratory and can 
be measured in the natural environment. The advantage of laboratory studies is that 
defined bacteria differing by a single allele can be tested within a single constant 
environment (Lenski & Travisano 1994). The advantage of using fitness values from 
naturally occurring populations is that all of the environmental factors affecting that 
genome are present. The disadvantage is that the alleles present in naturally occurring 
populations differ widely. This variation in fitness produced by other alleles can mask 
variation in fitness of the character tested for.
Populations that are very small are liable to be highly affected by chance mutations. 
This chance mutation occupies a disproportionately high proportion of small 
populations. Sampling error can then lead to this mutation becoming adopted as the 
mean cell type. Wright described small populations as drifting across the fitness 
landscape. The role of chance becomes of greater importance than selective pressure in 
small populations. Such a population moves at random over the landscape, it is more 
likely to occupy one of the many positions with lower fitness on the landscape than the 
few positions with improved fitness (see figure 1.3).
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The area of the fitness landscape occupied by the various genome sequences in the 
population is dependent on the mutation rate and the strength of selective forces. A high 
mutation rate or small difference in relative fitness between genome sequences will 
result in a larger area of the fitness landscape being occupied. This occupation of a large 
region of the fitness landscape indicates a high amount of genetic variation in the 
population. The amount of genetic variation is important in a changing environment. 
Selection acts where there exists in the population alleles better adapted to the 
environment than the population average. The higher the amount of genetic variation, 
the more likely it is that these ‘better adapted alleles’ exist. An optimum allele that is 
absent from the population can have no effect on that population (Bell 1997).
Eigen (1992) and Kauffman (1991) considered the size of gene space. Gene space is a 
mathematical model devised by Hamming (1980) linking the number of possible gene 
sequences of the same size with the number of steps or mutations required for one gene 
sequence to alter to a second. The size of gene space separated by a single substitution 
mutation is 3N, where N is the number of bases in the genome or gene considered. The 
size of gene space with two step mutations is 3N2 and where there are n step mutations is 
3Nn. The size of gene space increases logarithmically with increasing numbers of 
individual, or step mutations.
Eigen (1992) and Kaufman (1991) described gene space as a latticework of mutations. 
Each step on the lattice moved under selection must be such that the relative fitness
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increases. This lattice network of gene-space can lead to a number of peaks, if two 
equally optimal choices leads to opposing regions of the lattice (see figurel.4).
The assumption is that a simple hill-climbing algorithm such as described by Mitchell 
(1996) operates (figure 1.5). Large populations can behave as predicted by this hill- 
climbing algorithm. Lenski & Travisno (1994) working with E. coli and Novella et al. 
(1995) working with vesicular stomatitis virus have identified an increase in fitness with 
culture and passage of large numbers of organism.
The passage of small populations of bacteria and virus are more likely to be affected by 
genetic drift. The few surviving reproductive organisms are subject to sampling error. 
There is a high probability that disproportionately high proportions of the passaged 
organisms are of an unusual genotype. The likelihood of drift resulting in reduced 
fitness is then proportional to the proportion of the culture occupied by unfavourable 
mutants. This drift to unfavourable or rare mutants present in the initial inocula has 
been referred to as the ‘founder effect’ (Bell 1997).
The repeated passage of bacilli or virus using small inocula and culture size will 
generate few mutations. The number of favourable mutants leading to increased fitness 
is far fewer than that of unfavourable mutants leading to a decline in fitness as measured 
by the ratio of generations of parent and mutant. This technique is likely to lead to 
repeated adoption of unfavourable mutants leading to a continued decline in fitness.
This has been referred to as ‘Muller’s ratchet’ (Muller 1964).
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Figure 1.3 Population movement on a fitness landscape.
Large
population
increasing
fitness
Small
population
Difference in the genetic sequence o f each individual, from the 
genetic sequence with the highest fitness.
Genome sequences on a fitness landscape.
1. Each yellow dot represents an individual genome of the same population average 
fitness where there are n genomes. The two red dots are mutants of higher and 
lower fitness.
2. The larger the mutation rate or larger the population the more of the fitness 
landscape is covered by the population. This arises as there are more mutants 
present.
3. Each genome has a 1/n chance of being selected and dying regardless of position 
on the fitness landscape
4. The higher the position on the fitness landscape the more progeny are produced.
5. The movement of a large population is up the fitness landscape. Fitter mutants 
produce more progeny and so will if they survive become the population average. 
The fitter mutant may be selected and die but will be continually produced.
6. The movement of a small population is down the fitness landscape as more less 
fit mutants exist than more fit mutants. And the higher the probability that by 
chance the more fit population will be eliminated.
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Figure 1.4 The latticework models of gene space proposed by Eigen (1992) and 
Kauffman (1991).
The sequences consist of three letters either A or T. Sequences can move to any other 
linked sequence with a higher fitness but can not adopt fitness with a lower fitness. The 
starting genome consists of three letters AAA fitness 0.1. Change in the sequence 
produces a change in the fitness given in brackets in the diagram beside the sequence. 
The route taken by a population will be random for example the route AAA to AAT to 
ATT is a short route to optimal fitness. Alternatively the route AAA to AAT to TAT to 
TTT to ATT can also be taken. The final result is determinate depending on the fitness 
of the individual sequences. Two high fitness sequences are present TTA (fitness 0.8) 
and ATT (fitness 1.0). It is not possible for a genome of sequence TTA to adopt the 
higher fitness of the sequence ATT without passing through a period with a lower 
fitness. In this way two stable fitness peaks arise for that genome.
TTT (0.4)
TTA (0.8) TAT (0.3) ATT (1.0)
AAA (0.1)
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Figure 1.5 A hill-climbing algorithm.
The result of the algorithm is that a population of a higher fitness will be produced. This 
can be illustrated by assuming a population of organisms with a genome of 6 digits 
consisting of either 1 or 0. The fitness being the total number of Is in the genome. The 
higher the number of Is the more likely the genome is to be selected. Any mutation that 
converts a 0 to 1 will increase the fitness of that organism and so increase the likelihood 
of that genome being selected in future.
1. Start with a randomly generated population
2. Calculate the fitness of each member of the population
a) Repeat the steps three to five until n offspring have been selected.
3. Select a member of the population at random, the probability of being 
selected being an increasing function of fitness. Selection is done ‘with 
replacement’ meaning the same member of the population can be selected 
more than once.
4. Mutate the offspring at each locus with probability pm  (the mutation rate) 
and place any new mutants into the population.
5. Once n new members of the population have been selected replace the 
current population with the freshly selected population.
3. Go to step 2.
53
Clarke, Duarte, Moya et al. (1993) working with vesicular stomatitis virus repeatedly 
cultured individual plaques of virus. These plaques were derived from individual virus 
and by passaging these plaques Clarke et al (1993) restricted the culture at passage to an 
individual virus. These cultures revealed a continued decline in fitness as measured by 
the ratio of generations formed in competition with the parental strain of virus. This is 
an example of Muller’s ratchet in the laboratory. Andersson & Hughes (1996) repeated 
this methodology using Salmonella typhimurium to reveal the same decline in fitness 
attributed to Muller’s ratchet in bacilli.
Moran (1996) identified a more rapid rate of evolution in the aphid endosymbiot (genus 
Buchnera). Buchnera live in the aphid cell cytoplasm and are transmitted only to the 
progeny of the infected aphid. This introduces the low culture numbers and low passage 
number under which Muller’s ratchet can operate. The high rate of genetic drift does 
not however indicate that Buchnera are poorly adapted to the aphid. Wolbachia 
pipientis, a member of the Buchnera genus, can determine the sex of progeny of the 
infected aphid host (Vines 1999). W. pipientis infecting the host cytoplasm are not 
present in spermatozoa, and as such are only transmitted by the female aphid.
W.pipientis, by ensuring the infected aphid only produces female progeny, is able to 
ensure the maximum numbers of infected progeny are produced.
The accelerated evolution, or genetic change, introduced by Muller’s ratchet need not be 
detrimental to virulence of the infecting bacilli as in the case of W. pipientis. Individual 
clones may decline in fitness due to poor adaptation to the host but competition then
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continues between infected hosts introducing a larger population size. In this larger 
population the passage number is the number of infected aphids produced at each aphid 
generation.
M. tuberculosis is passed between patients by aerosol. This indicates a low infective 
dose. Such low inocula lead to the environment in which Muller’s ratchet can operate. 
However, the amount of genetic variation between species in the M. tuberculosis 
complex is low. As stated earlier the five species making up the M. tuberculosis 
complex have a 99.9 % similarity at the nucleotide level (Kapur, Whittam & Musser 
1994; Sreevatsan et al. 1997). This indicates that, unlike W. pipientis, there is not an 
accelerated rate of evolution.
1.9 The population size in tuberculosis infections
Tuberculosis infection undergoes a number of genetic restrictions. The infection is 
transmitted via an aerosol of droplet nuclei and a susceptible person can acquire 
infection by inhaling fewer than 10 bacilli (American Thoracic Society 2000; Barkley & 
Kupica 1994). A low infective dose indicates the infection starts with little genetic 
variation. This would enable the founder effect to have a strong influence on the 
continued tuberculosis infection. This would in turn favour genetic drift at the 
individual infected host level.
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Frost & McLean (1994) studying the evolution of drug resistance in HIV found that the 
initial distribution of genetic variation had an important effect on the resulting 
emergence of drug resistance.
Tuberculosis can undergo prolonged periods of stasis. This stasis, it is assumed, occurs 
at the heart of foci of infection. These foci are created by delayed type hypersensitivity, 
which destroys infected host cells and surrounding material creating a solid centred 
cavity. These cavities with reduced blood flow leading to reduced oxygen supply, a 
reduced pH, and inhibitory fatty acids, present a harsh and unfavourable environment for 
M  tuberculosis, a strict aerobe (Dannenberg, Jr. 1992). For these foci to become the 
source for re-emergence of tuberculosis infection, bacilli must survive these conditions 
for decades. The numbers of bacilli involved are unknown but this could again present a 
genetic restriction. The evidence that single therapy in the continued phase of anti- 
tuberculosis therapy can eliminate this population indicates low bacilli numbers.
The development of drug resistance must involve a genetic restriction; the population is 
restricted to those cells containing mutations that are drug resistant. Tuberculosis 
infection not only undergoes severe genetic restriction but can undergo massive 
population expansion within the host. This can lead to an increase in genetic variation. 
This increase of the population and genetic variation could enable selective forces to 
operate within a single host, as well as genetic drift created by genetic restriction at 
transmission and selection of essential alleles.
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The haploid reproductive system with no genetic transfer means that each genetic 
mutation produces in effect a novel lineage of bacilli. These lineages of bacilli then 
compete. The adaptation of M. tuberculosis can occur either from competition within 
the host generating fitter variants, which are then adopted within the host, or competition 
between hosts. Selection acts from competition between the frequency of infected 
individuals infected by differing lineages of bacilli.
The dogma of antibiotic control policies is that evolution of antibiotic resistance leads to 
a lower level of relative fitness (Levin, Lipsitch, Perrot et al. 1997). However it is 
possible that adaptation of M  tuberculosis to enhanced relative fitness would occur 
within the host. This would mean that a single MDR-TB case could lead to a lineage of 
bacilli as fit as the susceptible parental strain after passage within a single host. This 
would make a single MDR-TB case a possible epidemic.
The possibility of adaptation is dependent on the amount of variation prior to the 
exertion of lethal selective pressures such as antibiotic therapy. A low amount of 
variation will produce a high role for genetic drift. Allele selection for resistance will be 
dependent on the mutation rate. A large amount of genetic variation will lead to 
resistance selection being based more on the fitness of the allele.
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1.10 Mutant frequency is dependent on when the mutation occurs
Luria & Delbriick (1943) proved that mutations occur independently to the application 
of a selective pressure in haploid populations. Luria & Delbriick postulated that a 
mutation occurring in a population occurs during cell division and leads to an altered 
phenotypic character. The mutant following its creation will divide and grow in the 
normal haploid fashion.
Luria & Delbriick predicted a single regular mutation rate, this will result in a Poisson 
distribution of mutation events, with the same probability of mutation at each cell 
division. The number of mutation events will be dependent on the population size (N) 
and the mutation rate (p). The number of mutation events being on average Np.
The number of mutants will be dependent on when the mutation event occurred. A 
mutation that has only recently occurred will produce a single mutant cell. A mutant 
event occurring earlier in the broth will produce 28 cells, where g is the number of 
generations since the mutation event.
The key prediction made by Luria & Delbriick (1943) was that the mutation frequency 
will have a high variation between experiments. The time of mutation creation has a 
greater influence on the frequency of mutants than the number of mutation events. A 
distinction must be made between the mutation rate and the frequency of mutant cells. 
The frequency of mutants is the number of mutant cells per cell in the total population;
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this is more usually represented as the number of wild type per mutant. The mutation 
rate is the average rate at which mutation, the mis-incorporation or substitution of a 
base, occurs.
The mutant frequency is the product both of the mutation process, as well as the growth 
of the resultant mutants produced from mutation events. The frequency of mutant cells 
identified in a broth can vary widely. In figure 1.6 a pair of cultures are illustrated in 
which the total number of cells are identical. However in the first culture the mutation 
event occurs on the initial cell division after inoculation leading to half the cell culture 
being a part of that mutant lineage. In the second culture a single mutation event occurs 
in the last generation leading to a single mutant cell. Both cultures had a single mutation 
event, but the resulting frequency of mutants varies widely purely due to the timing of 
the mutation event.
The Luria-Delbruck distribution assumes that this mutation arises during replication of 
DNA and that the mutation event is as likely to affect any dividing cell. Jones (1994) 
illustrates the Luria-Delbruck distribution by imagining a synchronous dividing culture. 
In this culture one half of all the cells are produced at the last generation. This means as 
half of all the cells were produced in the last generation that one half of all mutation 
events are likely to have arisen in the last generation and one half of all mutation events 
will have produced a mutant cell lineage of one cell. One quarter of all the cells were 
produced in the generation before last so that in a synchronous culture one quarter of all 
mutation events are liable to have produced a mutant cell’s lineage of two cells. In a
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synchronous cell culture the probability of a mutation event at each preceding generation 
halves and the resulting number of mutant cells doubles. The probability of a mutation 
event producing a lineage of cells in this synchronous culture can be calculated as 
follows:
Equation 1.1 Cr = 1/ 2r
Where Cr is the probability of a mutation producing r cells, 
where r = 1,2,4,8,...2n.
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Figure 1.6 Illustration of 2 cultures both with a single mutation event. In figure 1.6a 
the culture ends with one half of all cells being mutants. In figure 1.6b, the culture ends 
with a single mutant cell present.
Figure 1.6.a.
Schematic diagram of a 
culture in which a 
mutation event arises early 
in culture leading to half 
the cell culture being 
derived from a single 
mutation event (filled 
circles) and half being of 
parent type empty circles.
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Figure 1.6.b.
Schematic diagram of a 
culture in which a 
mutation event arises late 
in culture leading to only a 
single mutant being 
present in the broth (filled 
circle). Time
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1.11 Measurement of the mutation rate
Two strategies for determining the mutation rate have been devised. The first strategy is 
to attempt to determine the mutation rate directly from the Poisson distribution. The Po 
technique and continuous culture techniques use this approach. The second strategy is 
to use the Luria-Delbruck distribution to attempt to determine the most likely number of 
mutation events which will have produced the mutation cell frequency identified.
Continuous culture methods of determining the mutation rate assume that there is no 
back mutation rate from mutant to wild type and the mutants grow at the same rate as the 
wild type cell. In a large culture, such that at each generation a mutant is liable to be 
produced, there will be an increase in the mutant frequency equal to that of the mutation 
rate. The mutation rate is determined by plotting the frequency of mutants against the 
total number of cells in the broth over a period of time and then calculating the gradient 
of the resulting line (Bachl, Dessing, Olsson et al. 1999; Foster 1999).
The Po technique requires a number of separate broths to be inoculated and grown to a 
standard size. The numbers of broths not containing any mutants are then recorded. The 
number of mutation events in broths containing mutations, is unknown, but the number 
of mutation events in broths mutant free is known. As the rate of mutation follows a 
Poisson distribution, this can be used to calculate the average number of mutation events 
per broth (see equation 1.2).
Equation 1.2 m=-ln Po
Where m is the average number of mutation events that have occurred in a series of 
broths and Po is the proportion of those broths in which no mutants were identified. The 
equation 1.2 assumes that all of the broth was sampled. Jones (1993) has calculated an 
equation for the Po technique taking into account only partial sampling of each broth.
The mutation rate is then calculated by dividing the average number of mutation events 
by the average cell numbers in each broth. This technique requires a simple scoring 
system: mutant cells being present or absent.
The frequency of mutants and the Luria & Delbriick distribution has been used as the 
basis of a number of methods for calculating the mutation rate. The use of the Luria 
Delbriick distribution to calculate the mutation rate requires that a series of broths need 
to be cultured so that mutants are present in all of the broths. The frequency of the 
mutant cells in these cultures is then determined. The mean number of mutants has been 
used to calculate the mutation rate. However, the effect of a single large mutant 
frequency can greatly affect the mean value and the median number of mutants is more 
accurate when used to calculate the mutation rate (Stewart 1994). Formulae for the 
calculation of mutation rate from the median number of mutants is given in section 2.11.
The most common lineage size or modal lineage size in the Luria-Delbriick distribution 
is one cell. The mean mutant lineage size is however greater than one. The normal and
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Poisson distribution requires both the mean and median to be the same, where they differ 
there is a skewed distribution. Parametric statistical tests such as the t test based on the 
normal distribution should not be used to compare mutant frequencies. Non-parametric 
statistical tests such as the Mann-Whitney U test, which makes no assumption on the 
distribution, should be used where such skewed distributions are found.
1.12 The number of mutants in a large population
M. tuberculosis has no transferable mechanisms of resistance. Development of 
resistance is almost solely by chromosomal mutation and selection of those resistant 
mutations. Resistance due to insertion sequences disrupting the pyrazimidase gene to 
produce resistance have been reported (Lemaitre et al. 1999). Resistance by insertion 
sequence as with point mutations is not transferable between strains and so will act 
similarly to mutations but with different mutant frequencies. The mutations associated 
with the development of resistance to various antibiotics have been reviewed (Blanchard 
1996; Ramaswamy & Musser 1998; Zhang & Young 1994). This raises the question: 
what is the probability of an antimycobacterial agent resistance mutant being present, in 
a population of M tuberculosis, at the start of therapy?
The number of bacilli in a mutant clone will be 2s , where g is the number of generations 
since the original mutation event forming that clone. It is apparent that there will be 
more mutants as g increases. The more generations that have occurred in a culture, the 
higher the likelihood that a mutant clone exists in which g is greater than 1. This means 
the larger a culture, the more mutants are liable to be present and to have grown. In this
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way the number of bacilli in culture will determine both the likelihood that a mutant is 
present and the number of mutants which are liable to be present.
A continuous culture in which a culture of constant cell frequency is maintained for a 
number of generations can undergo an infinite number of generations. The build up of 
mutant cell numbers will be dependant on the death rate of the mutant cell type in 
addition to the number of freshly created mutants and growth rate of the existing 
mutants. That is the fitness of the mutant defined as the ratio of generations of mutant 
formed per parent type cell generation.
Armitage (1952) outlined the relationship in the simple model outlined in figure 1.7.
The normal cell can mutate to form mutant cells, and the mutant cells can mutate back to 
form normal cells. Both mutant and normal cells replicate. In this way an equilibrium 
can be achieved between mutant and parent cell type.
Figure 1.7 The growth of mutants (M) and normal cell types (N).
M
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The exclusion of the mutant cell type by competition with the fitter wild type cell 
formed in a suitably large culture does not mean the elimination of the mutant cell type. 
A mutant cell with zero growth rate and the same death rate as the normal ‘parent cell 
type’, can at each generation be formed afresh by mutation, if the parent cell culture is 
large enough. If one considers an idealised culture in which 10 new mutants are formed 
at each generation, these mutants are incapable of growth and die at a rate of 0.5 per 
generation. An equilibrium will be established in which the death rate is matched by the 
birth (mutation) rate (see figure 1.8). The mutant cell population will continue to 
expand until the number of dying cells exactly matches the fresh mutant numbers. That 
is 10 new fresh mutants formed from the parent cell population are matched by 10 
deaths in the existing population.
An increase in the growth rate of mutant cells, from either an increased mutation rate of 
the wild type, or growth of existing mutants, will enlarge the number of freshly created 
mutants at each generation. To achieve equilibrium this must be matched by a larger 
number of deaths at each generation. Given a constant death rate of 0.5 per generation 
in a continuous culture this will produce a larger number of mutant cells forming 
equilibrium with their parent cell type.
This simple model predicts that, given a large population, a continuous pool of mutant 
cell types will be available. Drake (1991b) has identified a constant mutation rate of 
0.0033 per generation for DNA based organisms. This mutation rate will ensure 
continuous creation of fresh mutants, although not necessarily the same mutant.
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Those mutant types that are both fortunate and relatively rapidly growing compared to 
the parent cell type may remain as a constant source of phenotypic variation under 
altering environmental conditions, assuming a large population.
This simple model works only where the mutant cell type has a lower fitness than the 
parental cell type. The mutant cell type comes to predominate if the relative fitness of 
the mutant is greater than the parent cell. The mutant frequency will match the parent 
cell type where the relative fitness of both parent and mutant is the same.
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Figure 1.8 Production of a pool of mutants in a continuous culture. Each filled circle
represents a single mutant cell.
Generation 1
10 fresh mutants formed 
Growth zero 
5 mutants die (0.5)
5 survivorso o o o o
.
Generation 2
10 fresh mutants + 5 survivors = 15 mutants
Growth zero
8 mutants die (0.5)
7 survivorso o o o o oo1
Generation 3
10 fresh mutants + 7 survivors = 17 mutants
Growth zero
8 mutants die (0.5)
9 survivorso o o o o o o o o4
Generation 4
10 fresh mutants + 9 survivors = 1 9  mutants
Growth zero
10 die (0.5)
9 survivorso o o o o o o o o
r
Generation 5
10 fresh mutants + 9 survivors = 19 mutants
Growth zero
9 die (0.5)
10 survivorsoo o o oo o o o o
f
All future generations
10 fresh mutants + 10 survivors = 20 mutants
Growth zero
10 die
10 survivorso o oo o o o o o o
6 8
1.13 The rate of emergence of an advantageous mutation is dependent on the 
advantage produced by the mutation
Mayr (1997) describes two forms of selection: lethal and growth selection. Both of 
these forms of selection act by a single method, differentiated by the pace in which one 
clone rises to predominance. Lethal selective pressure is present where only one clone is 
able to survive. This leads to a more rapid rise to predominance than non-lethal or 
growth selection. The rise to predominance of rifampicin resistance over susceptible 
bacilli in M. tuberculosis is obviously under a lethal selective pressure.
Mutations that are selected by growth selection take longer to rise to predominance than 
those selected by lethal selection. Koch (1981) considered the time taken for small 
growth differences to lead to the emergence of a new mutation. Koch calculated that the 
rate of emergence of the more favourable mutation is dependent on both the rate at 
which the mutation arises and the growth differential between mutant and parental cell 
type. The effects of chance must be added to the time taken for small numbers of more 
rapidly growing mutants to rise in frequency to predominate in a culture. A small 
number of bacteria are more likely to be eliminated by a chance effect than are large 
numbers. Schuster & Sigmund (1989) in a series of tables calculated the probability of a 
single mutant replacing the parental population, assuming a constant population size. 
Schuster and Sigmund found that, as the growth differential increased, the probability 
that the mutant would supplant the parental strain also increased. The single mutant 
occupies initially 1/N of the population and so this is the probability that it will be
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selected by chance from the population. If the advantageous allele is rejected by pure 
chance in the first generation it can not then rise to predominance. Schuster and 
Sigmund describe a ‘boundary layer’ beyond which an advantageous mutation is not 
likely to be rejected by chance. The more rapidly the mutant grows, the faster it 
achieves this ‘boundary layer’ and so is unlikely to be rejected by chance.
1.14 Does a high mutation rate bring evolutionary advantages?
Taddei, Radman, Maynard-Smith et al. (1997) using mathematical modelling techniques 
found that cells with increased mutation rates could come to predominate in a 
population. Cells with high mutation rates were described as mutators. The larger range 
of variation generated by the mutator strains enable them to rapidly locate favourable 
mutations. The mutator also created unfavourable mutations, which reduced the 
genome’s fitness and so acted to select against the mutator phenotype. The advantage of 
an increased mutation rate is limited as both favourable and unfavourable mutations are 
created, unfavourable mutations being generated far more frequently than favourable 
mutations. Taddei et al. (1997) described how the mutator phenotype ‘hitchhiked’ on 
the selective advantage of advantageous mutations. The mutator phenotype evolved due 
to selection for the advantageous mutation provided by the wide range of mutation 
produced by the mutator phenotype, but not directly due to the mutator phenotype. The 
mutator advantage is at its greatest when there are a large number of possible 
advantageous mutations and the population spends a long time waiting for these 
advantageous mutations to arise. Mutators are at a disadvantage when there is either no
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or a limited range of advantageous mutations possible and when this produces too high a 
mutation rate.
Negri, Morosini, Baquero et al. (2002) found that mutator Streptococcus pneumoniae 
produced an advantage in acquiring antibiotic resistance. Two strains of S. pneumoniae 
R310 and R800 were used. Strain R310 had a mutation rate raised approximately 10 
times due to mutations in the methyl mismatch repair mechanism. Strain R800 was the 
wild type with no raised mutation rate. Both strains had the same MIC to cefotaxime 
0.008 pg/ml. The mutation rate to cefotaxime resistance was estimated at 3.7 x 10‘7 for 
R310 and 1.13 x 10‘8 for R800. Populations of about 2.2 x 107 CFU/ml were exposed to 
low concentrations of cefotaxime varying from 0.002 to 0.06 pg/ml for periods of up to 
8 hours. The proportion of R310 in the mixed cultures rose as the concentration of 
cefotaxime increased. After 8 hours of exposure there was no increase in the proportion 
of the strain R310 for concentrations of cefotaxime below the MIC (0.008 pg/ml), but 
above this concentration R310 occupied approximately 95% of the surviving population. 
The surviving populations were identified as having acquired a mutation in the pbp2x 
gene (Thr550 —►Ala), this is associated with resistance to cefotaxime.
Experimental populations not seeded with mutator phenotypes in an environment 
requiring adaptation have enabled mutation cell types to emerge. Sniegowski, Gerrish & 
Lenski (1997) cultured E. coli in a glucose-limited environment and identified clones 
with rapid mutation rates coming to predominate in 3 out of 12 populations.
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Raised mutation rates have been identified in clinical isolates. LeClerc, Li, Payne et al. 
(1996) identified one percent of E. coli and Salmonella enterica with raised mutation 
rates. This, it was hypothesised, ‘may help explain the rapid emergence of antibiotic 
resistance’. Raised mutation rates have been associated with ciprofloxacin resistance in 
E.coli. The raised mutation rate will have enabled a larger number of mutants to be 
produced and so enabled mutator bacteria to accumulate ciprofloxacin resistant 
mutations more rapidly. Lindgren, Karlsson & Hughes (2003) identified a strong 
correlation between the mutation rate and increasing ciprofloxacin resistance in 54 
clinical isolates from patients with uncomplicated urinary tract infections.
It is worth considering the advantage conferred by this raised mutation rate. The 
probability that a specific mutation is present is dependent on the population size. The 
average number of a specific mutation (p) with a mutation rate given by p present is 
given by the equation p=Np, where N is the population size. Increases in population 
size or mutation rate will increase the average number of mutations. If Np is equal to 1 
then there will on average be one mutation in the population. However, as this is an 
average there will sometimes be more than one and sometimes no mutations. What is 
the probability of a mutation being present?
The average number of mutations can be used to calculate the probability of no mutation 
present. This in turn can be used to calculate the probability of there being at least one 
mutation, if the average number of mutations is known. The probability that a mutation 
is absent is calculated from the Po calculation.
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Equation 1.3 Po = e
Where Po is the probability of there not being a mutation 
p is the mutation rate and N is the population size.
The probability there is at least one mutation present (Pm) then 
becomes 1-Po.
A graph of the probability of at least one mutation being present for S. pneumoniae 
mutation rates to cefotaxime based on the rates identified by Negri et al. (2002) for R310 
- a mutator strain and R800 - the wild type, at different population sizes, is given in 
figure 1.9. This graph is a sigmoid curve. The advantage conferred by the high 
mutation rate being the difference between the two curves and is shown as the curve 
R310-R800. It is apparent that this advantage has a peak at a population size of 107 and 
this advantage declines at larger or smaller populations. The population size used by 
Negri et al. (2002) was 2.2 x 107 cfu/ml. A larger population may have enabled the 
lower mutation rate R800 isolate to produce cefotaxime resistant mutants more 
frequently. A smaller population would have made the mutation less likely in both 
strains. This would have reduced, or eliminated, the advantage of the raised mutation 
rate in R310.
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Figure 1.9 Probability o f at least one cefotaxime resistant mutant being present in strain R 310 and R800 of 
Streptococcus pneumoniae and the difference in probability between these two strains 
(R310-R800) at different population sizes. Mutation rates taken from Negri et al. (2002)
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The probability that a mutation is present in a continuous culture will be dependant not 
only on population size but the fitness of the mutant and so the probability of that 
mutation remaining in the population instead of being diluted out of the population. The 
frequency of a clone of cells in a continuous culture will be proportional to p/S, where p 
is the mutation rate, and S is the fitness deficit of the clone. The equation for calculating 
the fitness deficit is:
S= 1-(growth rate of fastest clone/growth rate of individual clone).
As the individual clone’s growth rate approaches the growth rate of the fastest clone so 
p/S increases and the proportion of the population occupied by that clone increases (Bell 
1997).
The presence of a number of advantageous mutations may be expected to lead to an 
increase in the rate of adaptation in a bacterial culture. This advantage is obtainable 
both by raised mutation rate or larger population size. Arjan, Visser, Zeyl et al. (1999) 
examined the rate of adaptation in populations of E. coli in a novel environment for 
1000 generations in which the amount of variation was kept constant in both a mutator 
and wild type population. The mutation rate was raised by inserting repair deficient 
copies of mutS and mutY into a repair proficient strain. The cultures of both wild type, 
mutS and mutY were set to a constant effective population size, that is the calculation 
pN was kept constant between populations. Given the larger mutation rates (p) in the
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mutS and mutY populations, this meant using a larger total population (N) in the wild 
type culture at passage. All of the cultures adapted at the same rate regardless of the 
mutation rate given the same effective population size.
The critical figure is not the mutation rate but the amount of variation. Increasing the 
mutation rate or the population size can increase the amount of variation.
Genetic drift can enable unfavourable alleles as well as neutral alleles to be adopted. 
Increased mutation rates increase both favourable and unfavourable mutations This in 
turn makes mutator cell lines more prone to genetic drift under severe population 
restriction. Zeyl, Mizesko & de Visser (2001) studied the evolution of Saccharomyces 
cerevisiae for 2900 generations in 12 replicate populations under conditions of genetic 
restriction. Two of the populations suffered extinction and in both the populations 
mutator cells came to predominate just prior to extinction. The probability of a less 
favourable mutation being adopted is dependent on the proportion of the population with 
less favourable mutations. The presence of too high a variation in combination with 
severe genetic restriction can lead to a decline in fitness to that environment.
The evolution of drug resistance in M tuberculosis is associated with continuous genetic 
restriction both in transmission between patients and when the single drug resistant cell 
is selected. This may produce a restricting factor on the evolution of mutator 
phenotypes. The large bacilli numbers in pulmonary tuberculosis may mean that there is 
already a large range of genetic variation in the population so that the mutator phenotype
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provides no advantage. The Beijing strain, a widely disseminated strain associated with 
antibiotic resistance, does not have an increased mutation rate (Wemgren & HofFner 
2003).
Jacob (1977) describes selection as not only acting to eliminate detrimental mutations 
and favouring beneficial mutations, but ‘in the long run it orders them (mutations) into 
adaptively coherent patterns’. The driving force of selection is genetic variation in the 
population prior to selection.
Nilsson, Berg, Aspevall et al. (2003) identified resistance mutations to fosfomycin, an 
antibiotic used to treat urinary tract infection (UTI) to be associated with very low 
fitness. This low fitness resulted in a growth rate 10% to 25% lower than the 
fosfomycin susceptible strains. The high turn over rate of E. coli in the bladder and the 
low growth rate means that fosfomycin resistance was rapidly eliminated from the 
population in the absence of fosfomycin. This may explain why fosfomycin resistance 
is identified at a rate of about 1% of infections in countries both using and not using 
fosfomycin. This occurs despite calculations by Nilsson et al. (2003) from the rate of 
mutation rate (10‘7) and the bacterial load during UTI (>105 bacteria per ml) that 
fosfomycin resistance should be common (10‘2). The low fitness of fosfomycin 
resistance means that variation in resistance is absent prior to exposure to the selective 
pressure of fosfomycin.
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Shimao (1987) did not use the mutation rate but the probability of a mutation being 
present to identify the probability of drug resistance emerging. This requires knowledge 
of the effective population (Ne) or the amount of variation that is present in the 
population. The mutation rate is the generator of that variation but not its sole 
determinant. The mutation rate can also be dependant on the environment. The 
presence of mutagenic compounds will raise the mutation rate. Such mutagenic 
chemicals surround M. tuberculosis particularly in those populations inhabiting the 
inflammatory or necrotic loci, Boshoff, Durbach & Mizrahi (2001) outline many of 
these factors. This indicates that the mutation rate assessed in vitro may not be as high 
as that identified in vivo especially where the bacterium is being damaged by a 
successful immune response.
1.15 Essential mutations carry a physiological cost, this can be compensated for 
by other mutations
The basis of antibiotic policy is that variation of selective pressure will retard the 
emergence of antibiotic resistance (Levin et al. 1997). There is some debate as to 
whether antibiotic resistance carries with it a concomitant physiological cost (Gillespie 
& McHugh 1997).
There is evidence both for and against this physiological cost in M. tuberculosis. The 
reversion to susceptibility of streptomycin resistant M. tuberculosis suggests a 
physiological cost (British Medical Council 1950). However, isoniazid resistant M
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tuberculosis does not revert despite an apparent virulence advantage in susceptible M. 
tuberculosis (Medical Research Council 1953b). Isoniazid susceptible strains can 
accumulate but not come to predominate (Fox, Ellard & Mitchison 1999).
The presence of compensatory mutations is evidence for a physiological cost. 
Compensatory mutations ameliorate the physiological cost of a mutation without 
reversing the phenotypic alteration. An example of this is streptomycin resistance 
arising from mutation in the rpsL gene. This gene codes for the ribosomal protein S12 
and so can affect the rate of protein synthesis. Schrag & Perrot (1996) adapted E. coli 
resistant to streptomycin by continuous culture of a clone with a mutation in the rpsL 
gene. The non-adapted strains of E.coli, fresh streptomycin resistant mutants, were less 
able to grow in competition with susceptible strains. This growth inhibition was 
reflected in less rapid protein synthesis. The adapted strains of E. coli had a reduced 
phenotypic cost associated with streptomycin resistance and protein was synthesised at a 
faster rate (see table 1.5).
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Table 1.5 Adaptation to streptomycin resistance in E. coli based on the work of Schrag 
& Perrot (1996). The reduction in fitness deficit with adaptation is accompanied by an
increased peptide chain elongation rate.
Strain Evolutionary
status
DNA sequence at 
amino acid position 
42 of the rpsL gene
Cost of 
resistance (% 
per generation ± 
S.E)
Peptide chain 
elongation rate 
(amino acid per 
second, ± S.E)
STR1 Baseline ACA (Thr) 13.6 ±0.57 10.60 ±0.70
STR1-1 Evolved ACA (Thr) 6.97 ±0.6 17.54 ±1.1
STR1-2 Evolved ACA (Thr) 4.63 ± 0.55 17.93 ± 1.6
STR2 Baseline AAC (Asn) 18.8 ±0.79 8.74 ±0.56
STR2-1 Evolved AAC (Asn) 9.55 ± 1.3 18.45 ± 1.59
STR2-2 Evolved AAC (Asn) 6.68 ±0.51 18.47 ± 1.77
The adaptations to antibiotic resistance need not be of advantage in the susceptible 
genetic background. Isoniazid resistance is associated in M  tuberculosis with loss of the 
catalase enzyme (Zhang, Dhandayuthapani & Deretic 1996).
Mutations in the ahpQ gene are reported as associated with loss of the katG gene 
(Kelley, Rouse & Morris 1997; Rinder, Thomschke, Rusch-Gerdes et al. 1998). 
Sherman, Mdluli, Hickey et al. (1996) identified a higher susceptibility of M. bovis BCG 
lacking the katG gene to hydrogen peroxide: the katG gene product is catalase, an 
enzyme that converts hydrogen peroxide to water and oxygen, and so protects the cell 
from hydrogen peroxide. This indicates that resistance to isoniazid may make M. 
tuberculosis more susceptible to the oxidative burst of the macrophage.
The ahpC gene codes for alkyl hydroperoxide reductase, over production of the gene 
product ahpC can help protect against hydrogen peroxide. This over production of alkyl
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hydroperoxide reductase entails a physiological cost. This physiological cost will inhibit 
the ability of resistant strains to compete in the absence of hydrogen peroxide. This cost 
need not be borne by an isoniazid susceptible strain retaining catalase activity in the 
absence of isoniazid. Compensatory mutations in the ahpC gene enhance the fitness of 
the isoniazid resistant cell but not the fitness of an isoniazid susceptible cell.
Lenski (1988) studied the adaptation of E. coli to the selective pressure created by a 
plasmid. The initial insertion of the plasmid led to a decline in the ability of E. coli to 
compete with E. coli lacking the plasmid. This physiological cost declined on passage 
of E. coli in the presence of the plasmid. Lenski then removed the plasmid from the E. 
coli clone adapted to the presence of the plasmid. This removal of the plasmid lead to a 
decline in the cell’s relative fitness. Lenski concluded that the cell adapts to its total 
environment and alteration in that environment, including alteration of accompanying 
genes, affects the cell’s ability to compete.
The growth of haploid cells with no means of genetic exchange means that all cells 
effectively create their own separate lineage of cells. These different lineages must then 
compete on their ability to grow. Separate advantageous mutations arising on separate 
lineages must compete with only the most fortuitous or best-adapted rising to 
predominance.
The continuous growth of haploid cells in the same genetic environment enables a strong 
linkage between genes to develop. Bell (1997) states that linkage between genes such as
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pleotophy, where a single gene can affect a number of characters and epistasis where 
two or more genes affect the combined production of fitness, is increased in haploid 
cells. Each gene will have evolved in the same environment and optimal characters for 
that genetic environment will be produced.
The development of antibiotic resistance may or may not carry a physiological cost. 
Antibiotic resistance that compromises a virulence factor will obviously reduce the 
virulence of a bacillus, however MDR-TB is capable of causing disease (Department of 
Health 1998b; Pablos-Mendez et al. 1998). The development of a physiological cost, 
although not a recognised virulence determinant, will affect that clone’s ability to grow.
Selection can discriminate between cells with very small differences in fitness. The cell 
has evolved a characteristic G.C ratio and preferential usage of specific codons. The 
G.C ratio varies between cells. Insertion sequences and pathogenicity islands are 
recognisable from the alteration in G.C ratio compared to other genome contents 
(Groisman & Ochman 1996). The time since insertion can be estimated from the degree 
of variation in G.C ratio from the other genome contents. This indicates a selective 
pressure, selecting those mutations that lead the pathogenic island to contain a G.C ratio 
closer to the normal cell ratio. A very small loss of fitness associated with antibiotic 
resistance will over time affect the likelihood of that resistance remaining in a bacterial 
population.
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The codons in rapidly produced genes characteristically are those in which the cell has 
most tRNA molecules. The time delay introduced by codons for unusual or low 
frequency tRNA molecules introduce a slight physiological cost in the delayed 
translation of a gene (Sharp, Stenico, Peden et al. 1993; Wright 1990).
The adaptations of G.C ratio and codon usage in the genome indicate that adaptation is 
capable of differentiating very small differences in the growth abilities of haploid cells.
1.16 Fitness estimates of isolates with drug resistance in Af. tuberculosis
Reversion to susceptibility of drug resistant isolates in the absence of the drug is 
evidence that resistance has an associated disadvantage. The earlier trials with 
streptomycin and PAS identified that M  tuberculosis that became streptomycin resistant 
during treatment had high rates of reversion to streptomycin susceptibility if treatment 
was stopped. This reversion was identified as due to the higher growth rates of 
susceptible strains. The higher growth rate allowed any surviving streptomycin 
susceptible clones to out-compete a resistant strain in the absence of streptomycin 
(Mitchison 1950). Streptomycin resistance is still common. Pablos-Mendez et al. 
(1998) reported that the median frequency of mono M. tuberculosis streptomycin 
resistant world-wide was 2.5%.
There is some evidence that isoniazid resistance can reduce the virulence of M. 
tuberculosis in guinea pigs. Middlebrook and Cohn (1953) found that animals infected
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with a strain of H37Rv isoniazid resistant survived for over 60 days. Guinea pigs 
infected with H37Rv isoniazid sensitive died between 19 and 25 days after infection.
The isoniazid resistant strain lacked detectable catalase activity. Isoniazid is activated 
by the activity of catalase, however as discussed earlier, this is also a defence against the 
macrophage oxidative burst. Li, Kelley, Collins et al. (1998) infected BALB/c mice and 
guinea pigs intravenously with H37Rv both lacking catalase activity and with catalase 
activity. The catalase lacking H37Rv was unable to persist in the spleens of the mice or 
guinea pigs. Transformation of the H37Rv lacking catalase activity with the catalase 
gene from either M tuberculosis or M.intracellulare returned catalase activity and the 
ability to persist in the spleen of mice and guinea pigs. Transformation with an M. 
tuberculosis catalase gene with the mutation T275P returned only partial catalase 
activity. M. tuberculosis H37Rv strains with the mutation T275P were unable to persist 
in the guinea pig spleen, although they were able to persist in mouse tissues.
Isoniazid resistant strains of tuberculosis failed to revert to susceptible on removal of 
selective pressure (Medical Research Council 1953a; Medical Research Council 1954). 
This failure to revert to susceptible occurred despite M. tuberculosis with high resistance 
to isoniazid having a reduced virulence in guinea pigs. The failure of isoniazid 
resistance to revert to susceptible in the absence of antibiotic could be explained if 
susceptible strains were entirely absent. The use of isoniazid in combination with 
thiacetozone did produce favourable responses in at least 10 out of 30 patients with 
primary isoniazid resistant tuberculosis infection. The response of patients with primary 
isoniazid resistant tuberculosis to isoniazid in the first 3 months was not related to the
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MIC of the infecting strain, but the response was related to the amount of growth on the 
slope containing 0.2 ug Isoniazid per ml. Fox et al (1999) state this favourable response 
to isoniazid implies at least a portion of the infecting tuberculosis had reverted to 
susceptibility to isoniazid.
Transmission of M. tuberculosis with primary isoniazid resistance has been well 
reported. This leads to the suggestion that the difference in virulence in the guinea pig 
was an experimental artefact. However there is evidence of a decreasing isoniazid MIC 
in transmitted primary resistant tuberculosis (Fox, Ellard & Mitchison 1999).
Cohen, Sommers & Murray (2003), in a review of the effect of drug resistance on the 
fitness of M  tuberculosis, found that population based studies of fitness in MDR-TB 
produced a wide variation in fitness. From this variation he concluded that the fitness of 
M. tuberculosis is very heterogeneous and ‘this variation may preclude our ability to 
predict future trends of this pathogen’. This implies that genetic drift has a major role in 
M. tuberculosis evolution and that the differential reproductive ability or infectivity of 
strains of M  tuberculosis and the selective pressure this exerts will have less effect than 
the role of chance. I intend to address the roles of genetic drift and selection in the 
evolution of drug resistance in M  tuberculosis to test whether there is a role for 
selection.
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Chapter 2 
Methods
2.1 Maintenance, storage and bacteria strains used
Isolates were maintained by growth at 37°C on Lowenstein Jensen media (Southern 
Group Media), 7H9 broth (0.1 % tween 80, Difco, Hemel Hempstead, United Kingdom) 
BACTEC 12B media (Becton Dickinson, Oxford, United Kingdom) or growth on 
Middlebrook 7H10 agar. Isolates were stored by freezing at -20°C in fresh 7H9 broth. 
All culture work was carried out at the Royal Free Hospital under category 3 
containment safety rules (Health and Safety Executive 2002).
2.1.1 Isolates used:
2.1.1.a M tuberculosis H37Rv ATCC 9360 (National Collection of Type 
cultures, Central Public Health Laboratory, London, United Kingdom).
2.1.1.b Strains ET and AT are isolates from a pair of related patients. The 
isolates have an identical PGRS and IS6110 typing patterns (Davies, Billington, 
Bannister et al. 2000a). Full details given are given in chapter 5.
2.1.1.c Three isolates from a patient who was the source of an outbreak of 
MDR-TB in a London Hospital were obtained (Breathnach, de Ruiter,
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Holdsworth et al. 1998). One isolate from each of two patients who were a part 
of the outbreak was also obtained. The isolates from the source patient were 
labelled S-l, S-2 and S-Brompton. The isolate S-Brompton was obtained from 
the Brompton Hospital. The isolates from the two patients in the outbreak were 
labelled X and Y.
2.2 DNA extraction
To extract DNA from M. tuberculosis 1-ml of Middlebrook 7H9 broth culture was 
centrifuged (12,000-x g for 5 minutes) in a 1.5-ml microcentrifuge tube, and the 
supernatant discarded. The deposit was heated to 80°C for 20 minutes in a water bath to 
kill all M  tuberculosis. An aliquot of 100 pi of chloroform was added to the deposit and 
vortexed for 30 seconds. The sample was then centrifuged 12,000 g for 1 minute and 
the aqueous layer was retained for use in the subsequent PCRs (Wilson, McNemey, Nye 
et al. 1993).
2.3 rpoB Polymerase Chain Reaction methods (PCR)
Two PCR reactions were designed around the rpoB gene: PCR-120 which produced a 
PCR product 120 bp long and was used for SSCP-PCR analysis and PCR-411 which 
produced a PCR product 411 bp long and was used for sequencing. Telenti et al.
(1993b) sequenced the rpoB gene and PCR-120 and PCR-411 were designed based on 
this sequence.
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Telenti et al. (1993a) identified the rpoB hot spot leading to rifampicin resistance. 
Ramaswamy & Musser (1998) described the hot spot as 81 bp long between codons 
507-533. Both PCR-120 and PCR-411 were designed to amplify this region. The 
sequence of this region is given in figure 2.1. The two positions where mutation is most 
frequently clinically isolated leading to rifampicin resistance are marked with an 
asterisk.
A separate PCR product was required for SSCP and sequencing. SSCP requires a short 
stretch of DNA, which can not then be reliably sequenced. SSCP detects small changes 
in the conformation of single stranded DNA. As the DNA reanneals the folding is 
dependent on the formation of intramolecular bonds. Hayashi (1991) recommends a 
PCR product of less than 400 bp and Telenti et al. (1993b) produced a reliable result 
from PCR-SSCP of a PCR product 157 bp long from this region of the rpoB gene.
2.3.1 Polymerase Chain Reaction and Single Strand Conformation Pattern (PCR- 
SSCP)
The region of the rpoB gene identified previously by Telenti et al. (1993a) as a hot spot 
for rifampicin resistance was amplified by PCR. The primers employed were 5’-AGT 
TCT TCG GCA CCA GC-3’ and 5’-CGC TCA CGT GAC AGA CC-3\ The optimum 
reaction mixture was 1.5 nM. MgCl, 150-mM deoxynucleoside triphosphates, 5 U of 
Taq polymerase enzyme, and 500 pM primers for each PCR in a total volume of 90 pi. 
An aliquot of 10 pi of the M  tuberculosis DNA extract was added. The optimal PCR 
cycling conditions were one cycle 95°C for 1 minute and 30 cycles of 94°C for 1
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minute, 65°C for 2 minutes and 72°C for 3 minutes. This was followed by strand 
elongation for 7 minutes at 72°C. This produced a 120 base pair amplimer that was 
designated PCR 120. The size of the PCR product was confirmed by running a lOul 
aliquote of the PCR product on a 1.5-% agarose gel containing ethidium bromide to 
make the DNA visible under UV light. The size of the PCR product was estimated from 
comparison with a DNA ladder composed of phage ADNA.
The amplimers were analysed by single strand conformation polymorphism (SSCP) 
analysis. The PCR 120 product (6pl) was denatured at 95°C for 10 minutes with 3pi of 
SSCP loading buffer and 3pl of stop dye (Promega, Southampton, United Kingdom). 
Samples were quenched on ice and then loaded directly onto a 0.5% mutation detection 
enhancement acrylamide analogue gel (Flowgen, Lichfield, United Kingdom). The gel 
was run for 6 hours at 6 watts with 0.6 x Tris-borate-EDTA (Sigma, Poole, United 
Kingdom) at room temperature. DNA bands were visualised by the silver-staining 
technique, following the manufacturers instructions (Promega).
2.3.2 Polymerase Chain Reaction methods (PCR) for sequence analysis of the 
rpoB gene
An ampilimer 411 bp long was prepared for direct sequence analysis, and this amplimer 
was designated PCR411. The primers published by Telenti et al. (1993a) 5’- TAC GGT 
CGG CGA GTG ATC AA-3’ and 5’-TAC GGC GTT TCG ATG AAC C-3’ were used; 
the optimised reaction mixture was 50 mM KC1 buffer, 1.5 mM MgCL, and 150 mM 
deoxynucleoside triphosphates, and 5 U of Taq. The cycling conditions described for
89
the 120bp amplimer were also used in this reaction. These primers amplified a 411-bp 
fragment. The size of the PCR product was confirmed by running a lOul aliquote of the 
PCR product on a 1.5-% agarose gel containing ethidium bromide to make the DNA 
visible under UV light. The size of the PCR product was estimated from comparison 
with a DNA ladder composed of phage XDNA. The PCR product was sent for 
sequencing as in section 2.6.
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TACGGTCGGCGAGTGATCAAAACCAGATCCGGGTCGGCATGTCGCGGATGGAGCGGGT
TACGGTCGGCGAGTGATCAA ,------------------
RpoB3  ^
GGTCCGGGAGCGGATGACCACCCAGGACGTGGAGGCGATCACACCGCAGACGTTGATC
AACATCCGGCCGGTGGTCGCCGCGATCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCA
RpoBl
♦  *
ATTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGC
1GGGGCCCGGCGGTCTGTCACGTGAGCGTGCCGGGCTGGAGGTCCGCGACGTGCACCCG
^ ______________CCAGACAGTGCACTCGC
RpoBl
TCGC ACT ACGGCCGGATGTGCCCGATCGA A ACCCCTGAGGGGCCC A AC ATCGGTCTGAT
CGGCTCGCTGTCGGTGTACGCGCGGGTCAACCCGTTCGGGTTCATCGAAACGCCGTA
Figure 2.1 The rpoB gene amplified by PCR-411 (between primers RpoB3 and 
RpoB4) and PCR-120 (between PCR primers RpoBl and RpoBl). The bases 
underlined are those described by Ramaswamy and Musser (1998) where point 
mutation leads to rifampicin resistance. An asterisk is above the two bases where 
mutation leading to rifampicin resistance is most frequently clinically isolated.
AGTTCTTCGGCACCAGC
CC AAGT AGCTTTGCGGC AT 
RpoB A
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2.4 pncA Polymerase Chain Reaction methods (PCR)
The pncA  gene encoding pyrazinamidase (PZAase) described by Scorpio & Zhang 
(1996) was amplified by PCR. The primers employed were 5’-TGC GGG CGT TGA 
TCA TC 3’ AND 5’CAG GAG CTG CAA ACC AAC TC-3’. The optimal reaction 
mixture contained 1.5mM MgCl in KC1 buffer, 150 mM. deoxynucleoside triphosphates, 
and 5 U of Taq polymerase. The optimal PCR cycling conditions were one cycle 95°C 
for 1 minute and 35 cycles of 94°C for 1 minute, 55°C for 2 minutes and 72°Cfor 3 
minutes. This was followed by strand elongation for 7 minutes at 72°C.
The product of the PCR was an amplimer of 559bp. The size of the PCR product was 
confirmed by running a 10 pi aliquote of the PCR product on a 1.5 % agarose gel 
containing ethidium bromide to make the DNA visible under UV light. The size of the 
PCR product was estimated from comparison with a DNA ladder composed of phage 
ADNA. The PCR product was sent for sequencing as in section 2.6.
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ATGCGGGCGTTGATCATCGTGACCTGCAGAACGACTTCTGCGAGGGTGGCTC 
TGCGGGCGTTGA TCA TC C Z IZ I= l[>
GCTGGCGGT AACCGGCGGCGCCGCGCT GGCCCGCGCC AT C AGCG ACT ACCT G 
GCCGAAGCGGCGGACTACCATCACGTCGTGGCAACCAAGGACTTCCACATCG 
ACCCGGGTGACCACTTCTCCGGCACACCGGACTATTCCTCGTCGTGGCCACC 
GC ATT GCGT C AGCGGT ACTCCCGGCGCGG ACTT CC AT CCC AGT CT GG AC ACG 
TCGGCAATCGAGGCGGTGTTCTACAAGGGTGCCTACACCGGAGCGTACAGCG 
GCTTCGAAGGAGTCGACGAGAACGGCACGCCACTGCTGAATTGGCTGCGGCA 
ACGCGGCGTCG AT G AGGT CG AT GT GGTCGGT ATT GCC ACCG AT C ATT GT GT G 
CGCC AG ACGGCCG AGG ACGCGGT ACGC AAT GGCTT GGCC ACC AGGGT GCT G 
GT GG ACCT G AC AGCGGGT GT GTCGGCCG AT ACC ACCGT CGCCGCGCTGG AG A
T GCGC ACCGCC AGCGT CG AGTT GGTTT GC AGCT CCT GC
 -i CTCAACCAAACGTCGAGGAG
Figure 2.2 The pyrazinamidase/nicotinamidase gene described by Scorpio & Zhang 
(1996). The primers used are given in italics beneath the DNA sequence.
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2.5 DNA gyrase polymerase chain reaction methods
2.5.1 gyrA PCR
Primers were 5’-ATC GCC GGG TGC TCT ATG C-3’ and 5’-GTG GGT CAT TGC 
CTG GCG A-3\ The optimal reaction mixture contained 0.1 pM of each primer, 5 mM 
dNTPs, 50 mM KC1, 15 mM MgCl2and 1 unit Taq polymerase enzyme (Bioline, 
London UK).
The cycling conditions were 1 cycle 94°C for 1 min to ensure single stranded DNA. 
Amplification was by 30 cycles of 94°C for 1 min, 50°C for 2 min and 72°C for 3 min. 
The amplification cycles were followed by a strand elongation step of 7 min at 72°C.
The product of the PCR was an amplimer of 216 bp. The product was sent for 
sequencing as in section 2.5. This PCR was designed and optimised by Shreya Basu.
2.5.2 gyrB PCR
Primers were 5’ GAA GGC CCA AG A CGA 3’ and 5’ GAC TTC GAG CCG GGG 
TGG ATA 3’. The optimal mixture contained 0.1 pM of each primer, 5 mM dNTPs, 10 
mM NH4PO3,1.5 mM MgCL2 and 1 unit Taq polymerase enzyme (Bioline, London 
UK). This PCR was designed and optimised by Shreya Basu.
The cycling conditions were 1 cycle 94°C for 1 min to ensure single stranded DNA. 
Amplification was by 30 cycles of 94°C for 1 min, 60°C for 2 min and 72°C for 3 min. 
The amplification cycles were followed by a strand elongation step of 7 min at 72°C.
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The product of the PCR was an amplimer of 394 bp. The product was sent for 
sequencing as in section 2.6. This PCR was designed and optimised by Shreya Basu.
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atcgccgggtgctctatgcaatgttcgattccggcttccgcccggaccgcagccacgccaagtcggcccgg 
atcgccgggtgctctatgc [
tcggttgccgagaccatgggcaactaccacccgcacggcgacgcgtcgatctacgacagcctggtgcgca
tggcccagccctggtcgctgcgctacccgctggtggacggccagggcaacttcggctcgccaggcaatga
gcggaccgttact
cccac
gggtg
Figure 2.3a The section of the gyrA gene amplified by the primers used. The primers 
used are illustrated beneath the sequence. The DNA sequence is from Takiff, Salazar, 
Guerrero et al. (1994).
gaaggcccaagacgaatacggcgctgcgtctatcaccattctcgaagggctggaggccgtccgcaaacgt
gaaggcccaagacga
cccggcatgtacattggctcgaccggtgagcgcggtttacaccatctcatttgggaggtggtcgacaacgcg
gtcgacgaggcgatggccggttatgcaaccacagtgaacgtagtgctgcttgaggatggcggtgtcgaggt
cgccgacgacggccgcggcattccggtcgccacccacgcctccggcataccgaccgtcgacgtggtgatg
acacaactacatgccggcggcaagttcgactcggacgcgtatgcgatatctggtggtctgcacggcgtcgg
cgtgtcggtggttaacgcgctatccacccggctcgaagtc
ataggtgggccgagcttcag
Figure 2.3b The section of the gyrQ gene amplified by the primers used. The primers 
used are illustrated beneath the sequence. The DNA sequence is from Takiff et al. 
(1994).
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2.6 Sequencing polymerase chain reaction products
PCR products were purified using the Wizard PCR cleaning kit following the 
manufacturer’s instructions (Promega, Southampton UK). Sequencing was performed 
commercially by cycle sequencing with dye technology (Cambridge Biosciences, 
Cambridge, UK).
2.7 Miles and Misra plate count
This is a viable count technique devised by Miles & Misra (1938) in which the number 
of colony forming units (CFU) produced from a series of small drops of broth diluent are 
counted.
M  tuberculosis was cultured in Middlebrook 7H9 broth containing tween 80 (0.1%) to 
reduce clumping. The broth culture was passed 8 to 10 times through a 1-ml fine-needle 
syringe (28-gauge Sherwood, Crawley, United Kingdom) prior to dilution or subculture.
The dispersed broth was serially diluted 1:10 in tween-albumin broth (0.1% tween 80, 
Difco, Hemel Hempstead, United Kingdom) and 0.2% bovine albumin (Sigma, Poole, 
United Kingdom) to form a dilution series from 10'1 to 10'7. The tween albumin broth 
was briefly vortexed three times prior to sampling. At least three samples of 50ul were 
placed onto the surface of a Middlebrook 7H10 agar plate.
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The agar plates were dried at 37°C for 15 minutes prior to inoculation. The plates were 
incubated agar surface up for 48 hours at 37°C to allow the drops to soak into the agar. 
The plates were then incubated at 37°C and over 2 to 4 weeks the numbers of colonies 
were counted for each drop.
The frequency of colonies growing in a viable count technique will follow a Poisson 
distribution (Meynell & Meynell 1970). This means the number of organisms counted, 
not the number of repeated counts, determines the accuracy of a count. The standard 
error being VN of a count of N organisms. The counts in this work were in the region of 
between 100 CFU giving a standard error of 10 and 95% confidence limits of 
approximately 20% of the count. Counts were only acceptable if at least 50 CFU were 
present.
2.8 Fitness assays
The relative fitness of drug resistant M. tuberculosis compared to a susceptible strain 
was determined by the ratio of generations produced by the two strains in a mixed 
culture.
The number of bacteria present in a broth was determined using a Miles and Misra plate 
count (section 2.7). Plate counts on drug free Middlebrook 7H10 agar gave the total 
number of bacteria (T) present in a broth. Plate counts on Middlebrook 7H10 agar with
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5 mg/L rifampicin gave the number of drug resistant bacteria (R). The number of 
susceptible bacteria (S) could then be calculated from formula 2.1
The number of generations (G) of bacteria that had been produced in a broth was 
calculated from formula 2.2.
Where Nt is the number of bacteria present at the end of growth.
No is the number of bacteria inoculated at the start of growth.
The fitness of the multi-drug resistant strain was determined using formula 2.3
Formula 2.3 Fitness = Generations of MDR-TB / Generations of fully sensitive TB.
The accuracy of a fitness estimate will be in part determined by the Miles and Misra 
plate count (see section 2.7). The accuracy will also be dependent on the calculation of 
the number of susceptible organisms in the mixed broth using formula 2.1. There is an 
upper and lower 95% confidence limit to counts on both drug free and drug containing 
agar. An estimate for the upper and lower counts for the number of susceptible colonies 
present can then be identified from the worst cases of these two estimates see formula
Formula 2.1 S=T-R.
Formula 2.2
2.4 and 2.5
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Formula 2.4 Upper limit of sensitive count Su = Tl- Ru
Formula 2.5 Lower limit of sensitive count Sl = Tu- Rl
Where Su and Sl are the upper and lower limits of sensitive CFU estimate.
Tu and Tl are the upper and lower limits of total CFU estimate, 
and Ru and Rl are the upper and lower limits of resistant CFU estimate.
The error of the sensitive estimate is magnified by the size of the estimated number of 
resistant organisms present. The larger the number of resistant organisms the larger the 
error in the estimated number of sensitive colonies. If the numbers of resistant 
organisms are too great then the number of colony forming units on drug free and drug 
containing plates become the same.
To determine the relative fitness of resistant M. tuberculosis a larger number of sensitive 
organisms were used in the inocula of the mixed broths. The very much smaller number 
of drug resistant organisms meant that the error in calculated sensitive organisms was 
determined by variation in the drug free plate count alone.
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2.9 Ciprofloxacin susceptibility
The ciprofloxacin susceptibility test was that recommended by the manufacturer of the 
Bactec 460.
Two pH 6.4 vials were prepared one containing lug/ml ciprofloxacin. A 0.5 McFarland 
broth culture of M. tuberculosis was prepared in Middlebrook 7H9 broth. This broth 
culture was diluted 1:40 in Middlebrook 7H9 broth and 0.1-ml of the dilute culture 
inoculated into the vial containing lug/ml ciprofloxacin. The broth culture was then 
diluted 1:100 in tween albumin broth and 0.1 ml of this dilution inoculated into the drug 
free vial.
The two vials were read daily and the growth index recorded. Susceptibility was 
recorded if on the day that the drug free control read greater than 30, the change on that 
day in the growth index for the drug-containing vial was less than the change in the 
control vial. Resistance was recorded if the change in the drug-containing vial was 
greater than the control vial, or the drug-containing vial had reached a growth index of 
999.
A fully susceptible control H37Rv was set up with each batch of sensitivity tests to 
confirm activity of the antibiotic.
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2.10 Pyrazinamide susceptibility
The pyrazinamide susceptibility test was that recommended by the manufacturer of the 
Bactec 460. Two vials were prepared one containing 100-ug/ml pyrazinamide the 
second being drug free, both vials at a ph of 6.0. An equal size bacteria inocula was 
made into both vials. The vials were incubated at 37°C and read daily on the Bactec 460 
and the growth values recorded. Resistance to pyrazinamide was recorded when the 
drug free vial read >200 if the drug vial was >11% of the drug free vial. Susceptibility 
was recorded if when the drug free vial was reading 200 the drug containing vial was 
<9% of the drug free vial. The test was repeated if the drug free vial failed to show a 
growth index of >200 in 10 days, or reach a growth index of >200 in less than 4 days. 
The test was also repeated if the drug vial was between 9 and 11% of the drug free vial 
when a growth index of 200 was reached in the drug free vial.
2.11 Measuring the mutation rate
Crane, Thomas & Jones (1996) described a simple formula, which enables the mutation 
rate to be determined from an estimation of the median frequency of mutants where the 
total broth was not sampled. This formula was used in chapter 3 to determine the 
mutation rate of each individual mutant type leading to rifampicin resistance. The 
formula was used for this purpose as only a sample of the rifampicin resistant mutants 
need be typed from each broth culture. The formula of Crane et al. (1996) is given in 
formula 2.6.
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Formula 2.6 Me = (Tm-0.693)/(ln Tm+0.367).
Where Me is the average number of mutation events which have occurred 
in per broth and Tm is the median frequency of mutants identified in that 
series of broths.
The mutation rate (ju) is then calculated from formula 2.7
Formula 2.7 p = Me/ median broth total colony forming units.
The aim of determining the mutation rate in chapter 3 is to identify whether rifampicin 
resistant alleles are formed at different rates. The mutation rates are not directly 
compared, mutation rates are calculated from the frequency of mutants, calculation of 
their similarity would require a knowledge of the standard deviation of these estimates.
To identify if more mutants are able to grow at 5 mg/L than 10 mg/L rifampicin, it is 
necessary only to test that in each broth any difference in colony count on rifampicin 
containing media, is determined by chance. The number of cells sampled from a single 
broth will follow a Poisson distribution, variation in sampling alone being tested. This 
distribution allows tests based upon the normal distribution to be used. The matched 
pair t test is used in chapter 3 to compare the frequency of mutants isolated at two 
antibiotic concentrations (5mg/L and 10 mg/L).
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The frequency of rpoB mutation types required frequencies from a number of different 
broths to be compared. The numbers of these mutants will be described by the Luria- 
Delbriick distribution. This is not a normal distribution and statistical tests based on the 
normal distribution can not be used. The Mann-Whitney U test a non-parametric test is 
applicable to this data and is recommended for comparison of mutant frequencies 
(Rosche & Foster 2000).
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Chapter 3
The mutation rate of rpoB mutations leading to rifampicin resistance in vitro
3.1 Introduction
Antimicrobial drug resistance arises during tuberculosis infection either by primary 
infection with a drug resistant strain or from acquired drug resistance. Acquired 
resistances to anti-tuberculosis agents in M  tuberculosis arise solely by chromosomal 
mutation and selection under antibiotic pressure (Levin et al. 1997; Livermore 1998; 
Mitchison 1998; Gillespie 2002). Rifampicin resistance arises from mutation in a small 
(81 bp) region of the rpoB gene (Telenti et al. 1993). No transferable genetic elements 
have been described that can carry antibiotic resistance genes in M  tuberculosis 
(Bjorkman, Hughes & Andersson 1998; Blanchard 1996; Cole 1994).
In each patient in whom drug resistant M. tuberculosis evolves, the infecting strain of 
bacteria must develop resistant mutants and antibiotic selective pressure then drives 
these mutants into predominance.
Shimao (1987) proposed a calculation to give the probability of multiple antimicrobial 
agent resistance arising simultaneously by spontaneous mutation. This required 
determining the frequency at which resistance to each individual antimicrobial agent 
arose. The probability that resistance to both antimicrobial agents arose at the same time 
was determined by multiplying these individual probabilities together. As an example
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Qthe frequency of rifampicin resistant mutants arising was determined as 10' and 
isoniazid resistance as 1 O'6 in a fully susceptible unselected population. Therefore the 
probability of both mutations occurring simultaneously in the same bacilli is 
10'8xl0 '6=10"14. Shimao assumed that in a pulmonary cavity where there are 108 bacilli 
the probability of resistance to both rifampicin and isoniazid arising simultaneously is 
lO-6
Shimao (1987) derived the probability of a mono-drug resistant mutant being present 
from the frequency of drug resistant bacilli in a broth culture (with units of drug resistant 
cells per susceptible cell). This frequency, as outlined in the introduction, is dependent 
on the size of broth used to determine the mutant frequency (section 1.10). Mutation 
rates are independent of broth size. David (1970) measured the mutation rate to 
resistance and produced figures of 10'8 and 10'10 for isoniazid and rifampicin 
respectively (see table 3.1). The probability of a double mutation, leading to both 
rifampicin and isoniazid resistance, occurring in a single generation can then be 
calculated from David’s mutation rates as 10'18 per bacteria per generation.
Mitchison (1998) stated that the general model for the emergence of drug resistance in 
M  tuberculosis is due to sequential effective monotherapy. Mono-resistance to 
rifampicin is very rare and is associated with use of rifamycins with prolonged serum 
half lives and malabsorption, possibly leading to altered uptake and altered 
pharmokinetics of antituberculosis agents (Munsiff, Joseph, Ebrahimzadeh et al. 1997; 
Sandman, Schluger, Davidow et al. 1999; Weiner, Burman, Vernon et al. 2003).
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The low frequency of rifampicin mono-resistance and far higher frequency of 
streptomycin and isoniazid mono-resistance is noticeable (see table 3.1). Mitchison 
(1998) commenting on British Medical Research Council relapse cultures states: ‘The 
complete absence of resistance to rifampicin alone is noteworthy, probably because 
mutants to rifampicin are much less common than those to isoniazid in a sensitive 
bacterial population. ’ The association of rifampicin mono-resistance with specific 
clinical conditions and the low mutation rate to form rifampicin resistance, indicates that 
the mutation rate may form a possible limiting factor. This implies there is an absence 
of available mutations to be selected during therapy. Evolution can only operate on 
those alleles actually present. Through a complete cell cycle a population of genetically 
identical bacteria will react identically with no genetic advantage or disadvantage.
The frequency of clinical mono-resistance identified by Pablos-Mendez et al. (1998) and 
the mutation rate to individual anti-tubercular agents is given in table 3.1. There is not a 
direct correlation between mutation rate and frequency of clinical isolation. Variation in 
antibiotic usage may explain the lack of correlation of clinical mono-resistance and 
mutation rate, or the mutation rate may not be the rate-determining factor in clinical 
mono resistance.
Ramaswamy & Musser (1998), in a review of antimicrobial resistance in mycobacteria, 
compiled a list of the various mutations identified in the hot spot of the rpoB gene and 
the number of clinical isolates reported. The mutation position and the number of
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clinical isolates identified with that mutation are illustrated in figure 1.2. It is apparent 
that some rpoB mutants are isolated more frequently than others are. The mutation at 
position 531 in the rpoB gene Ser531 to Leu occurred in 237 (49%) out of 478 isolates.
Table 3.1 Median frequency of mono resistance reported world-wide (Pablos-Mendez 
et al. 1998) and mutation rate of antibiotic resistance of M. tuberculosis (David 1970)
Median frequency of clinical 
mono-resistance identified 
world wide
(Pablos-Mendez et al. 1998)
Mutation rate to resistance 
measured in M. tuberculosis 
(David 1970)
Streptomycin 2.5 % 2.56 x lO'"
Isoniazid 3.2% 2.95 x lO-8
Rifampicin 0.2 % 2.25 x 10'10
Ethambutol 0.8% 1.0 x l 0‘7
The hypothesis tested in this chapter is that alleles of rifampicin resistance identified by 
Ramaswamy & Musser (1998) as the most frequently clinically isolated, are formed at a 
higher mutation rate. This assumes that the mutation rate is the limiting factor, the 
infecting strain of M. tuberculosis must adopt any available rifampicin resistant mutant 
under rifampicin antibiotic selective pressure. This leads to evolutionary drift. Those 
mutants most likely to occur will be selected more frequently than those mutants less
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likely to occur. The mutation rate is proportional to the rate of isolation; those mutants 
isolated most frequently having a higher mutation rate than those mutants occurring less 
frequently.
3.2 Method
3.2.1 Isolation of rifampicin resistant mutants
A flow diagram describing the method used to isolate and identify the rpoB mutations 
leading to rifampicin resistance is given in figure 3.1. M. tuberculosis H37Rv was 
cultured in eight 100-ml Middlebrook 7H9 broths (Difco, Hemel Hempstead, United 
Kingdom) supplemented with ADC enrichment (Difco, Hemel Hempstead, United 
Kingdom) for 3 to 4 weeks at 37°C. The inocula used for each of these broths was 100 ul 
taken from a 2 week 7H9 broth of M  tuberculosis. The broth culture was concentrated 
by centrifugation at 2,000 x g for 30 minutes, and the deposit volume measured. A 
Miles and Misra viable-cell count was performed on 0.1-ml of the cell deposit to 
estimate the total number of cells (See Method 2.5). The remaining deposit was spread 
on the surface of a series of Middlebrook 7H10 agar plates (Difco, Hemel Hempstead, 
United Kingdom) supplemented with OADC enrichment (Difco, Hemel Hempstead, 
United Kingdom) containing 5 or 10 mg per litre of rifampicin (Sigma, Poole, United 
Kingdom). The plates were sealed in polyethylene specimen bags to prevent desiccation 
and incubated at 37°C for 4 weeks (see figure 3.1).
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The total number of colonies with dispersed growth on the plates was counted, and the 
total number of resistant cells was estimated as colonies counted /proportion of broth 
deposit plated. The median number of resistant cells formed by spontaneous mutation in 
the eight broths (Tm) was estimated and the number of mutation events (Me) occurring in 
the broths was calculated using the formula devised by Crane et al. (1996):
Formula 3.1 Me = (Tm-0.693)/(ln Tm+0.367).
Where Me is the number of mutation events that have occurred in the 
median broth and Tm is the median number of mutant colony forming 
units in the series of broths.
This was used to estimate the mutation rate (p) by using the median broth viable cell 
counts as follows p = MJ  median broth total colony forming units.
The mutation rate for individual alleles was estimated by first calculating the proportion 
of each allele present in each broth. This was estimated by subjecting approximately 20 
colonies from each experiment to PCR-SSCP (see chapter 2.3). The proportion of this 
sample giving each SSCP pattern was then multiplied by the total number of resistant 
cells estimated. The median number of each mutant type was used to calculate the 
number of mutation events and so the mutation rate using the formula of (Crane et al. 
1996).
3.2.2 Selection of rifampicin resistant mutants for further study
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Samples of approximately 20 colonies were subcultured from each broth that was used 
to isolate rifampicin-resistant mutants. The colonies were selected by drawing a line 
across a plate and picking all the colonies on that line. Each colony was confirmed as 
rifampicin resistant by culture in a Middlebrook 7H9 broth containing 5 mg/L of 
rifampicin. DNA was extracted from the isolated colony and subject to PCR-SSCP as 
described in chapter 2.3. The rpoB gene from colonies showing different PCR-SSCP 
patterns were sequenced as described in chapter 2.6.
i l l
Figure 3.1 Outline of the protocol used to isolate and identify rifampicin resistant 
mutants.
Measure 
volume of  
deposit.
Centrifuge at 
2000xg for 
30 minutes.
M. tuberculosis cultured 
in 100 ml Middlebrook 
7H9 broth at 37°C.
Plate out cell 
measured volume of 
deposit onto 
rifampicin containing 
media.
Miles and Misra 
plate count to 
determine total 
number of colony 
forming units in 
broth.
Select 20 colonies at 
random and subject to 
PCR -SSCP to identify 
the mutation in the rpoB 
gene leading to rifampicin 
resistance.
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3.3 Results
M. tuberculosis was cultured in eight 100-ml Middlebrook 7H9 broths for 3 to 4 weeks. 
The first six of the eight broths were plated on both 5mg/L and lOmg/L rifampicin- 
containing plates. The mean frequency of resistant cells detected was 1.03 x 10' on 5 
ug/ml plates and 9.87 x 10'9 per cell grown 10 pg/ml plates (see table 3.2). This 
difference was not significant (P= 0.57) with the matched pair t test. A parametric 
statistical test was used here to test if the broths contain more bacteria capable of growth 
at 5 than at 10 ug/ml rifampicin. A paired t test means that each broth is matched with 
itself and is not compared with other broths in the series. Analysis of the results of these 
six broths indicated that there was no difference in the frequency of mutants isolated at 5 
and 10 pg/ml and so only 5 jxg/ml was used on the last two broths.
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Figure 3.2 Mutation detection enhancement gel electrophoresis demonstrating 
representative resistant genotype SSCP pattern A, B and C and the sensitive genotype 
H37Rv.
a a c b b a H37 c
—
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Table 3.2 Rate of mutants isolated from six broths plated out on 5 and 10 mg/L 
rifampicin. The rate is measured as mutant cells per cell plated. This measurement 
overcomes the effect of different volumes being plated on different media.
Broth Rate of mutants per cell 
isolated on 5-mg/L rifampicin 
plate.
Rate of mutants per cell isolated 
on 10-mg/L rifampicin plate.
A 2x10's 1.5xl0'8
B 1.05x10'" 1.28xl0'8
C 2.79x10'* 2.86x10*
D 4.35x10'* 5x10'*
E 2.06x1 O'8 1.99x10'"
F 3.64x10* 3.66x10'*
PCR-SSCP analysis of 20 colonies selected at random from each broth revealed only 
three PCR-SSCP patterns from the rpoB gene. These patterns were designated type A, 
B and C and are illustrated in figure 3.2. The estimated numbers of each pattern present 
in each of the eight broths is given in table 3.3. The median number of mutants was 
used to estimate the mutation rate for each mutant type. The total mutation rate for all 
rifampicin resistant mutations was 6 x 1010. The mutation rates were 2 x 10'10,
4 x 10'10, and 2 x 10’10 mutations per cell per generation for SSCP patterns A, B and C 
respectively. No significant difference could be identified in the frequency of mutants 
of PCR-SSCP pattern A, B and C indicating no difference in the mutation rate (Mann- 
Whitney U test, P>0.5).
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A selection of the mutants from each PCR-SSCP pattern was sequenced. The mutants 
were selected so that mutants with the same PCR-SSCP pattern came from separate 
broth cultures so that the mutations had arisen independently for each isolate (table 3.4).
Table 3.3 Number of mutants present in broths, after correction for proportion of broth 
plated and proportion of resistant cells subject to PCR-SSCP. The row marked A was 
from a broth in which the cell count could not be made due to a fungal contaminant
Total
mutations
rifampicin
resistant
SSCP 
pattern A
SSCP 
pattern B
SSCP 
pattern C
CFU in 
broth
118 21 76 11 1 X 1010
96 5 62 29 3 x 1010
124 12 107 6 3 x 1010
219 41 133 41 8 x 10"
72 23 19 33 6x  10"
1220 933 311 156 4 x 1010
444 313 67 67 8x 10"
22 93 29 A
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Table 3.4 The PCR SSCP pattern and sequence alteration identified in the rpoB gene.
PCR-SSCP 
pattern A
No. of 
isolates
PCR-SSCP 
pattern B
No. of 
isolates
PCR-SSCP 
pattern C
Number of 
isolates
His 526=> 
Tyr
CAC => 
TAC
2 Ser 531=> Leu 
TCG => TTG
3 His 526==> 
Arg
CAC => 
CGC
3
His 526=> 
Asp
CAC => 
GAC
1
3.4 Discussion
The number of colonies growing on 5 and 10 pg/ml rifampicin was compared from the 
same broth. This turned this part of the experiment into a simple comparison of the 
frequency of cells growing in the same or matched broth. Statistical theory states that 
cell counts should obey the normal distribution and enables the colonies capable of 
growth on 5 and 10 ug/ml rifampicin to be compared using statistics based on the normal 
distribution (Meynell & Meynell 1970). The number of mutants growing in a broth does 
not obey a normal distribution. The comparison of different mutation frequencies could 
not then be based on the normal distribution. It is for this reason the Mann-Whitney U 
test has been used to compare the frequency of mutants in different broths (Rosche & 
Foster 2000).
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The hypothesis, that more frequent clinically isolated rpoB mutations are associated 
with a higher mutation rate, must be rejected. The Mann-Whitney U test (P>0.05) used 
to compare the frequency of mutants of different PCR-SSCP types indicates no 
differential accumulation of mutant types.
The range of SSCP types identified in this study was very much smaller than that 
identified from clinical samples. Moghazeh et al. (1996), Bodmer et al. (1995) and 
Ohno et al. (1996) compared the MIC and rpoB mutation in a number of clinical isolates 
(table 3.5). Three mutant types Ser 531 => Leu, His 526=> Asp, and Ser 531=> Trp were 
associated in all three studies with an MIC of > 8 mg/L rifampicin. In this study only 
the first two were isolated in vitro by rifampicin selection.
Variation in the MIC occurs with different methods used to measure the MIC. Tests on 
LJ media produce higher MIC values than tests on Middlebrook media, where the MIC 
can be reduced by the addition of tween. Tween makes the cell more permeable to 
rifampicin and so increases the intracellular rifampicin concentration (Hui et al 1977). 
Moghazeh et al. (1996) and Bodmer et al. (1995) used the proportional technique, 
Moghazeh et al. (1996) using Middlebrook 7H10 and Bodmer et al. (1995) using the 
Bactec method with Middlebrook 7H12 broth. Ohno et al. (1996) used an absolute MIC 
technique using 7H9 broth. Tween may have been present in the broth used by Ohno et 
al. (1996) its presence or absence not being noted. The variation in technique may have 
been responsible for some of the variation in MIC between the studies. Ohno et al. 
(1996) finding in general the mutations associated with lower MIC values.
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In this study the presence of tween in the culture broth preparing cells for selection may 
have influenced the selection of mutants. The cell wall being more permeable to 
rifampicin when it is plated out on rifampicin containing media. The high concentration 
of rifampicin used may also have excluded mutants that are clinically rifampicin 
resistant, but are selected at lower effective rifampicin concentrations in vivo.
The mutation rate does not appear to be a limiting factor for the appearance of 
rifampicin resistant mutants in vivo. Morlock, Plikaytis & Crawford (2000) using the Po 
technique identified a higher mutation rate for the most common mutant type Ser 531=> 
Leu relative to the other mutant types. Morlock et al. (2000) identified the rpoB 
mutation from a single colony from each broth and as such, may have not identified 
correctly those broths with more than one mutant type. This question will be more fully 
addressed in chapter 4.
The ability of a population to evolve is affected by the amount of genetic variation 
present. The effective population size is related to the chance of selecting two bacteria 
at random and them both having an identical genome (Brown & Richman 1997). The 
larger the amount of genetic variation the larger the effective population size (Ne) and 
the lower the probability of selecting two bacteria at random that are genetically 
identical.
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Table 3.5 Correlation of rifampicin minimum inhibitory concentration with rpoB 
mutation from three studies with clinical isolates of M  tuberculosis (Moghazeh et al. 
1996, Bodmer et al. 1995, and Ohno et al. 1996).
Mutation Moghazeh et al. 
(1995)
Ohno et al. (1996) Bodmer et al. (1996)
Pro 511 >8
Lys 513 >32
Leu 513 >32 >8
Val 515 0.063
Tyr 516 128 2
Val 516 4 >8
Leu 521 0.063
Leu 522 >8
Gly 526 8
Asn 526 16
Leu 526 8 16
Arg 526 512 8
Asp 526 >32 >512 >8
Pro 526 512 >8
Tyr 526 >32 >8
Leu 531 >32 512: 128:64 >8
Trp 531 >32 >512 >8
Tyr 531 >8
Pro 533 >32 1 :0.5
Wild type 1 Not stated 0.25 -0.5
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A population with a high genetic variation will be more likely to have favourable 
mutants present under changing environments than a population with a small amount of 
genetic variation. This in turn means a population with a high genetic variance is more 
likely to be able to adapt to a changing environment. This will not just affect evolution 
to antibiotics, but adaptation to other local host conditions. If the mutation rate to 
rifampicin resistance, approximately 10'10 per bacteria per generation, is not a limiting 
factor for evolution in M. tuberculosis, then this argues for a high value for genetic 
variation in the host.
Periods of antibiotic therapy followed by lack of effective therapy, as discussed by 
Mitchison (1998) are associated with emergence of drug resistance. This periodic 
therapy leads to an effective higher growth rate of the drug resistant mutants relative to 
the susceptible parental cell line. Multi-drug resistance then emerges when this growing 
pool of mono-resistant cells generates a lineage containing two drug resistant mutations.
Genetic variation in a population is increased by mutation. This increase in variation 
needs to be controlled or the cells suffer information death. The constant accumulation 
of mutations will lead to the information coded in the genome being lost. Stabilising 
selective pressures will exclude those unfavourable mutants so restricting the 
accumulation of genetic variation (Bell 1997).
The mutation rate calculated in this study for a single base change was 2 x 10*10 per 
bacterium per generation. The genome of M. tuberculosis consists of 4,411,529 base
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pairs (Cole et al. 1998). This gives a probability of a base change at each generation of 
0.000882 per bacteria. This compares with the calculations of Drake (1991b) who 
identified a general mutation rate for all DNA based organisms of 0.0033 mutations per 
genome per DNA replication. The mutation rate per base at the rpoB gene appears 
slightly lower than the universal mutation rate calculated by Drake (1991b). The rpoB 
gene is however an essential gene and has a lower mutation rate (Koch 1981). The 
mutation rate of other genes would be needed to be compared to determine if M 
tuberculosis has a higher or lower mutation rate than is found in other bacteria.
In this chapter I have demonstrated that there is no significant difference in the mutation 
rate for different alleles of rifampicin resistance. The rate of mutation can not be used to 
explain the differential rate of isolation of rifampicin resistant alleles described by 
Ramaswamy & Musser (1998). In the next chapter the growth rate of M tuberculosis 
with different rpoB mutations was compared to determine if differential reproduction 
could explain the distribution of rifampicin resistance alleles isolated clinically.
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Chapter 4
The fitness of rpoB mutations
4.1 Introduction
As outlined in the introduction to chapter 3 the alleles of rpoB leading to rifampicin 
resistance are found with different frequencies from clinical cases of MDR-TB. In 
chapter 3 the hypothesis that these different clinical frequencies reflected a difference in 
the mutation rate and that some rpoB mutations occur more frequently than others was 
tested. No evidence for this difference in the mutation rate was identified. In this 
chapter the hypothesis is tested, that a difference in growth rate enables some bacteria 
with rpoB mutations to out compete other bacteria which bare rpoB alleles for 
rifampicin resistance which lead to retarded growth. The hypothesis is that evolution of 
rifampicin resistance is determined by Darwinian survival of the fittest allele.
The rpoB gene encodes the (3-protein of RNA polymerase. Von Hippel, Bear, Morgan 
et al. (1984) described RNA polymerase is a key enzyme in the economy of the cell. 
Correct functioning of RNA polymerase ensures that not only are the appropriate genes 
transcribed, but that transcription occurs at the right time and in the required amounts. 
This requires the enzyme to be responsive to a number of controlling factors.
The P protein of RNA polymerase has a role in the stability of the DNA-RNA 
polymerase interaction. Mutation in the rpoB gene leading to resistance to rifampicin in
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E. coli has been described as reducing the stability of RNA polymerase DNA 
interactions (Zhou & Jin 1998). Stringently controlled promoter sites with very weak 
RNA polymerase-DNA binding were further weakened by these rpoB mutations, 
leading to loss of gene expression. This indicates that mutations in the rpoB gene can 
affect the repertoire of genes recognised.
RNA polymerase must not only recognise promoter sites but is also involved with 
termination of transcription. This requires recognition of the termination sequence and 
can involve other proteins. Point mutations in the rpoB gene have been described in E. 
coli that produce phenotypes with altered transcription termination characteristics (Jin & 
Gross 1988).
Rifampicin resistance in E. coli has been associated with a variety of phenotypic side 
effects, including temperature sensitivity, and auxotrophy for glutamine (Wehrli 1983). 
The role of RNA polymerase in the cell means that mutations in the rpoB region can 
have a direct effect on the transcription of other genes. This in turn can affect the ability 
of the cell to produce proteins and enzymes and so the rpoB allele can affect the cell’s 
ability to reproduce
Mayr (1997) briefly outlined two forms of selection, which he names survival and 
reproductive. Reproductive selection achieves its effect by differential growth rates of 
cells. Reproductive selection can only operate if the competing organisms are both 
present and able to survive and reproduce. Tempest (1978) produced a formula
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(formula 4.1) which enables the proportions of two competing cell types to be 
calculated. In this chapter fitness is defined by Tempest’s model. The competitive 
ability of an organism is calculated by the number of generations of each type of 
organism produced in a mixed broth.
Formula 4.1 Na/Nb = 2<«a'8b).Na/Nb
Where Na/Nb = The ration of cells a and b after a time interval 
ga and gb = The number of generations of organisms a and b 
respectively that occur in that time interval 
Na/Nb = The ratio of cell types a and b respectively at time zero
Bell (1997) describes mutation in a haploid cell line as generating its own cell lineage. 
The different cell lineages then must compete, if the different alleles reproduce at 
different rates then that competition will be by reproductive selection. Differential rates 
of reproduction generate a difference in allele frequency leading to the predominance of 
one allele type as described by formula 4.1.
Tempest’s model of competition allows a small reproductive difference to produce a 
large change in the frequency of alleles. Small differences in fitness will, given time, 
alter the frequency of alleles. An organism with an assumed fitness of 0.99 composing 
99% of the population, in competition with an organism with a fitness of 1.0 occupying 
the remaining 1% of the population, declines in frequency to below 0.5 after
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approximately 13 generations. The smaller the difference in fitness between alleles, the 
longer it takes for the fitter allele to come to predominate.
In this chapter the ability of clones with known rpoB mutations to reproduce and 
compete with the rifampicin susceptible parent clone was measured. The hypothesis 
was that the frequency of clinical isolation of the rifampicin resistant allele would be 
reflected in the relative fitness of that rpoB allele in competition with the parent 
rifampicin susceptible rpoB allele.
4.2 Method
4.2.1 Bacteria
Rifampicin resistant mutants isolated from the parent fully susceptible strain (H37Rv) 
were isolated as described in chapter 3. Three colonies from each of the SSCP patterns 
described in chapter 3 were sequenced. The isolation of rifampicin resistant mutants 
involved growing a broth culture of M  tuberculosis H37Rv and plating the entire culture 
onto media containing 5 and 10 pg/ml rifampicin. The rifampicin resistant clones with 
each SSCP pattern originated from a single colony picked from a separate broth to 
reduce the possibility that mutants with the same SSCP pattern had a more recent 
ancestor than the rifampicin susceptible parent strain. The clones used had the rpoB 
region associated with rifampicin resistance tested using the SSCP technique and 
sequenced as described in chapter 3.
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4.2.2 Fitness assay
A flow diagram describing the method used to determine the fitness of the rpoB 
mutations leading to rifampicin resistance is given in figure 4.1. Broth cultures of M  
tuberculosis H37Rv fully sensitive (the parent strain) and each of the rifampicin resistant 
clones was grown to approximately 0.5 McFarland over approximately 2 to 3 weeks in a 
4-ml Middlebrook 7H9 broth culture. The Miles and Misra plate count technique was 
used to estimate the viable cell count as described in section 2.7. This estimates the 
number of rifampicin resistant bacteria present by counting the colony forming units 
formed on media containing rifampicin. The total number of organisms was estimated 
by counting the number of colony forming units growing on media with no antibiotic 
present, that is both the rifampicin resistant and susceptible bacteria. By subtracting the 
estimate of the number of rifampicin resistant organisms from the total number, the 
number of susceptible organisms can be estimated. As explained in section 2.8 the 
estimate of the susceptible organisms is more accurate if a low number of rifampicin 
resistant organisms are present. This was achieved by using a lower inocula of 
rifampicin resistant cells than susceptible cells. A 10 fold dilution of rifampicin 
susceptible and 100 fold dilution of rifampicin resistant cells were prepared; and from 
each a 50pl sample was inoculated into 4 ml of fresh Middlebrook 7H9 broth to create a 
mixed culture of rifampicin resistant and susceptible cells.
After 2 to 3 weeks of incubation at 37°C when growth had reached about 1 McFarland, a 
count of viable cells was performed by the Miles and Misra technique on media 
containing 5 mg/L rifampicin and drug free media as described in section 2.7. The
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number of rifampicin resistant cells present was estimated from the number of colonies 
growing on the rifampicin containing media. The number of colonies growing on the 
drug free media was used to estimate the total number of cells present, both rifampicin 
resistant and susceptible in the mixed broth culture. The number of rifampicin 
susceptible cells present could then be calculated by subtracting the numbers of 
rifampicin resistant cells from the total number of cells (see section 2.8.). The number 
of generations of rifampicin resistant and rifampicin susceptible bacilli growing in the 
mixed broth culture could then be calculated as given in section 2.8. The fitness of the 
mutant cell (rifampicin resistant) line is the ratio of generations formed compared to the 
parent (susceptible) cell line.
4.2.3 Statistical methods
Regression analysis was performed with Unistat version 1.13 and JMP IN version 3.17 
(SAS Institute Inc) to identify if the frequency of isolation clinically was reflected in the 
fitness associated with the presence of the three rpoB mutations examined. The 
difference in generations of rifampicin resistant and susceptible clones were compared 
using students t test using Excel version 4.0 and JMP IN version 3.17 (SAS Institute Inc) 
to confirm higher growth rates by the susceptible parent strain.
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Figure 4.1 Flow diagram of the relative fitness experiment comparing the numbers of 
generations formed in mixed culture of both rifampicin susceptible (parent) cells and 
rifampicin resistant (mutant cells).
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4.3 Results
Clones 26, 35 and 112 had a rpoB PCR-SSCP pattern type A. The rpoB gene was 
sequenced and mutation at codon 526 was identified. These mutations were clones 26 
and 112 (His 526 Tyr) and clone 35 (His 526 Asp). Ramaswamy & Musser (1998) 
reported 19% of clinical rifampicin resistant isolates containing the mutation His 526 
Tyr in the rpoB gene, whilst His 526 Asp was responsible for 6% of rifampicin resistant 
isolates.
Clone 7, 68, 88 and 209 had a rpoB PCR-SSCP pattern type B. The rpoB gene was 
sequenced and mutation at codon 531 in the rpoB gene (Ser 531 Leu) was identified in 
all clones. This mutation was reported by Ramaswamy & Musser (1998) to be 
responsible for 49% of clinical rifampicin resistant isolates.
Clones 66, 118 and 25 had an rpoB PCR-SSCP pattern type C. The rpoB gene was 
sequenced and mutation at codon 526 in the rpoB gene (His 531 Arg) was identified in 
all clones. This mutation was reported by (Ramaswamy & Musser 1998) to be 
responsible for 4% of clinical rifampicin resistant isolates.
Tables 4.1 to 4.3 show the relative fitness of the rifampicin resistant clones compared to 
the fully susceptible parent clone. Clones with SSCP pattern A and C do not form as 
many generations as do their susceptible parents (P=< 0.02; students paired t test). Four 
clones with SSCP pattern B had their fitness determined relative to the susceptible
130
parent (table 4.2). There was no significant difference between mutant type B and its 
susceptible parent (p=0.09). Mutations associated with PCR-SSCP patterns A and C 
suffered a reduction in fitness relative to the susceptible parent clone (see tables 4.1 and 
4.3). Using data on the clinical frequency of resistance mutations presented by the 
review of Ramaswamy & Musser (1998), it was possible to correlate the frequency of 
clinical isolation and the in vitro fitness of different mutations as determined in these 
experiments (see figure 4.2 regression analysis p=0.026). There is a direct correlation 
between the frequency of clinical isolation of rpoB mutation and the in vitro relative 
fitness associated with the rpoB mutation.
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Table 4.1 Relative fitness of SSCP pattern A mutants.
NUMBER OF GENERATIONS MEAN FITNESS MUTATION
strain 26 8.1 7.1 5.7 6.9 0.80 CAC 526 =>TAC
H37Rv 9.6 8.6 8.4 8
strain 35 2.8 3.0 2.6 0.42 CAC 526=>GAC
H37Rv 5.4 7.6 7.2
strain 112 4.2 4.9 4.9 4.5 0.79 CAC 526=>TAC
H37Rv 5.4 6.5 5.4 6.3
Table 4.2 Relative fitness of SSCP pattern B mutants.
NUMBER OF GENERATIONS MEAN FITNESS MUTATION
strain 7 9.3 4.7 4.9 0.90 TCG531=>TTG
H37Rv 8.6 5.7 6.2
strain 68 5.4 4.8 4.3 0.50 TCG 531=>TTG
H37Rv 10 9.6 9.2
strain 88 7 11 4.3 0.93 TCG 531==>TTG
H37Rv 7.7 10.3 5.2
strain 209 8.1 9.2 8.8 7.6 7.8 1.1 TCG 531=>TTG
H37Rv 8.3 9.2 8.5 6.6 6.9
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Table 4.3 Relative fitness of SSCP pattern C mutants.
NUMBER OF GENERATIONS MEAN FITNESS MUTATION
strain 66 1.1 1.6 0.21 CAC 526=>CGC
H37Rv 6.3 6.5
strain
118
3.6 1.4 0.38 CAC 526 =>CGC
H37Rv 7.3 5.4
strain 25 4.8 4.7 5.6 6.3 7.0 0.57 CAC 526=>CGC
H37Rv 10.4 9.4 10.5 10.2 9.7
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Figure 4.2 Correlation of mean fitness of rpoB mutations identified in vitro and the 
number of clinical isolates reported by Musser (1995) in a review of reported clinical 
isolates. The four most commonly clinically isolated rpoB mutations leading to 
rifampicin resistance had the fitness estimated Ser 531 Leu (128 reported isolates), His 
526 Tyr (70 reported isolates), His 526 Asp (21 reported isolates), and His 531 Arg (9 
reported isolates). The graph shows the upper and lower 95% confidence limits of 
correlation (plotted using JMP IN version 3.17 (SAS Institute Inc)).
1.25 
1.00
Mean fitness
determined in vitro of clones 
containing an identified rpoB ^  ^  
mutation.
Q5D 
Q25 
QCD
0 25 53 75 10 125 153
The number of clinical isolates reported by 
Musser (1995) with the rpoB mutation used in the 
fitness assay
134
4.4 Discussion
4.4.1 The correlation between isolation rate and fitness in the rpoB gene
There is a positive correlation (p=0.026) between the rates at which mutants in the rpoB 
gene causing rifampicin resistance are reported and the relative fitness of rpoB mutant 
clones measured in vitro (figure 4.2). This indicates that the relative fitness of the rpoB 
mutation affects the probability that it will rise to predominance clinically.
Mariam, Mengistu, Hoffner et al (2004) compared the growth rate of rifampicin resistant 
mutants of M. tuberculosis (strain Harlingen). This comparison was determined in three 
methods: growth rate in pure culture, comparative growth rate in mixed culture, and 
growth rate in macrophage in pure culture. Three rifampicin resistant mutations were 
compared His 526 ->Tyr, Ser 522-*Leu and Ser 531 ->Trp. The relative order of 
fitness determined in the three methods is given in table 4.4. It is apparent that in both 
macrophage and competition determined fitness the mutation His 526 —»Tyr is the most 
fit isolate. The other two mutations are both isolated very rarely clinically and this is 
reflected in their lower fitness. In pure culture however Ser 522—>Leu has a higher 
fitness than His 526 —»Tyr. Determination of the growth rate is inherently variable as 
there may be variation between growth rates in different bottles due to slight changes in 
environment. These can vary from micronutrients carried over in the container to slight 
variations in temperature in the incubator (Bell 1997). However the variation in fitness 
values does indicate that caution is required in interpreting fitness values determined in 
vitro and their comparison to the situation in vivo.
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Table 4.4 Fitness of rifampicin resistant alleles of M. tuberculosis (strain Harlingen) 
determined by Mariam et al. (2004) using three methods. Growth rate in pure culture in 
Middlebrook 7H9 broth, growth rate in mixed culture, and growth rate in pure culture in 
Macrophage.
MUTATION FITNESS 
DETERMINED 
BY GROWTH 
RATE IN 
PURE 
CULTURE
COMPETITION
DETERMINED
RELATIVE
FITNESS
PURE GROWTH 
IN
MACROPHAGE
CLINICAL 
ISOLATION % 
BASED ON 
RAMASWAMY & 
MUSSER (1998)
His 526 ->Tyr 0.86 ±0.03 0.89 ±0.05 0.63 ± 0.02 20%
Ser 522—>Leu 0.95 ± 0.02 0.54 ±0.03 0.50 ±0.16 1 %
1 Ser 531 -»Trp 0.71 ±0.09 0.67 ± 0.06 0.28 ± 0.06 1 %
Morlock et al (2000) identified a higher frequency of the most frequent clinical rpoB 
mutant type (Ser 531 to Leu) and concluded the raised mutation rate of Ser 531 to Leu 
was the reason for this mutant types high rate of clinical isolation. In chapter 3 a raised 
mutation rate for this resistance allele was not detected.
Morlock et al (2000) identified a far higher range of mutant types than was identified in 
this study (table 4.5). A possible explanation for this is that a lower concentration of 
rifampicin (lug/ml) was used by Morlock et al (2000). than was used in this study (5 
ug/ml) to isolate rifampicin resistant mutants. Comparison of the MIC to rifampicin of 
clinical isolates and the rpoB mutation has shown some variation in the MIC both for 
different alleles of rpoB and with different isolates with the same rpoB mutation (see 
table 3.6). The variation in rifampicin MIC for isolates with the same rpoB mutation 
reflects the situation in coliforms. Wehrli (1983) found no direct correlation between
the MIC of coliforms and the concentration required to inhibit by 50% RNA production 
by purified RNA polymerase from rifampicin resistant isolates. The lack of correlation 
indicates in coliforms the MIC is affected by other factors such as cell permeability in 
addition to the rpoB allele.
Morlock (2000) adopted the Po technique as described by (Luria & Delbrtick 1943) to 
compare the mutation rate of rpoB alleles. A total of one hundred 5-ml Middlebrook 
7H9 broth cultures of M  tuberculosis H37Rv were prepared and incubated with shaking 
for 32 days at 37°C. The cultures were harvested after incubation. Morlock et al. (2000) 
describes the technique as: ‘Approximately 2 ml of culture containing most of the cell 
mass was pipetted from the bottom of each tube and transferred to a sterile screw-cap 
microcentrifuge tube’. The tube was centrifuged and supernatant discarded. The 
deposit was examined for rifampicin resistant mutations by plating out the deposit on 
Middlebrook 7H10 agar containing 1 pg/ml of rifampicin. Of the 100 cultures 32 did 
not have mutations present. The number of mutant colonies isolated per broth varied 
from 1 to 288 with 62 plates having between 1 and 11 colonies. A single rifampicin 
resistant mutant was sequenced from each broth except in two broths from which high 
numbers of mutant colonies were isolated. Morlock et al. (2000) ‘expected this 
procedure to produce independent mutational events in each culture’ allowing 
comparison of the frequency of broths containing different rpoB mutations.
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Table 4.5 The mutations isolated by Morlock, Plikaytis & Crawford (2000) and the 
mutations isolated in this study. The frequency of rpoB alleles identified by Morlock et 
al (2000) in all broths and from the group of broths producing 1 mutant colony are 
shown.
Mutation Rifampicin resistant 
mutant frequency reported 
by Morlock, Plikaytis & 
Crawford (2000)
This study Clinical 
frequency 
reported by 
Ramaswamy 
& Musser 
(1998)
All broths Broths with 
1 mutant
Ser 531 Leu 39 (60.9) 18 PCR-SSCP type B 237
His 526 Tyr 6 (9.4) 2 PCR-SSCP type A 94
His 256 Arg 5 (7.8) 3 PCR-SSCP type C 19
His 526 Asp 4 (6.2) 1 PCR-SSCP type A 31
Ser 521 Leu 4 (6.2) Not found 7
Ser 531 Trp 2 (3.1) 2 Not found 7
His 526 Pro 1 (1.6) Not found 6
Asp 516 Val 1 (1.6) 1 Not found 6
Deletion codon 
516 GAC
1 (1.6) 1 Not found
Insertion TTC 
after codon 513
1 (1.6) 1 Not found
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The Po technique is dependent on the number of broths in which mutants have not 
arisen. The number of mutation events that have occurred in a broth containing mutants 
is not known. The number of mutation events that have occurred in a broth with no 
mutants must be nil. The important characteristic of this technique is that broths need to 
be scored simply for mutants present or absent. Morlock et al. (2000) assumed each 
broth will have contained a single mutation event. However, does each broth contain a 
single mutational event and can this be tested?
Identifying the number of mutational events occurring in a broth is analogous to 
attempts to isolate pure cultures from broth culture prior to the use of agar plates. This 
was achieved using the Poisson distribution, the same distribution as is expected in 
mutation events, and the bases of the Po technique. Morlock et al. (2000) calculated that 
there was an average of 1.02 mutation events per broth. The generalised Poisson 
distribution is given in formula 4.2
Formula 4.2 P= e ". nr/r!
Where r is the number of mutation events = 0,1,2,3 ... 
and n = the mean number of events.
Where r = 0 and n is 1.02 the probability the probability of zero 
mutants becomes the Po formula and is given in formula 4.3
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-1 02Formula 4.3 Po =  e
The probability of a single mutant being present where the average number of mutations 
n is 1.02 is given by substituting a value of r = 1. This is produced in formula 4.4.
Formula 4.4 Pi= 1.02. O '1
This enables the calculation that the probability that a broth contains a single mutation 
event Pj = 0.368 and no mutation events Po = 0.36. The probability a broth contained 
more than a single mutation event then becomes P>, = 1- (0.368+0.36) = 0.27.
If more than one mutation is present then selection of a single colony will skew the 
results towards those mutants that have achieved greatest numbers. Mutants can be 
present at higher frequencies either from earlier mutation or faster growth rates of the 
mutants. In this study, 20 colonies were picked from each broth to estimate mutant 
frequencies and the frequency of mutants was compared using non-parametric methods. 
Non-parametric statistics are recommended to compare mutant frequencies. These non- 
parametric statistical tests do not assume a normal distribution and so are not as affected 
by the skew in frequency (Rosche & Foster 2000). There is a probability that some of 
the broths assumed to contain a single mutation event contained more than one mutant in 
the study conducted by Morlock et al. (2000). Where two or more mutations have 
occurred the increased probability that more rapid growing mutants will be detected,
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may have skewed the frequency of rpoB mutants towards detection of more rapidly 
growing rpoB alleles.
There is a very short window of time in the history of the broth, after a mutational event 
but prior to the mutant cell dividing, called the ‘phenotypic lag’. This arises due to the 
necessity of replacing ancestral gene products with the parent lineages. The cell will not 
show resistance until resistant rpoB gene products replace sensitive rpoB gene products. 
Phenotypic lag has a larger effect on the small number of mutational events used in the 
Po technique than techniques with more mutational events (Rosche & Foster 2000). The 
technique used in chapter 3 to determine mutant frequency is not as heavily affected by 
phenotypic lag due to the large number of mutations that have arisen in each broth. 
Mutation types with low relative fitness and therefore longer generation times may be 
expected to suffer a longer phenotypic lag than mutants with higher relative fitness.
This difference in phenotypic lag may account for the skew in mutant types identified by 
Morlock et al. (2000) in the group where a single rifampicin resistant colony was 
isolated.
Morlock et al. (2000) attempted to exclude the number of broth cultures with more than 
one mutation event by only using those broths in which a single mutant colony was 
isolated. From single isolates Morlock et al. (2000) identified a bias of 18 out of 29 
(62%) mutants of the type Ser 531 to Leu. Morlock et al. (2000) did not plate out all of 
the broth and so whether isolation of a single mutant cell indicates a single mutant was 
present in the broth is uncertain.
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The second most common mutation type reported by Ramaswamy & Musser (1998) His 
526 to Tyr (see table 3.2) did not have a raised isolation rate if only those broths 
showing a single mutant colony are considered. This is despite His 526 to Tyr being 
isolated more than three times more frequently than the next most frequent mutant type. 
The determination of the relative fitness gives the same order of relative fitness and the 
clinical isolation rate for the four mutant types identified. This indicates that relative 
fitness of mutants is important to the rate of clinical isolation.
4.4.2 Will the mutant with the highest relative fitness always be isolated?
Bell (1997) states that ‘the sorting limit of asexual populations is the extent of variation’. 
This means that a selective pressure will not affect a population if there are no available 
mutants with an enhanced relative fitness under that selective pressure available. This 
emphasises the importance of the range of mutants in a bacterial population at the start 
of a lethal selective pressure such as antibiotic treatment.
Small populations such as emerging antibiotic resistant populations are very susceptible 
to chance events. Schuster & Sigmund (1989) considered the probability of an 
advantageous mutation coming to predominance in a population. A boundary layer was 
described below which the population could become extinct despite a selective 
advantage. Consider a hypothetical organism with an assumed growth at the end of each 
generation producing 2 cells for every cell and a 40% chance of each cell dying before 
reproducing. As the probability of dying is lower than the reproduction rate, the
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population is expected to grow. But when a single organism is present the probability of 
the population dying during the first generation before reproducing is 0.4. The 
probability that the same population will all be eliminated in a single generation when 
the population becomes greater than 10 cells is very small (p<10'4). An antibiotic 
resistant cell during an infection is prone to just such chance events. The cell may be 
resistant to the antibiotic therapy, but the immune system can kill that cell prior to 
infection becoming established or the cell simply shed from the host.
Frost & McLean (1994) studying quasi-species and the development of zidovudine 
resistance in HIV, argued that initial quasi species distribution prior to drug treatment 
will have an important effect on the allele that comes to predominate. The sequential 
emergence of mutations in HIV during treatment was accompanied by a sequential 
increase in drug resistance. Frost & McLean (1994) stated that: ‘The patterns that 
emerge during therapy are deterministic because mutation does not play an important 
part in the dynamics compared with competition. However the level of resistant mutants 
is determined stochastically (by mutation). Variability in the emergence of resistance 
between individuals can be credited to this pre-therapy stochasticity’.
The allele of rifampicin resistance that emerges in M. tuberculosis clinically will have a 
similar stochastic and deterministic component. Mutation supplying the availability of 
rifampicin resistant alleles, will be a stochastic determinant. Competition between those 
mutations, once grown above the boundary where chance can eliminate the population,
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will then be deterministic. Those mutations associated with a higher relative fitness will 
come to predominate.
The range of rifampicin resistant mutations available during infection will be dependant 
on the infection size and so the probability of a mutant being present. The probability of 
a rifampicin resistant mutation being present will be dependent on its mutation rate. A 
population will contain on average one rifampicin resistant mutation if the population 
size is 1/p where the rifampicin resistance mutation rate is p.
Reproductive selection can only operate if more than one allele is present, including the 
sensitive allele. Following the start of antibiotic therapy rifampicin resistant alleles 
obtain a selective advantage. If two or more alleles for rifampicin resistance are present 
these must compete, the allele with the fastest growth rate coming to predominance. If 
the optimal allele is not present or is lost by genetic drift then it can not be driven by 
selective pressure to predominance.
The role of chance during tuberculosis infection will ensure that the perfect allele with 
the highest fitness is not selected on all occasions. In some infections the allele may not 
be present. In others it may be present in small numbers and lost due to chance events. 
The higher fitness will however enable it to more frequently come to predominate.
The range of rifampicin resistant mutations available during infection is dependant on 
the infection size and so is the probability of a mutant being present (Mitchison 1998).
144
The probability of a rifampicin resistant mutation being present will be dependent on its 
mutation rate. A population will contain, on average, one rifampicin resistant mutation 
if the population size is 1/p where the rifampicin resistance mutation rate is p.
Antibiotic resistant mutants may have a fitness cost relative to the susceptible parent 
strain in the absence of antibiotic. The proportion of mutants in a continuous culture 
will be proportional to p/w, where p is the mutation rate and w is the selection 
coefficient (Bell 1997). The smaller the selection coefficient the higher the proportion 
of the broth culture that can be attained by the less fit clone. The selection coefficient is 
related to the relative fitness using formula w= 1-Fitness (Bell 1997). The higher the 
relative fitness of an rpoB mutant, relative to the susceptible parent strain, the smaller 
the selection coefficient and so the higher the proportion of a population that mutant can 
attain when there is no rifampicin present. If the proportion is high enough and the 
population large enough then a constant pool of rpoB mutants may be available.
The model used by Lipsitch & Levin (1998) to calculate the probability of multi-drug 
resistant M. tuberculosis is based on the mutation rate for resistance to each individual 
antibiotic. They gave an example, ‘if the frequency of drug resistance to drug 1 is 10'7 
and to drug 2 is 10'7, then on average, a population of 1010 bacteria will contain 1000 
bacteria resistant to each drug, but the likelihood of observing a bacterium resistant to 
both drugs will be of the order 10"4’. Lipsitch & Levin (1998) estimate the probability of 
a bacterium containing a gene for resistance to both antibiotics as 10'14, that is 107 x 
10' . This is the probability of both mutations producing resistance to drug 1 and drug 2 
occurring on the same genome, at the same time. This is based on the theory that
mutation rates control the rate of emergence of resistance. Assuming sequential gene 
acquisition is more complicated, being dependant on the number of cells with resistance 
to one of the antibiotics. If selection in part controls the rate of emergence of resistance 
then the proportion of mutants present during infection will be dependent on the 
selection coefficient. This alters the probability of a single mutation being present and 
so a double mutation occurring.
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Chapter 5
Comparison of the fitness of two isolates of Mycobacterium tuberculosis one of 
which developed multi-drug resistance during the course of treatment
5.1 Introduction
Anderson (1999) states: ‘Drug rotation is essential because it is important to keep 
varying the selective pressure’. Programs to limit or reduce the rise in antibiotic 
resistance have been based on the theory that antibiotic resistance has an associated cost 
to the bacterium.
There is a correlation between the increasing use of an antibiotic and an increase in 
resistance to that antibiotic. Magee, Pritchard, Fitzgerald et al. (1999) in a study of 
urinary tract infections found the frequency of resistant coliforms correlates with 
increasing antibiotic usage by individual general practitioners. The introduction of each 
anti-tubercular drug has been associated with emergence of resistance to that drug as it is 
used (Ramaswamy & Musser 1998; Fox, Ellard et al. 1999).
A decline in the frequency of antibiotic resistance on removal of antibiotics has been 
reported. Sulphonamide resistance in Neisseria meningitidis demonstrates an example 
of such a decline. Sulphonamide was last used for prophylaxis against meningococci in 
1986-88. At this point sulphonamide resistance was about 40%, this level of resistance 
declined to 25% in 1995 (Kaczmarski 1997). Reversion to susceptibility of tuberculosis
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has been recorded for streptomycin resistance (Fox, Ellard et al. 1999). However, such 
reversion to susceptibility does not arise with isoniazid, this despite an apparent reduced 
virulence reported with isoniazid resistance (see section 1.15).
The reduction in frequency of resistance on removal of antibiotic selective pressure is 
not universal. Streptomycin has not been used against the Enterobacteriacea for 25 
years and yet Chiew, Yeo, Hall et al. (1998) identified over 20% of E. coli isolates 
resistant to streptomycin in their 1998 study. Resistance to streptomycin was associated 
with transposon Tn21. Transposon Tn21 has the ability to collect antibiotic resistance 
determining sequences. The ability of Tn21 to accumulate antibiotic resistance has 
allowed it to play an important role in the spread of antibiotic resistance in gram 
negative bacteria (Liebert, Hall & Summers 1999). The use of one antibiotic with 
resistance coded for on Tn21 will help to conserve all of the antibiotic resistance genes 
held by Tn21.
Retention of antibiotic resistance genes by sharing a genome with antibiotic resistance 
genes under active selective pressure is not restricted to Tn21. Magee et al. (1999) 
found that in GP practices, combined resistance to ampicillin and trimethoprim occurred 
in 21% of isolates. There was a correlation between use of either antibiotic and 
resistance to both antibiotics. Plasmids with combined resistance to trimethoprim and 
ampicillin are common in E. coli and use of either antibiotic would provide a selective 
pressure for the retention of these plasmids (Amyes 1989).
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Gilliver et al. (1999) studied Enterobacteria isolated from bank voles (Clethrionomys 
glareolus) and wood mice (Apodemus sylvaticus) in woodland sites in Northwest 
England. Gilliver et al. (1999) found 89% of E. coli isolates were resistant to 
amoxicillin and 14% resistant to tetracycline. The presence of antibiotic resistance in a 
wild animal population indicates antibiotic resistant strains may not be eliminated by 
removal of antibiotic selective pressure.
The ability of antibiotic resistance genes to be preserved in the absence of antibiotic 
pressure may be associated with compensatory mutations. Lenski (1988) found that on 
initial insertion of a plasmid into E. coli there was an associated decline in fitness. 
Continued culture in the presence of antibiotic pressure allowed the E. coli strain to 
adapt to the presence of the plasmid. The fitness cost associated with the plasmid’s 
presence declined. Removal of the plasmid from the clone of E. coli adapted to the 
plasmid’s presence revealed a fitness cost with the plasmid’s absence. Lenski concluded 
from this that the genome adapts to its total environment including the environment 
created by its own genes. Mutation in the genome is an alteration in the cell’s 
environment.
Adaptation to streptomycin resistance by compensatory mutations has been identified in 
E. coli (Schrag, Perrot & Levin 1997). Compensatory mutations in M. tuberculosis to 
isoniazid resistance have similarly been identified (Sherman et al. 1996). However 
whether there is an associated cost with removal of antibiotic resistance has not been 
identified.
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Bjorkman, Hughes & Andersson (2000) examining compensatory mutations to fusidic 
acid resistance in Salmonella typhimurium strain LT2 found a different compensatory 
mutation when the bacteria were cultured in mice or Luria Bertani broth (LB) media. 
Fusidic acid resistance was created by mutation in the fusA  gene, which codes for 
elongation factor G. Fusidic acid affects the growth rate when cultured in LB and in 
mice. Compensatory mutations were selected by serial passage either through LB media 
(28 isolates), or mice (25 isolates). At each passage the growth rate was determined in 
LB media and if raised then compensatory mutations were assumed to be present.
Compensatory mutations in mice were predominantly by reversion to susceptibility (14 
isolates out of 25). The mutation leading to resistance had been eliminated and the wild 
type or susceptible form of the gene fusA  was present. Fusidic acid resistant mutants 
have alterations in the concentrations of (p)ppGpp which is a regulator of gene 
expression. Reversion to susceptibility will have returned this regulator to its normal 
value. Compensatory mutations, while improving the rate of protein synthesis, may not 
have affected the regulator concentration. Serial passage in LB media almost always led 
to compensatory mutations, not reversion to susceptibility (26 out of 28 isolates).
There is a single mutation that can lead to reversion to susceptibility. However, there 
are a large number of possible mutations that can lead to improved gene expression. 
These compensatory mutations are more likely to arise than true reversion. The failure 
of compensatory mutations to return the cell regulation to normal may not have affected
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bacteria grown on artificial media. However, bacteria grown in mice require full 
expression of virulence related genes, normal expression of (p)ppGpp may have 
provided a selective pressure for reversion to susceptibility.
Compensatory mutations that arise in vitro are not necessarily the same mutations that 
arise in vivo. Selective pressures operating in these environments will differ, and so the 
range of adaptive mutations required in vitro and in vivo are different. The question of 
whether compensatory mutations to antibiotic resistance carry a cost in the sensitive cell 
can only be addressed once it is established that resistant mutations carry a selective cost 
in vivo.
Ordway, Sonnenberg, Donahue et al. (1995) examined the ability of M. tuberculosis 
resistant to one or more antibiotics to grow in mice and in vitro. 15 isolates of 
Mycobacteria were compared to the virulent laboratory strain of M. tuberculosis 
Erdman. No correlation between resistance and growth rate was identified, however 
each of these isolates was unrelated. The genetic variation will have extended beyond 
antibiotic resistance. To examine the effect of antibiotic resistance it is necessary to 
examine matched isolates with a common heritage to minimise genetic variation 
between the isolates.
This chapter is addresses the hypothesis that there is a fitness cost associated with 
antibiotic resistance in M. tuberculosis in vivo. This was studied by comparing the 
fitness of two isolates of M. tuberculosis from matched clinical cases.
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5.2 Method
5.2.1 Isolates
Isolates were obtained from siblings who presented at the Royal Free Hospital. The first 
to present was a male HIV sero-negative (ET). The initial isolate in 1991 was fully 
sensitive. The infecting strain of tuberculosis developed resistance over a period of 3 
years to nine antibiotics (rifampicin, isoniazid, streptomycin, ciprofloxacin, 
clarithromycin, amikacin, PAS, cycloserine, and capreomycin). No isolates were 
obtained from ET during the intervening period so it was not possible to state when 
resistance first developed.
ET’s sister (AT) was HIV sero-negative and lived with her brother ET. AT developed 
tuberculosis 9 months after her brother and this strain remained fully drug susceptible 
(AT) (Davies et al. 2000a).
The strains of M. tuberculosis isolated from both AT (fully drug susceptible) and ET 
(MDR-TB) were primary clinical isolates. The strains were isolated from sputum 
samples on Lowenstein Jensen media within 14 days of each other. The laboratory 
control strain fully drug susceptible H37Rv was used as a control. The original slopes 
and H37Rv were sub-cultured into Middlebrook 7H9 broth and incubated at 37°C for 21 
days. These broths were then used as the inocula for the fitness assay.
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5.2.2 PCR sequencing of rpoB gene
The technique described in section 2.3 was used.
5.2.3 Assay of relative fitness of drug resistant isolates (ET) compared to 
reference strain H37Rv
Both drug-resistant (ET) and susceptible strain (H37Rv) were diluted 1:400 into two 
fresh 4 ml Middlebrook 7H9 broth cultures. These mixed broth cultures were incubated 
at 37°C for 6 days. At the start and end of this time a Miles and Misra plate count 
determined the numbers of bacteria.
The set of mixed broths were sub cultured into fresh broth for a second fitness assay.
The broths were diluted 1:40 into fresh Middlebrook 7H9 broths (4 ml). These broths 
were incubated for a further 14 days and the numbers of bacteria determined again using 
a Miles and Misra plate count. In this way the fitness from 2 consecutive matched 
broths incubated for 6 and 14 days could be compared.
5.2.4 Relative fitness assay drug-resistant isolate (ET) and matched clinical drug 
susceptible strain (AT)
Broth cultures of the strains of M. tuberculosis (ET and AT) were diluted 1:400 into 
three fresh 4 ml Middlebrook 7H9 broth to create three mixed broths. These mixed 
broths were incubated at 37°C for 6 days. This set of mixed cultures containing both ET 
(MDR-TB) and AT (drug susceptible M. tuberculosis), was then used as the inoculum 
for a second set of broths. In this way both strains had been exposed to an identical 
environment.
153
The mixed broths containing both ET and AT clones were diluted 1:40 in fresh 
Middlebrook 7H9 broth (4ml). These broths were incubated at 37°C for 14 days. A 
Miles and Misra plate count determined the numbers of bacteria both at the start and end 
of the 14 days incubation period.
5.3 Results
Both strains were typed by A. Dickens (Department of Medical Microbiology Royal 
Free Hospital) using the international IS6110 method (Van Embden, Cave, Crawford et 
al. 1993) and PGRS technique (McHugh, Dickens & Gillespie 2000), and the patterns 
identified were identical (figure 5.1).
The number of generations formed in each mixed broth culture for ET and H37Rv and 
the calculated relative fitness of ET is shown in table 5.1. The mean relative fitness of 
ET compared to H37Rv was 0.52 with a standard deviation of 0.1.
The number of generations formed in each mixed broth culture for ET and AT and the 
calculated relative fitness of ET compare to AT are given in table 5.2
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Figure 5.1 IS6110 RFLP pattern of the two patient strains AT and ET revealing the 
same pattern indicating a common ancestor. MT is the standard reference strain 
MT14323 (photograph supplied by A. Dickens)
1 5 5
The mechanism of drug resistance has not been elucidated for all of the antibiotics to 
which the strain ET became resistant. The rpoB gene of ET does however show a type 
B mutation PCR-SSCP as described in chapter 3, this indicates a mutation Ser 531 => 
Leu in the rpoB gene.
The ratio of generations formed by ET compared to H37Rv did not depend on the length 
of incubation. The fitness tests after 6 and 14 days did not produce a significantly 
different ratio (matched pairs t test p=0.5 see table 5.1).
The difference in generations of ET, AT and H37Rv were compared using students t test 
using Excel version 4.0 and JMP IN version 3.17 (SAS institute Inc). The number of 
generations produced by the MDR-TB strain (ET) was lower than the number of 
generations of either the matched clinical susceptible strain (AT) or H37Rv (matched 
pairs t test p = 0.002 and 0.03 respectively). There was a larger reduction in fitness of 
ET compared to H37Rv than the reduction in fitness of ET compared to AT (t test p 
= 0 .02).
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Table 5.1 Relative fitness of ET compared to H37Rv
Number o f generations 
(6 day broth)
relative fitness 
(6 day broth)
Number of generations 
(14 day broth)
relative fitness 
(14 day broth)
ET 2.49 2.76 0.55 4.12 7.04 0.50
H37Rv 5.58 4.27 9.17 12.8
Table 5.2 Relative fitness of ET compared to AT
Number of generations formed in mixed broth culture. Mean fitness (SD)
ET 9.07 8.14 6.81 0.73 (0.03)
AT 12.3 10.9 9.67
5.4 Discussion
The initial infection of case ET was antibiotic sensitive but he complied with therapy 
poorly, attended for follow-up only intermittently, and multi-drug resistance emerged. 
Patient AT, the sister of patient ET, was infected prior to ET’s infecting strain of M. 
tuberculosis developing multi-drug resistance. Like her brother AT complied with 
therapy poorly and attended follow-up erratically. The infection of AT however 
remained fully drug susceptible (Davies, Billington et al. 2000a). The close 
epidemiological link and identical IS6110 pattern indicate that the two isolates were 
recently derived from a common ancestor. Changes in fitness would therefore be 
associated with alterations in their environment including those caused by the 
acquisition of alleles for antibiotic resistance.
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The drug resistant isolate (ET) has a relative fitness when compared to H37Rv of 0.52. 
The relative fitness for strain ET increases to 0.73 when compared to the drug 
susceptible clinical isolate AT. Direct comparison of H37Rv and AT, both isolates 
being drug susceptible, could not be performed. However, the higher relative fitness of 
ET compared to AT than H37Rv means that AT had a lower relative fitness than H37Rv 
in this test. Both the clinical isolates had a lower relative fitness than H37Rv measured 
in vitro.
H37Rv is a strain of tuberculosis isolated prior to the use of antimycobacterial agents. 
This has led to this strain being used internationally to control sensitivity tests. The 
isolate used in these experiments has been used to control susceptibility tests at the 
Royal Free Hospital for over 5 years. It is likely that H37Rv has adapted to artificial 
media and may show reduced clinical fitness. It is from such repeated subculture in 
artificial media that the vaccine strain of tuberculosis BCG was derived (Calmette & 
Guerin 1920). Thus caution must be observed as the relative fitness determined in vitro 
would not always reflect the position in vivo.
The isolate ET developed resistance to nine anti-tuberculosis agents. The mechanism of 
resistance has been elucidated for rifampicin. Rifampicin resistance was produced by a 
mutation in the rpoB gene which is associated with the lowest cost in vitro and is also 
the most common isolated clinically (Chapter 4). The lower relative fitness of ET 
compared to AT implies a physiological cost had been acquired by ET with drug 
resistance.
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The physiological cost associated with drug resistance in the isolate ET may not be due 
to the alleles of resistance selected, but the forced selection of less optimal alleles at 
genes not related to drug resistance. The infection has undergone a series of genetic 
restrictions during the development of drug resistance. These restrictions must have 
reduced the population to a single cell, the original drug resistant mutant on acquiring 
each resistance gene.
Sampling error increases as populations reduce in size. A single poor allele sharing the 
chromosome with an essential gene such as drug resistance has more probability of 
rising to predominance from this reduced population. Clarke et al. (1993) working with 
an RNA virus, vesicular stomatitis virus found that large populations of virus increased 
their relative fitness on repeated subculture. Conversely cultures in which low virus 
numbers were passaged, causing severe genetic restriction, led to a reduction in relative 
fitness. This reduction in fitness was due to the accumulation of unfavourable 
mutations. In any population unfavourable mutations will arise. In small samples, such 
as one with continued restriction to a single cell, the probability of fixation of 
unfavourable mutants increases. This reduction has been described as Muller’s ratchet 
(Andersson & Hughes 1996).
The strain ET has undergone a series of genetic restrictions. With the development of 
each resistance allele the population will have effectively been reduced to the single cell
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that originally carried each resistant mutation. A set of nine genetic restrictions to a 
single cell over the three-year period could have produced the decline in fitness 
identified in this paper via Muller’s ratchet.
It is possible that over a period of time the strain ET could adapt to produce the same 
relative fitness as the drug susceptible strain AT. Adaptation of drug resistant E. coli to 
the physiological cost of drug resistance has been studied in vitro (Schrag et al 1997). 
Compensatory mutations have been identified in M. tuberculosis in relation to isoniazid 
resistance (Sherman et al. 1996).
The multi-drug resistant isolate (ET) remained virulent and fully capable of causing 
progressive disease, the patient ET dying in 1999. Multi-drug resistant M tuberculosis 
(MDR-TB) is pathogenic and fully capable of causing disease. The proportion of 
tuberculosis infection attributed to MDR-TB where anti-tuberculosis control programs 
have failed amply supports evidence for the pathogenicity of MDR-TB (Pablos-Mendez 
et al. 1998).
The fact that MDR-TB is capable of causing infection does not mean that it has an 
equivalent fitness to drug susceptible tuberculosis in the absence of antibiotic pressure. 
The reduced fitness identified in vitro, if reflected in vivo would mean that in the 
absence of antibiotic pressure MDR-TB would decline in competition with drug 
susceptible tuberculosis. The rate at which antibiotic resistance disappears would be
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dependent on the probability of multiple infection by both resistant and sensitive strains 
of M  tuberculosis.
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Chapter 6
An attempt to explore the adaptive landscape of the human host
6.1 Introduction
Bell (1997) states any character that evolves can only do so if it leads to a higher 
proportion of its progeny in subsequent generations. The selection of different alleles 
conferring the same phenotypic character, such as rifampicin resistance, is dependent on 
the relative fitness of the alleles (Billington et al. 1999).
Wright (1932) described the genome of a species as existing on an adaptive landscape. 
Wright, discussing the role of mutation and selection in evolution, described these 
mutant loci (which would now be referred to as alleles) as moving the genome within 
this adaptive landscape. A precise combination of alleles produces a specific phenotype, 
which interacts with the environment to produce a fitness value. This value correlates to 
a single position on the adaptive landscape. Is the fitness landscape for M  tuberculosis 
within the human host identical between hosts? An identical fitness landscape would 
indicate a single ideal sequence. A difference in landscape between hosts would require 
adaptation to each host and a range of ideal sequences.
This chapter explores the fitness landscape between individual hosts by comparing the 
fitness of isolates from three patients with MDR-TB. Three isolates from the source 
patient were compared, to measure the consistency of fitness estimates from a single
patient, and the fitness of three patient isolates were compared to identify any trends in 
relative fitness.
6.2 Method
6.2.1 Isolates
M tuberculosis H37Rv (ATCC9360) was used as a control strain in the fitness assay.
Isolates from three patients involved in an MDR-TB outbreak in a London hospital were 
studied. As described by Breathnach et al. (1998) the strains had the same IS6110 
RFLP pattern and epidemiological data indicated a common source for all the isolates. 
Three isolates were obtained from the source patient (patient S). Two isolates from the 
Royal Free Hospital and a third from the Brompton Hospital. A single isolate was used 
from the other two patients X and Y.
Sensitivity tests were performed on initial isolation for four of the five isolates. The 
isolates from the Royal Free Hospital had susceptibility tests performed at the Dulwich 
Hospital using the resistance ratio technique. The Brompton isolate had susceptibility 
tests carried out at the Brompton using the Bactec 460 and proportion technique. The 
sensitivity patterns for each of the isolates was identical for 9 antibiotics. Differences in 
susceptibility arose only in pyrazinamide and ciprofloxacin (see table 6.1). The 
ciprofloxacin and pyrazinamide susceptibility results were confirmed using the Bactec 
460 and proportion technique at the Royal Free Hospital.
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6.2.2 Ciprofloxacin susceptibility testing
The ciprofloxacin susceptibility test was performed using the Bactec 460 using the 
method recommended by the manufacturer.
Two Bactec 460 vials (pH 6.4) were prepared one containing lug/ml ciprofloxacin. A 
0.5 McFarland broth culture of M. tuberculosis was prepared in Middlebrook 7H9 broth. 
This broth culture was diluted 1:40 in Middlebrook 7H9 broth and 0.1-ml of the dilute 
culture inoculated into the vial containing lug/ml ciprofloxacin. The broth culture was 
then diluted 1:100 in tween albumin broth and 0.1 ml of this dilution inoculated into the 
drug free vial.
The two vials were read daily and the growth index recorded. Susceptibility was 
recorded if on the day that the drug free control read greater than 30, the change on that 
day in the growth index for the drug-containing vial was less than the change in the 
control vial. Resistance was recorded if the change in the drug-containing vial was 
greater than the control vial, or the drug-containing vial had reached a growth index of 
999.
A fully susceptible control H37Rv was set up with each batch of sensitivity tests to 
confirm activity of the antibiotic.
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6.2.3 Pyrazinamide susceptibility testing
The pyrazinamide susceptibility test was performed using the Bactec 460 using the 
method recommended by the manufacturer. Two vials were prepared one containing 
100-ug/ml pyrazinamide the second being drug free, both vials at a ph of 6.0. Equal size 
bacteria inocula were made into both vials. The vials were incubated at 37°C and read 
daily on the Bactec 460 and the growth values recorded. Resistance to pyrazinamide 
was recorded when the drug free vial read >200 if the drug vial was >11% of the drug 
free vial. Susceptibility was recorded if when the drug free vial was reading 200 the 
drug containing vial was <9% of the drug free vial. The test was repeated if the drug 
free vial failed to show a growth index of >200 in 10 days, or reach a growth index of 
>200 in less than 4 days. The test was also repeated if the drug vial was between 9 and 
11% of the drug free vial when a growth index of 200 was reached in the drug free vial. 
A fully susceptible control H37Rv was set up with each batch of sensitivity tests to 
confirm activity of the antibiotic.
6.2.4 Pyrazinamidase gene PCR and sequencing
See section 2.6
6.2.5 gyrA PCR and sequencing
See section 2.5.
6.2.6 gyrB PCR and sequencing
See section 2.5.
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6.2.7 Viable counts
Viable counts were performed by the technique of (Miles & Misra 1938) on rifampicin- 
containing and rifampicin-free plates. The dispersed broth was serially diluted 1:10 in 
tween-albumin broth (0.01% tween 80; Merck, Nuneaton, United Kingdom) and 0.02% 
bovine albumin (Sigma, Poole, United Kingdom) to form a series from 10'1 to 10'7. The 
Tween albumin broth was vortexed briefly three times. Aliquots of these dilutions (50 
uL) were inoculated onto Middlebrook 7H10 agar (Difco) containing either 5 mg/L 
rifampicin or no drug. The total colony count was estimated from the drug free media 
and the count of resistant cells was calculated from the drug containing plate. The 
number of susceptible colonies was calculated by subtracting the number of resistant 
colonies from the total.
6.2.8 Fitness assay
A mixed culture of MDR-TB isolate and H37Rv was prepared in a 4 ml 7H9 broth. The 
inocula were 100 uL of a 10-fold dilution of susceptible and 100 uL of a 100 fold 
dilution of MDR-TB from fully confluent broth cultures. The number of viable 
organisms was estimated, using the Miles and Misra plate count technique, at the 
beginning of incubation and after 2 weeks incubation at 37°C. The number of 
generations (G) could then be calculated with formula 6.1.
Formula 6.1 G = (log Ti- log T0 )/Log 2.
Where Ti is the final number of cells and T0 is the initial number of cells.
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The relative fitness of each isolate was calculated from the ratio generations of MDR-TB 
to susceptible H37Rv occurring in the same broth culture.
6.3 Statistics
The relative fitness of different isolates was compared using the one way ANOVA test. 
Differences between patients relative fitness values were confirmed using the students-t 
test and Tukey Kramer technique. All statistical tests were performed on JMP-IN (SAS 
Institute Inc).
6.4 Results
The ciprofloxacin susceptibility test indicated that both a single isolate from the source 
patient (S) and from patient X was ciprofloxacin resistant MIC (>4 ug/ml). No 
mutations were detected in the gyrB region but identical mutations were found in the 
gyrA gene (see table 6.4). This mutation (Asp 94 Gly) has been reported previously as 
leading to ciprofloxacin resistance in M. tuberculosis (Xu, Kreiswirth, Sreevatsan et al. 
1996).
The pyrazinamide susceptibility data indicated that two of the strains 1S-RF from patient 
S and isolate Y from patient Y were resistant. There were no mutations identified in the 
pyrazinamidase gene.
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The isolates from the source patient (patient S) had mean relative fitness values of 0.70, 
0.86, and 0.84 (see table 6.2). There is no significant difference (one way ANOVA 
p=0.34) between fitness values and combined these produced a mean relative fitness 
value of 0.78 compared to H37Rv.
The relative fitness of the patient isolates S, X and Y are 0.78, 1.1 and 0.50 respectively 
compared to H37Rv (see table 6.3). There is a significant difference in the relative 
fitness values (one way ANOVA p<0.001). There is a significant difference between 
patient X, and Y and the source patient (S) using the t test and Tukey Kramer technique
(p<0.01)
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Table 6.1 Susceptibility test results of the isolates. Isolates S-1RF and S-B were from 
the source patient (S). Isolate X was from patient X and isolate Y from patient Y.
Isolate S-1RF Isolate S-B Isolate X Isolate Y
Streptomycin S S S S
Isoniazid R R R R
Rifampicin R R R R
Ethambutol S S S S
Ansamycin R R R R
Ethionamide S S S S
Capreomycin S s S S
Amikacin S s s S
Cycloserine s R R R
Pyrazinamide s R S R
Ciprofloxacin s R R S
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Table 6.2 Relative fitness of three isolates from patient Z determined against H37Rv in 
Middlebrook 7H9 broth.
Number of fitness assays Mean relative fitness 
(standard deviation)
S-1RF 8 0.700 (0.228)
S-2RF 5 0.860 (0.193)
S-Brompton 4 0.84 (0.181)
Table 6.3 Relative fitness of isolates from the three patients S, X, and Y determined 
against H37Rv in Middlebrook 7H9 broth.
Number of fitness assays Mean relative fitness 
(standard deviation)
Patient S 17 0.778 (0.211)
Patient X 8 1.05 (0.163)
Patient Y 7 0.495 (0.122)
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Table 6.4 Position of mutations in 4 of the 5 isolates detected in pncA gene affecting 
pyrazinamide resistance, rpoB gene affecting rifampicin resistance, gyrA and gyrB gene 
affecting ciprofloxacin resistance. The initials WT indicate wild type and no mutations 
were identified.
Isolate Gene pncA Gene rpoB Gene gyrA Gene gyrB
S-l WT Ser 531 Leu WT WT
S-B WT Ser 531 Leu Asp 94 Gly WT
X WT Ser 531 Leu Asp 94 Gly WT
Y WT Ser 531 Leu WT WT
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6.5 Discussion
6.5.1 The effect of storage on isolates
When the temperature is above 0°C there is the possibility of growth, although at a 
reduced rate. Koch (1997) in a review of slow growth detailed the differences and 
similarities between slow and rapid growth. Koch described how slow growth is not just 
normal growth at a reduced rate. For example, DNA must be copied to RNA: this 
involves production of single stranded DNA which is very susceptible to mutagens. 
Copying of DNA must occur at the same rate as in normal growth, but longer periods 
between copying is then required. Furthermore the proteins produced in slow growth 
are different to those produced in normal growth. All of these aspects can be subject to 
genetic variation and so selection.
Extended periods on the same media, even with slow growth, must lead to a decline in 
nutrients and an increase in waste products. This will lead to competition for the 
nutrients and for resistance to waste products.
Storage of isolates of M. tuberculosis can provide a selective pressure and so lead to 
selection of alleles not predominate in the parent population. This variation in selective 
pressure during storage will result in different fitness values after storage, and between 
slopes stored in different environments. Two of the isolates from the source patient S- 
1RF and S-2RF were isolates identified isolated and stored at the Royal Free Hospital.
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These isolates were stored at room temperature on LJ slopes. A third isolate from the 
source patient was isolated at the Brompton Hospital storage conditions are unknown.
There is no significant difference in the relative fitness of the three different isolates 
from the source patient (one way ANOVA p=0.34). This indicates variation during 
storage did not affect fitness of the source patient isolates.
6.5.2 The time of transmission of infection
Conventional epidemiological investigation basing the order on the time of the samples 
would indicate that patient X acquired infection before patient Y. However, isolate X 
from patient X was resistant to 5 drugs whilst the isolate from patient Y was resistant to 
only 4 of the 10 drugs tested. The increased resistances in isolate Y either indicates a 
later infection, when more resistance had been acquired, or that resistance developed in 
patient X. Comparison of resistance patterns and mutations may be used to further 
elucidate the order of transmission and where resistance arose.
Isolate S-1B was resistant to both ciprofloxacin and pyrazinamide. Isolate Y was 
susceptible to ciprofloxacin but resistant to pyrazinamide, and isolate X was resistant to 
ciprofloxacin and susceptible to pyrazinamide. Transmission of infection appears to 
have occurred prior to the double resistance arising in S-1B. But in which order did 
transmission occur, to patient X first and then patient Y or vice versa.
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The mutation producing resistance in isolate Y and isolate Sl-B is the same (see table 
6.4). The common resistance allele in both the isolate S-1B and isolate X could indicate 
that patient X was infected only after ciprofloxacin resistance was developed.
Resistance to ciprofloxacin was absent from isolate Y and this could indicate that patient 
Y was infected prior to patient X.
Ramaswamy & Musser (1998) in a review of antimycobacterial resistance mechanisms 
identified gyrA mutations as being more common than gyrQ mutations in 
fluoroquinolone resistant M. tuberculosis . The specific mutation Asp94Gly isolated 
here is associated with a 60-fold increase in MIC, the largest increase reported by Xu, 
Kreiswirth, et al. (1996). The frequency of isolation of the different gyr^ mutations is 
not reported.
Pyrazinamide resistance was absent from isolate X but present in both Sl-B and isolate 
Y. The mutation leading to pyrazinamide resistance was not present in gene pncA  for 
either isolate Sl-B or isolate. Pyrzinamidase activates pyrazinamide by converting it 
into the pyrazinoic acid. Mutations in the pyrazinamidase gene render the cell resistant 
by removing this activity. This is not however the only mechanism of pyrazinamide 
resistance. Davies et al. (2000b) found that 4 (21%) out of 19 M. tuberculosis isolates 
resistant to pyrazinamide using the Bactec 460 technique did not have a mutation in the 
pncA gene. The probability of two mutations outside the pncA gene occurring 
independently is therefore 4% (0.2 lx 0.21).
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In order to deduce from the susceptibility data the order of infection, a greater 
understanding of the factors leading to the selection of resistance alleles and the 
probability of the same allele being independently isolated would need to be identified. 
The pattern of resistance can give an order of infection of patient X, then patient Y, if 
pyrazinamide is considered, or patient Y was infected then patient X if ciprofloxacin is 
considered. The order depends on the likelihood of both the specific mutations in the 
gyrA gene leading to ciprofloxacin resistance, the likelihood a mutation outside of the 
pncA gene leading to resistance to pyrazinamide, and the possibility of either mutation 
occurring independently on two separate occasions.
6.5.3 Evidence of adaptation to the host
The relative fitness of the M. tuberculosis isolate affecting patient X (1.1) is higher than 
the relative fitness of the isolates affecting the source patient S (0.78). The relative 
fitness of the M. tuberculosis isolate affecting patient Y (0.50) is lower than the isolate 
affecting the source patient.
The artificial media in which the relative fitness of the three patient’s clones were 
measured was not the environment to which these strains had adapted. The measured 
alteration in relative fitness, whilst it reflects a change, need not, reflect the direction in 
which the change had occurred within the patient. An improvement in relative fitness in 
vitro does not necessarily lead to an improvement in relative fitness in vivo. However 
this is evidence for a genetic difference between isolates.
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Evolution, the inherited change in gene frequency distribution, can occur either through 
selection, indicating changes are of benefit, or through genetic drift. Genetic drift is the 
random accumulation of genetic alterations, which occurs purely from chance with no 
beneficial effect. The M. tuberculosis isolates of both the infected patients X and Y 
altered from the source patient isolates’ relative fitness. This alteration in the relative 
fitness indicates an alteration in the genome.
Genetic change was too frequent to be by chance, or genetic drift. This indicates 
selective pressures were great enough to lead to the emergence of adaptive changes in 
M tuberculosis gene sequence in the isolates from patients X and Y. That there was an 
observable difference in the genetic fitness of these isolates as compared to the parent 
indicates that the adaptive landscapes of patients X and Y were significantly different to 
S.
Compensatory mutations, which reduce or eliminate the relative fitness reduction 
created by antibiotic resistance, must compete along with other unknown adaptive 
mutations specific to the individual host.
The Government’s report to the House of Lords’ Select Committee on Science and 
Technology on antibiotic resistance entitled ‘The path of least resistance’ (Department 
of Health 1998b) asked the pertinent question ‘is antibiotic resistance a one way street?’. 
Is retention of antibiotic resistance dependent on the selective pressure of antibiotic 
usage? The answers, it would appear, are at least in part dependent on the fitness cost
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associated with antibiotic resistance, the possibility of compensatory mutations reducing 
this cost and the relative cost of adaptation to each new host.
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Chapter 7
The role of selection and genetic drift in the evolution of drug resistance
Drug resistance in M. tuberculosis only arises as a result of mutation and selection. The 
necessity of generating variation by mutation is amply illustrated by the history of the 
development of chemotherapy. Single therapy has been effective where low numbers of 
bacilli are present such as the continuation phase of therapy. Triple therapy is however 
essential where numerous bacilli are present such as in pulmonary tuberculosis (Chan & 
Iseman 2002). The necessity for generating genetic variation emphasises the 
importance of the mutation rate.
One prediction of such variation is that it can lead to genetic drift. Genetic drift is the 
adoption of mutations or alleles not due to any advantage but due to chance alone (Bell 
1997). The forced adoption of a rare but essential mutation such as antibiotic resistance 
would enhance the role of genetic drift. If advantageous alleles were not rare and there 
is a wide amount of genetic variation, then the role of selection would be enhanced.
There is evidence of genetic variation in M tuberculosis during infection. De Boer, 
Kremer, Borgdorff et al. (2000) examined the IS6110 restriction fragment length 
polymorphism banding pattern (RFLP) of 1,277 isolates of M  tuberculosis for low 
intensity bands. Isolates with identical IS6110 RFLP patterns are considered to have 
originated from the same ancestral strain. Multiple low intensity banding can indicate 
multiple infection with two or more strains of M. tuberculosis (Pavlic, Allerberger,
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Dierich et al. 1999). De Boer et al (2000) identified no multiple low intensity bands in 
the 1,277 isolates but identified 94 (7.4%) single low intensity bands. 6 single colonies 
picked from cultures with low intensity bands revealed the culture to consist of two 
populations with the RFLP differing by the single band. Low intensity banding patterns 
were produced when there was a population differing by a single band and this 
population made up 10% to 30% of the DNA used to produce the RFLP. This indicates 
large sub-populations of M. tuberculosis can exist in clinical infections
The frequency of antibiotic resistance isolated in vivo in M. tuberculosis as noted in 
chapter 3 is not reflected in the measured mutation rate (table 3.1). The predominance 
of one allele of rifampicin resistance Ser 531 to Leu which accounted for 42% of clinical 
isolates with identified rifampicin mutations reported by Ramaswamy & Musser (1998) 
is not explained by a raised mutation rate for that allele (chapter 3). That allele was 
however associated with a low fitness deficit measured in vitro (chapter 4). Wichelhaus, 
Boddinghaus, Besier et al. (2002) found the same association between fitness and the 
allele of rifampicin resistance in S. aureus. The higher fitness means that that allele is 
both more likely to be present and is more likely to outcompete less fit resistant alleles 
and so come to predominance (see 1.13). The association with fitness and emergence of 
resistant alleles is not restricted to rifampicin.
Pym, Saint-Joanis & Cole (2002) studied the fitness of strains of isoniazid resistant 
mutants in vivo. The mutation S315T in the katG gene leads to clinically significant 
resistance to isoniazid (5ug/ml) with an active catalase gene product, the reduction in
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activity was about 12%. This mutant is the most commonly clinically isolated isoniazid 
resistant allele (Ramaswamy & Musser 1998). Pym et al. (2002) injected mice with M. 
tuberculosis both deficient in katG with normal JcatG activity and with the mutation 
S315T. The growth of bacilli with the mutation S315T in mice lungs and spleen over a 
forty-day period after injection was larger than that of the katG deficient strains 
approaching if not equalling that of the wild type strains. This supports the hypothesis 
that the mutation S315T mutation is selected not only due to the resistance to isoniazid 
conferred, but its catalase activity is needed to detoxify host antibacterial radicals.
S315T has a higher fitness in vivo due to this ability to neutralise the oxidative burst of 
host macrophage and other such antibacterial radicals.
Evidence that streptomycin leads to growth rate inhibition due to a reduced rate of 
protein synthesis, and that adaptive mutations can then ameliorate that fitness deficit was 
supplied by Schrag, Perrot & Levin (1997) and is described in the introduction (section 
1.15). In all the cases described, the allele of resistance selected most frequently 
produces the least fitness deficit.
Antibiotic control programs are based on the theory that there is a fitness deficit 
associated with antibiotic resistance (Anderson 1999). In chapter 5 a fitness deficit 
associated with an isolate of MDR-TB was identified compared to a closely related fully 
susceptible isolate. These isolates sharing a close common ancestry will share a 
common genomic heritage, the difference in fitness reflecting recent genomic changes. 
This does not mean the isolates were isogenic differing only in terms of specific drug
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resistance mutations. The genomic history of clinical isolates is unknown. Mutations 
other than drug resistance may have been present either from adaptation to host 
environments or from drift or founder effects. Mutations sharing the genome with 
essential mutations, such as drug resistance, can be selected for due to the essential 
allele’s presence (Bell 1997). A number of matched clinical isolates, drug resistant and 
susceptible, would need to be tested to overcome this uncertainty in the history of 
clinical isolates.
Ordway et al. (1995) measured the growth rate of 15 clinical isolates in mice. This 
included 3 MDR-TB isolates (defined as resistant to isoniazid and rifampicin). Growth 
rates were compared to that of a laboratory control strain, the Erdman strain. No 
correlation with antibiotic resistance and growth rate was identified. These isolates were 
not related and so revealed that heterogeneity in M. tuberculosis isolates is a larger 
factor in variance in growth rate than antibiotic resistance.
Cohen et al (2003) reviewed population-based evidence for a reduction in fitness 
associated with drug resistance. The evidence was that fitness estimates of M 
tuberculosis are very variable. Cluster analysis was highly dependent on both the 
population studied and the size of the study. Both laboratory and population studies do 
reveal that heterogeneity in M. tuberculosis growth and infectivity does exist. This 
indicates that M. tuberculosis is currently evolving in areas other than drug resistance.
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The heterogeneity in growth rates of M. tuberculosis raises the question: what is the 
fitness landscape of the human host? Is the landscape a single peaked landscape with a 
single ideal M. tuberculosis sequence or a multiple peaked landscape indicating a range 
of different ideal genomes?
In chapter 6 evidence is produced that there is variation in the fitness of isolates between 
patients. This alteration in fitness was apparent with none of the three isolates from a 
multi-drug resistant tuberculosis outbreak sharing the same fitness. This high amount of 
variation indicates there is some alteration in the genome with the transfer of infection 
between patients.
Musser, Amin & Ramaswamy (2000) found little genetic change in cell wall 
components. Identifying the reason for the alteration in fitness between patient isolates 
may reveal more about the adaptive necessities of M  tuberculosis to the host and those 
genes where selective pressures are produced by the host.
Kato-Maeda, Rhee, Gingeras et al. (2001) identified wide variation in the genome of 
clinical isolates of M. tuberculosis. The genome of 19 isolates of M. tuberculosis was 
compared to that of H37Rv and H37Ra. Each isolate was missing an average 0.3% 
(13,248 bp) of the genome present in H37Rv. This correlates to some or all of 17.2 open 
reading frames with no isolate having more than 38 open reading frames deleted. Due to 
the method used, DNA sequences absent from H37Rv but present in the clinical isolates 
could not be detected. No evidence was found for variation during chains of infection,
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no change being detected in three isolates from a recognised chain of infection.
However the method used could not detect deletions shorter than 350 bp. This indicates 
that the heterogeneity detected in fitness estimates between unrelated M. tuberculosis 
isolates, is reflected in wide variation in the genome contents. However the variation in 
fitness found between isolates in chain of infection relies on more subtle causes than the 
350 bp deletions Kato-Maeda et al. (2001) could detect.
The presence of wide-spread strains and clades of M. tuberculosis such as the Beijing 
strains have been identified indicating a range of infectivity in M. tuberculosis (Filliol, 
Driscoll, van Soolingen et al. 2003). Analysis of the IS6610 patterns of M. tuberculosis 
isolates collected in London has revealed that patients were more likely to be infected 
with strains of tuberculosis related to their racial origin (Maguire et al. 2002). Hirsh, 
Tsolaki, DeRemier et al. (2004) examined the genetic relationship of 100 M 
tuberculosis isolates using microarrays to identify deletions present in the clinical 
isolates but absent from H37Rv. All of the clinical isolates were from separate genetic 
lineages collected over 12 years in San Francisco. Molecular phylogenetic analysis of 
the deletions revealed the isolates related most closely to the racial origin of the patient. 
Four large geographic regions, East Asia, the Philippines, Americas, and a group 
consisting of African, European and Middle Eastern origin were identified.
Hirsh et al. (2004) identified that the population of infection between Philippine and 
East Asian tuberculosis separated between 240 and 1000 years ago. This separation of 
infection into human racial groups over such a prolonged period led Hirsh at al. (2004)
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to speculate on the possibility ‘of adaptation by specific M. tuberculosis lineages to the 
genetic cultural or environmental characteristics of particular populations of hosts’.
The heterogeneity in tuberculosis growth rates and genome structure raises the 
possibility that antibiotic use is not as great a selective pressure as it would appear. 
Methicillin resistant Staphylococcus aureus has increased greatly over the last decade. 
Enright, Robinson, Randle et al. (2002) identified methicillin resistance as repeatedly 
emerging from successful clones of methicillin susceptible clones of Staphylococcus 
aureus. It is the combination of drug resistance and strains well adapted to transmission 
in hospitals that produce epidemic MRSA strains.
Antibiotic resistance is a vital character for treatment of infection. It is however only 
one component of the infective repertoire of the infecting organism. The ease with 
which antibiotic resistance is measured and the importance of this character for 
treatment has lead to this being emphasised. However, the combination of drug 
resistance and infectivity may be required to produce an epidemic MDR-TB strain.
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Appendix A 
Media
Tween albumin broth.
0.2% bovine fatty acid free albumin 
0.01% Tween 80 
Dissolve in deionised water and filter sterilised.
Middlebrook 7H9 Broth
4.7g Middlebrook 7H9 powder (Difco)
2 ml Tween 80
900 ml deionised water.
ADC supplement, Albumin, Dextrose, Catalase solution (Difco).
Autoclave in 180 ml aliquotes. To use add 20 ml ADC supplement (Difco) to 180 ml 
broth and distribute using sterile technique.
Middlebrook 7H10 Agar.
1.9g 7H10 agar powder (Difco)
0.5 ml Glycerol 
90 ml deionised water.
OADC supplement, Oleic acid, Albumin, Dextrose, Catalase solution (Difco). 
Autocalve and cool to 50 C in a water bath. Add 10 ml OADC supplement (Difco) and 
any desired antibiotic. Pour molten agar in 20 ml aliquotes into petri dishes.
198
Appendix B
Papers published as a result of the research carried out for this thesis
Billington, O. J., McHugh, T. D., & Gillespie, S. H. 1999,
"Physiological cost of rifampin resistance induced in vitro in 
Mycobacterium tuberculosis", Ant imicrob.Agents Che mot her., vol.
43,no. 8, pp. 1866-1869.
Davies, A. P., Billington, O. J., Bannister, B. A., Weir, W. R., McHugh, 
T. D., & Gillespie, S. H. 2000a, "Comparison of fitness of two isolates 
of Mycobacterium tuberculosis, one of which had developed multi-drug 
resistance during the course of treatment", J.Infect, vol. 41,no. 2, pp. 
184-187.
Gillespie, S. H., Billington, O. J., Breathnach, A., & McHugh, T. D. 
2002, "Multiple drug-resistant Mycobacterium tuberculosis: evidence 
for changing fitness following passage through human hosts",
Microb.Drug Resist, vol. 8,no. 4, pp. 273-279.
199
Antimicrobial Agents and Chemotherapy, Aug. 1999, p. 1866-1869 
0066-4804/99/504.00+0
Copyright ©  1999, American Society for Microbiology. A ll Rights Reserved.
Vol. 43. No. 8
Physiological Cost of Rifampin Resistance Induced 
In Vitro in Mycobacterium tuberculosis
O. J. BILLINGTON, T. D. M cH U G H , and S. H. GILLESPIE*
1866
Vol. 43, 1999 P H Y S IO L O G IC A L  C O S T  O F  R IF A M P IN  R E S IS T A N C E  1867
1868 B IL L IN G T O N  E T  A L. Antimicrob. Agents Chemother.
V o l. 43, 1999 P H Y S IO L O G IC A L  C O S T O F  R IF A M P IN  R E S IS T A N C E  1869
Journal of Infection (2 0 0 0 ) 4 1 ,1 -4  ®
do i:1 0 .10 53 /jin f.2 000 .071 1 , available online at hup.V/www.idcalibniry.com on I D l ^ l
CASE REPORTS
Comparison of Fitness of Two Isolates of Mycobacterium 
tuberculosis, one of Which had Developed Multi-drug 
Resistance During the Course of Treatment
A. P. Davies1, O. J. Billington1, B. A. Bannister2, W. R. C. Weir2, T. D. McHugh1 
and S. H. Gillespie1*
©  2 0 0 0  The British Infection Society
OK) 1-445 5/OO/UOOOOO t- OO *  55 .00/0 <. 2 0 0 0 't he British tnlcclion Society
2 Case Reports
•/
Case Reports
4 Case Reports
M IC R O B IA L  D R U G  R E S IS T A N C E , 
Volume 8 , Num ber 4, 2002 
© M a ry  Ann Liebert, Inc. 1
Multiple Drug-Resistant Mycobacterium tuberculosis: 
Evidence for Changing Fitness Following Passage Through 
Human Hosts
STEPH EN  H. GILLESPIE , 1 OW EN J. B ILLIN G TO N , 1 A O D H A N  B R E A T H N A C H , 2  
and TIM OTHY D. M cH U G H 1
273
27 4 G IL L E S P IE  ET AL.
M DR M. TUBERCULOSIS CHANGING FITNESS 275
I
9\
G
ILLESPIE 
ET 
A
L.
MDR M. TUBERCULOSIS CHANGING FITNESS 277
278 G IL LE SPIE  ET AL.
MDR M. TUBERCULOSIS CHANGING FITNESS 279
A n t i m i c r o b i a l  A g h n t s  a n d  C h e m o t h e r a p y ,  A u g .  1999, p .  1866-1869 
0066-4804/99/$04.00 + 0
Copyright (r) 1999, American Society for Microbiology. A ll Rights Reserved.
Vol. 43, No. 8
Physiological Cost of Rifampin Resistance Induced 
In Vitro in Mycobacterium tuberculosis
O. J. BILLINGTON, T. D. M cH U G H , a n d  S. H. GILLESPIE*
1866
V o l .  43, 1999 P H Y S IO L O G IC A L  C O S T O F  R IF A M P IN  R E S IS T A N C E  1867
1868 B IL L IN G T O N  E T  A L. A n t i m i c r o b . A g e n t s  C h i  m o t h e r .
V o l .  43, 1999 P H Y S IO L O G IC A L  C O S T O F  R IF A M P IN  R E S IS T A N C E  1869
Journal of Infection (2 0 0 0 ) 4 1 ,1 - 4  @
d o i:1 0 .1 0 5 3 /jin f.2 0 0 0 .0 7 1 1, available online at h llp ://w ww.idcalibrary.com on ID E ^ L
CASE REPORTS
Comparison of Fitness of Two Isolates of Mycobacterium 
tuberculosis, one of Which had Developed Multi-drug 
Resistance During the Course of Treatment
A. P. Davies1, O. J. Billington1, B. A. Bannister2, W. R. C. Weir2, T. D. McHugh1 
and S. H. Gillespie1*
©  2 0 0 0  The British Infection Society
oir> 1-4451/00 /000000 +  00 *1 5 .0 0 /0 < • 2 0 0 0 The British Infection Society
2 Case Reports
Case Reports 3
4 Case Reports
M IC R O B IA L  D R U G  R E S IS T A N C E , 
Volume 8 , Num ber 4, 2002 
© M ary Ann Liebert, Inc.
Multiple Drug-Resistant Mycobacterium tuberculosis: 
Evidence for Changing Fitness Following Passage Through 
Human Hosts
ST E P H E N  H. GILLESPIE , 1 OW EN J. BIL LIN G TO N , 1 A O D H A N  B R E A T H N A C H , 2
and TIM OTH Y D. M cH U G H 1
273
274 GILLESPIE ET AL.
MDR M. TUBERCULOSIS  CHANGING FITNESS 275
bJ
Ov
G
ILLESPIE 
ET 
A
L
.
MDR M. TUBERCULOSIS CHANGING FITNESS 111
278 GILLESPIE ET AL.
M D R  M . T U B E R C U L O S IS  C H A N G IN G  F IT N E S S 279
